Pa ge [ADDRESS_205827] u d y  E v al u ati n g  t he  Effic ac y  a n d  S afet y  of  Ge ne  
T her a p y i n S u bjects wit h Tr a nsf usi o n -de pe n de nt β -T h al asse mi a, w h o d o n ot 
h a ve  a  β 0/ β [ADDRESS_205828] a nt ati o n of A ut ol o g o us C D 3 4 + Ste m Cells 
Tr a ns d uce d  E x  Vi v o  wit h  a  Le nti vir al  β A- T [ADDRESS_205829] or  i n  S u bjects  
≤ [ADDRESS_205830] u d y S p o ns or:  bl ue bir d bi o, I n c. 
[ADDRESS_205831] 
Ca m bri d ge, M A 0 2 1 4 2 U S A 
Res p o nsi ble Me dic al Officer:  , M D  
Se ni or Me dical Direct or  
Cli nical Researc h De vel o p me nt  
bl ue bir d bi o, I nc. 
Office tele p h o ne:  
E mail:  
Pr ot oc ol V ersi o n:  Versi o n 6. 0  
D oc u m e nt D ate:  [ADDRESS_205832] P h o ne N u m bers  
C o u ntr y  P h o ne N u m ber  
Fra nce  
Ger ma n y  
Ital y  
T haila n d  
U nite d Ki n g d o m  
U nite d States of A merica  
 
C CI P P D 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 
 S U M M A R Y O F C H A N G E S  
D oc u me nt c o ncer ne d: Pr ot oc ol H G B‑ 2 0 7  
N u m ber  a n d  dat e  of  t he  pre vi o us  v ersi o n:  Versi o n  5. 0  ( [ADDRESS_205833] o ber  2 0 2 0)  
N u m ber a n d d ate of t he n e w versi o n:  Versi o n 6. 0 ( 1 0 J u ne 2 0 2 1) 
T his pr ot oc ol ( Versi o n 6. 0, 1 0 J u ne 2 0 2 1) re pl aces pre vi o us Versi o n 5. 0 ( [ADDRESS_205834] o ber 2 0 2 0). 
S u bsta ntial c ha n ges c o m pare d t o St u d y H G B -[ADDRESS_205835] t y p o gra p hi cal err ors a n d ali g n t he use of ter mi n ol o g y a n d 
f or matti n g wit h c urre nt sta n dar ds. 
N ote: i n t he f oll o wi n g ta ble, a d de d te xt is i n b ol d it alics  a n d delete d te xt is i n stri ket hr o u g h. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 D E S C RI P TI O N O F E A C H S U B S T A N TI A L C H A N G E  
I niti al w or di n g  A m e n de d or Ne w W or di n g  Re as o n/ J ustific ati o n f or c h a n ge  
Secti o n(s) c o ncer ne d:  
Secti o n 4. [ADDRESS_205836] has u n detecta ble V C N 
( < 0. [ADDRESS_205837] oi d ge n o me ) i n peri p heral 
bl o o d cells f or [ADDRESS_205838] 1 
m o nt h a part. T his deter mi nati o n is base d o n a ver y 
se nsiti ve q u a ntitati ve p ol y merase c hai n reacti o n  ( q P C R) 
assa y.  Secti o n(s) c o ncer ne d:  
Secti o n 4. [ADDRESS_205839] ha s u n detecta ble V C N 
( < 0. [ADDRESS_205840] oi d ge n o me ) i n peri p heral 
bl o o d cells f or [ADDRESS_205841] 1 
m o nt h a part. T his deter mi nati o n is base d o n a ver y 
se nsiti ve q ua ntitati ve p ol y merase c hai n reacti o n  ( q P C R) 
assa y.  Treate d s u bj ects s h o ul d re mai n i n t he 
st u d y re gar dless of t heir vect or c o p y 
n u m ber after treat me nt t o e ns ure 
c o m pre he nsi ve f oll o w -u p of safet y 
a n d efficac y.  
Secti o n(s) c o ncer ne d:  
Secti o n  5. 9. 2  C o nc o mita nt  Me dicati o ns  a n d  T hera pi[INVESTIGATOR_014]:  
Ge neral  
[ …] Secti o n(s) c o ncer ne d:  
Secti o n 5. 9. 2 C o nc o mita nt Me dicati o ns a n d T hera pi[INVESTIGATOR_014]: 
Ge neral  
 
F or t he p ur p oses of t his st u dy, v acci nes (e. g., C O VI D -1 9 
v acci nes) are c o nsi dere d c o nc o mit a nt me dic ati o ns. 
Alt h o u g h i nter acti o ns bet wee n a v acci ne a n d 
Le nti Gl o bi n B B [ADDRESS_205842] are n ot e x pecte d, t he 
pr ot oc ol i ncl u des use of i m m u n o m o d ul at ory ( pleri x af or) 
a n d i m m u n os u p pressive me di c ati o n ( b us ulf a n). L oc al 
g ui deli nes s h o ul d be f oll o we d re g ar di n g a mi ni m u m ti me 
peri o d  bet wee n a ny me dic ati o n t o be pr ovi de d as p art of 
tre at me nt wit h Le nti Gl o bi n B B [ADDRESS_205843] a n d 
a ny v acci ne; it is rec o m me n de d t h at v acci nes are n ot 
a d mi nistere d t o s u bjects wit hi n [ADDRESS_205844] i nf usi o n s h o ul d be c o nsi dere d per I nvesti g at or's 
discreti o n d ue t o p ote nti al l oss of i m m u nity after Pr o vi de d c o nsi derati o ns f or vacci nes 
as c o nc o mita nt me dicati o ns per 
g ui da nce fr o m re g ulat or y a ge nc y.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 I niti al w or di n g  A m e n de d or Ne w W or di n g  Re as o n/ J ustific ati o n f or c h a n ge  
myel o a bl ative c o n diti o ni n g a n d m ay be a d mi nistere d 
f oll o wi n g l oc al g ui deli nes.  
T he prescri bi n g i nf or m ati o n of t he v acci ne a d mi nistere d 
s h o ul d be referre d t o f or t he l atest i n dic ati o n, 
c o ntr ai n dic ati o ns a n d s afety i nf or m ati o n as well a s t he 
l atest ge ner al cli nic al rec o m me n d ati o ns o n v acci ne 
a d mi nistr ati o n i n t he c o u ntry or re gi o n.  
All  v acci n ati o ns  d uri n g  t h e  st u dy  peri o d  s h o ul d  be  
d oc u me nte d i n t he C R F.  
Secti o n(s) c o ncer ne d:  
Secti o n 6. 1 Sc he d ule of E ve nts  
Ta ble 4 Sc he d ule of E ve nts: Scree ni n g a n d C D 3 4 + Cell 
Har vest; F o ot n ote 1 5  
B o ne marr o w c ollecti o n f or m or p h ol o g y, cell ularit y, cell 
c o u nt a n d ir o n stai ns. F or s u bj ects u n der g oi n g re -scree ni n g, 
b o ne marr o w c ollecti o n d oes n ot nee d t o be perf or me d.  Secti o n(s) c o ncer ne d:  
Secti o n 6. 1 Sc he d ule of E ve nts  
Ta ble 4 Sc he d ule of E ve nts: Scree ni n g a n d C D 3 4 + Cell 
Har vest; F o ot n ote 1 5  
B o ne marr o w c ollecti o n f or m or p h ol o g y, cell ularit y, cell 
c o u nt a n d ir o n stai ns. F or s u bjects u n der g oi n g re -scree ni n g, 
b o ne marr o w c ollecti o n d oes n ot nee d t o be perf or me d. If 
s ufficie nt  s a m ple  is  av ail a bl e,  s a m ple  m ay  be  arc hive d 
a n d/ or ot her rese arc h tests (e. g., ge netic testi n g) m ay be 
perf or me d.  S peci fie d t hat b o ne marr o w sa m ples 
ma y be arc hi ve d a n d t hat ge netic 
testi n g ma y be perf or me d if cli nicall y 
i n dicate d.  
Secti o n(s) c o ncer ne d:  
Secti o n 6. 1 Sc he d ule of E ve nts  
Ta ble 6 Sc he d ule of E ve nts: F oll o w -u p; F o ot n ote [ADDRESS_205845] u dies (retic ul oc ytes, 
n ucleate d R B C, ser u m tra nsferri n rece pt or, he pci di n, a n d 
er yt hr o p oieti n),  as  well  as  m or p h ol o g y,  cell ularit y,  cell  
c o u nt, a n d ir o n c o nte nt; ot her researc h tests (e. g., V C N, 
I S A,  H P L C)  ma y  be  perf or me d  if  s ufficie nt  sa m ple  is  
a vaila ble  Secti o n(s) c o ncer ne d:  
Secti o n 6. 1 Sc he d ule of E ve nts  
Ta ble 6 Sc he d ule of E ve nts: F oll o w -u p; F o ot n ote [ADDRESS_205846] u dies (retic ul oc ytes, 
n ucleate d R B C, ser u m tra nsferri n rece pt or, he pci di n, a n d 
er yt hr o p oieti n) ,  as  well  as  m or p h ol o g y,  cell ularit y,  cell  
c o u nt, a n d ir o n c o nte nt; if s ufficie nt s a m ple is av ail a ble, 
s a m ple m ay be arc hive d a n d/ or  ot her researc h tests (e. g., 
V C N, I S A, H P L C , ge netic t esti n g ) ma y be perf or me d  if 
s ufficie nt sa m ple is a vaila ble  
  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 Secti o n (s) c o ncer ne d:  
Secti o n  6. 2. [ADDRESS_205847] u dies (see Secti o n  6. 2. 1 6. 2 ), as well as m or p h ol o g y, 
cell ularit y, cell c o u nt a n d ir o n c o nte nt, at Scree ni n g a n d 
M o nt h [ADDRESS_205848] or c o p y 
n u m ber ( V C N), a n d f or β A- T [ADDRESS_205849] f or mi n g u nits ( B F U -E).  
If a n u nsc he d ule d b o ne marr o w c ollecti o n is perf or me d at 
a n y p oi nt d uri n g st u d y, s uc h sa m ples ma y als o be use d f or 
t he deter mi nati o n of V C N, a n d f or β A- T 8 7 Q -gl o bi n 
e x pressi o n i n B F U -Es.  Secti o n(s) c o ncer ne d:  
Secti o n  6. 2. [ADDRESS_205850] u dies (see Secti o n  6. 2. 1 6. 2 ), as well as m or p h ol o g y, 
cell ularit y, cell c o u nt a n d ir o n c o nte nt, at Scree ni n g a n d 
M o nt h 1 2 a n d M o nt h 2 4 Visits. If s ufficie nt sa m ple is 
a vaila ble, t he  b o ne marr o w s a m ple  ma y als o  be teste d 
f or arc hive d a n d/ or ot her rese arc h tests (e . g.,  vect or c o p y 
n u m ber ([V C N ]), a n d f or  βA- T [ADDRESS_205851] f or mi n g u nits ([B F U - E ). ], I S A, H P L C, 
ge netic testi n g) m ay be perf or me d.  
If a n u nsc he d ule d b o ne marr o w c ollecti o n is perf or me d at 
a n y p oi nt d uri n g st u d y, s uc h sa m ples ma y als o be use d f or 
t he deter mi nati o n of arc hive d a n d/ or ot her rese arc h tests 
(e. g.,  V C N, a n d f or βA- T 8 7 Q -gl o bi n e x pressi o n i n B F U -Es , 
I S A, H P L C, ge netic testi n g) m ay be perf or me d .  
Secti o n(s) c o ncer ne d:  
6. 2. [ADDRESS_205852]  
Res ults  
• B o ne marr o w bi o ps y  Secti o n(s) c o ncer ne d:  
6. 2. [ADDRESS_205853]  
Res ults  
• B o ne marr o w bi o ps y a n d/ or as pir ati o n ( m ay 
als o be arc hive d f or a d diti o n al a n alysis i n 
t he f ut ure, see Secti o n  6. 2. 1 0 ) 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 9 Secti o n(s) c o ncer ne d:  
Secti o n  6. 2. 1 8. 2. Ot her Crite ria t hat ca n  Tri g ger  Cli nical 
W or k -u p f or Mali g na nc y  
• A n y cli nical s us pi[INVESTIGATOR_37180] o n of mali g na nc y 
i ncl u di n g le u ke mia or l y m p h o ma  
• U ne x plai ne d W B C c o u nt > 3 0, 0 0 0 (cells/ μ L) 
o n t w o c o nsec uti ve meas ure me nts  
• After ac hie ve me nt of a W B C c o u nt wit hi n t he 
n or mal ra n ge p ost -dr u g pr o d uct i nf usi o n a n d 
e n graft me nt of ge ne -m o difie d cells, t he 
de vel o p me nt of a W B C < 1 0 0 0 (cells/ μ L) o n 2 
c o nsec uti ve meas ure me nts  Secti o n(s) c o ncer ne d:  
Secti o n  6. 2. 1 8. 2. Ot her  Criteria t hat ca n  Tri g ger  Cli nical 
W or k u p f or Mali g na nc y  
• A n y cli nical s us pi[INVESTIGATOR_37180] o n of mali g na nc y 
i ncl u di n g le u ke mia or l y m p h o ma  
• U ne x plai ne d W B C c o u nt > 3 0, 0 0 0 (cells/ μ L) 
o n t w o c o nsec uti ve meas ure me nts  
• After ac hie ve me nt of a W B C c o u nt wit hi n t he 
n or mal ra n ge p ost dr u g pr o d uct i nf usi o n a n d 
e n graft me nt of ge ne m o difie d cells, t he 
de vel o p me nt of a W B C < 1 0 0 0 (cells/ μ L) o n 2 
c o nsec uti ve meas ure me nts   
  
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 0 Secti o n(s) c o ncer ne d:  
Secti o n 6. 2. 1 8. 3 Cli nical W or k -U p f or Mali g na nc y  
If a n y of t he a b o ve criteria is met, t he Me dical M o nit or will 
be n otifie d, a n d a w or k -u p will be perf or me d t hat ma y 
occ ur i n sta ges a n d ma y i ncl u de s o me of t he f oll o wi n g at 
eac h sta ge:  
• P h ysical e xa m  
• C B C wit h differe ntial  
• L y m p h oc yte s u bsets  
• St u dies t o r ule o ut i nfecti o us ca use  
• St u dies t o r ule o ut a ut oi m m u ne disease  
• I ma gi n g st u dies  
• B o ne marr o w a nal ysis  
If cli nical res ults i n dicate a dia g n osis of a mali g na nc y or 
m yel o d ys plasia, e nr oll me nt i nt o t his st u d y will be 
s us pe n de d, a n d f urt her a nal yses will be deter mi ne d b y t he 
S p o ns or, i n c o ns ultati o n wit h t he D M C (see als o 
Secti o n  3. 2 ). It s h o ul d be n ote d t hat it ma y n ot be p ossi ble 
t o disti n g uis h t he s o urce of mali g na nc y (e. g. arisi n g fr o m 
tra ns pla nt -relate d me dicati o ns or pr oce d ures, or fr o m 
e x pa nsi o n of ge ne -m o difie d cells d ue t o i nserti o nal 
m uta ge nesis), a n d all eff orts s h o ul d be ma de t o c o nfir m t he 
s o urce of mali g na nc y bef ore deter mi ni n g t o halt or 
alter nati vel y t o res u me t he st u d y.  
If t here is n o e vi de nce of mali g na nc y or m yel o d ys plasia, 
t he s u bj ect will c o nti n ue t o be m o nit ore d as per t he 
pr ot oc ol -defi ne d S O E, or m ore fre q ue ntl y at discreti o n of 
t he I n vesti gat or a n d S p o ns or.  Secti o n(s) c o ncer ne d:  
Secti o n  6. 2. [ADDRESS_205854] asi a, le u ke mi a, or 
ly m p h o m a , t he Me dical M o nit or will be n otifie d , a n d a 
w or k -u p will be perf or me d t hat ma y occ ur i n sta ges a n d 
ma y i ncl u de s o me of t he f oll o wi n g at eac h sta ge:  
• P h ysical e xa m  
• C B C wit h differe ntial  
• L y m p h oc yte s u bsets  
• St u dies t o r ule o ut i nfecti o us ca use  
• St u dies t o r ule o ut a ut oi m m u ne disease  
• I ma gi n g st u dies  
• B o ne marr o w a nal ysis  
• Cyt o ge netic a n d m olec ul ar a n alyses  
If cli nical res ults i n dicate a dia g n osis of a mali g na nc y or 
m yel o d ys plasia, e nr oll me nt i nt o t his st u d y will be 
s us pe n de d, a n d f urt her a nal yses will be deter mi ne d b y t he 
S p o ns or, i n c o ns ultati o n wit h t he D M C (see als o 
Secti o n  3. 2 ). It s h o ul d be n ote d t hat i t ma y n ot be p ossi ble 
t o disti n g uis h t he s o urce of mali g na nc y (e. g. arisi n g fr o m 
tra ns pla nt relate d me dicati o ns or pr oce d ures, or fr o m 
e x pa nsi o n of ge ne m o difie d cells d ue t o i nserti o nal 
m uta ge nesis), a n d all eff orts s h o ul d be ma de t o c o nfir m t he 
s o urce of  mali g na nc y bef ore deter mi ni n g t o halt or 
alter nati vel y t o res u me t he st u d y.   
C CI 
Pr ot oc ol H G B - [ADDRESS_205855] asi a, le u ke mi a, or 
ly m p h o m a, t he S p o ns or will c o nve ne a n ur ge nt s afety 
revie w meeti n g. F urt her a n al yses will be deter mi ne d by 
t he S p o ns or, i n c o ns ult ati o n wit h t he D M C. It s h o ul d be 
n ote d t h at it m ay n ot be p ossi ble t o disti n g uis h t he s o urce 
of m ali g n a ncy (e. g., arisi n g fr o m u n derlyi n g 
p at h o p hysi ol o gy of t he dise ase, tr a ns pl a nt -rel ate d 
me dic ati o ns or pr oce d ures, or fr o m e x p a nsi o n of ge ne -
m o difie d cells d ue t o i nserti o n al o nc o ge nesis), a n d all 
eff orts s h o ul d be m a de t o c o nfir m t he s o urce of 
m ali g n a ncy.  
F or  cli nic al  w or k -u p  after  i de ntific ati o n  of  a  persiste nt  
pre d o mi n a nt cl o ne a n d c o nfir me d prese nce of a b n or m al 
C B C,  b o ne  m ar r o w  a n alysis  is  rec o m me n de d  if  n ot  
previ o usly perf or me d as p art of t he cli nic al w or k -u p.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 2 D E S C RI P TI O N O F E A C H N O N -S U B S T A N TI A L C H A N G E  
• M o difie d la n g ua ge t hr o u g h o ut t he pr ot oc ol t o i n dicate t hat s u bjects w h o c o m plete 
t his st u d y will be e x pecte d t o e nr oll i n t he l o n g- ter m f oll o w - u p st u d y L T F- 3 0 3.  
• N u m bers f or s u bject e nr oll me nt as of 0 3 Marc h 2 0 2 0 were u p d ate d i n t he Secti o n 1 
I ntr o d u cti o n. 
• U p date d t he title pa ge t o reflect c ha n g e i n Res p o nsi ble Me dical Offi cer  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 3 C LI NI C A L S T U D Y P R O T O C O L S Y N O P SI S  
Pr ot oc ol Title:  A P hase [ADDRESS_205856] u d y E val uati n g t he Efficac y a n d Safet y of Ge ne T hera p y 
i n S u bjects wit h Tra nsf usi o n -de pe n de nt β-T halasse mia, w h o d o n ot ha ve a β0/ β 0 
Ge n ot y pe, b y Tra ns pla ntati o n of A ut ol o g o us C D 3 4 + Ste m Cells Tra ns d uce d E x 
Vi v o wit h a Le nti viral βA- T [ADDRESS_205857] or i n S u bjects ≤ 5 0 Years of A ge  
Pr ot oc ol N u m ber:  H G B -2 0 7  
O bjecti ves:  Pri m ar y:  e val uate t he efficac y of treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205858] i n s u bjects ≤ 5 0 years of a ge wit h tra nsf usi o n -de pe n de nt β -t halasse mia 
( T D T) w h o d o n ot ha ve a β0/ β 0 ge n ot y pe at t he H B B  ge ne  
Sec o n d ar y: e val uate t he safet y of treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205859] i n s u bjects ≤ 5 0 years of a ge wit h T D T w h o d o n ot ha ve a β0/ β [ADDRESS_205860] u d y Desi g n:  T his is a si n gle -ar m, m ultisite, si n gle -d ose, P hase 3 st u d y wit h 2 c o h orts of 
s u bjects wit h T D T w h o d o n ot ha ve a β 0 m utati o n at b ot h  alleles of t he β -gl o bi n 
(H B B ) ge ne (i.e., n o n -β0/ β 0): C o h ort [ADDRESS_205861] 1 5 s u bjects ≥ 1 2 a n d ≤ [ADDRESS_205862] 8 s u bjects < [ADDRESS_205863] u d y will e val uate t he efficac y a n d safet y of a ut ol o g o us he mat o p oietic ste m 
cell ( H S C) tra ns pla ntati o n ( H S C T) usi n g Le nti Gl o bi n B B [ADDRESS_205864] f or 
t he treat me nt of β -t halasse mia (I N N/ U S A N: beti be gl o ge ne a ut ote mcel), a n 
a ut ol o g o us C D 3 4 + cell -e nric he d p o p ulati o n t hat c o ntai ns he mat o p oie tic ste m 
cells tra ns d uce d wit h B B [ADDRESS_205865] or e nc o di n g t he β A- T 8 7 Q -gl o bi n ge ne, 
s us pe n de d i n cr y o preser vati o n s ol uti o n.  
S u bjects ≥ 1 2 a n d ≤ [ADDRESS_205866] 1 0 0 m L/ k g/ year of pac ke d re d bl o o d ce lls ( p R B Cs) i n t he 2 years 
prece di n g e nr oll me nt, or be ma na ge d u n der sta n dar d t halasse mia g ui deli nes (e. g., 
T halasse mia I nter nati o nal Fe derati o n, 2 0 1 4; see A p pe n di x  1 0. 4 ) wit h ≥ 8 
tra nsf usi o ns of p R B Cs per year i n t he 2 years prece di n g e nr oll me nt (s u bjects ≥ 1 2 
years; Rac h mile witz a n d Giar di n a, 2 0 1 1 ). S u bjects < [ADDRESS_205867] 1 0 0  m L/ k g/ year of p R B Cs i n t he [ADDRESS_205868] 
1 0 0  m L/ k g/ year of p R B Cs i n t he 2 years prece di n g e nr oll me nt, s u bjects < [ADDRESS_205869] uri n g pr ocess.  
Treat me nt will pr ocee d i n a sta g gere d fas hi o n. After 2 s u bjects ≥ [ADDRESS_205870] 
i nf usi o n i n C o h ort 1, t he i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C) will 
re vie w t heir safet y data a n d deter mi ne w het her t he st u d y ca n safel y pr ocee d wit h 
t he treat me nt of s u bjects ≥ 5 a n d < [ADDRESS_205871] 2 s u bjects ≥ 5 a n d 
< [ADDRESS_205872] u d y ca n safel y pr ocee d wit h t he treat me nt of s u bjects y o u n ger t ha n 
5 years of a ge. S u bjects < [ADDRESS_205873] a ge 1: Scree ni n g t o deter mi ne eli gi bilit y f or treat me nt   
S u bjects wit h pre vi o usl y k n o w n β 0/ β 0 ge n ot y pes s h o ul d n ot e nter Scree ni n g.   
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 4 F or t he p ur p oses of scree ni n g, t he H B B  m utati o n I V S I -1 1 0 ( G A) will be 
c o nsi dere d e q ui vale nt t o a β 0 m utati o n. S u bjects wit h T D T w h o are d oc u m e nte d 
t o ha ve ot her H B B  ge n ot y pes (i.e., n o n -β0/ β 0) ma y e nter Scree ni n g. H B B  ge n ot y pe 
f or all s u bjects will be c o nfir me d d uri n g Scree ni n g al o n g wit h a d diti o nal 
para meters of eli gi bilit y.  
St a ge 2:  A ut ol o g o us C D 3 4 + cell c ollecti o n, Le nti Gl o bi n B B [ADDRESS_205874] or ( G -C S F; e. g., fil grasti m, le n o grasti m) a n d pleri xaf or. Peri p heral 
bl o o d m o n o n uclear cells ( P B M Cs) f or dr u g pr o d uct ma n ufact ure will be  c ollecte d 
b y a p heresis. A t otal of [ADDRESS_205875]. A p heresis pr o d ucts ca n 
als o be use d f or resc ue cells; alter nati vel y, a b o ne marr o w har vest is als o all o we d 
t o pr oc ure cells f or resc ue.  
St a ge 3: M yel oa blati ve c o n diti o ni n g ( 4 da ys of c o n diti o ni n g f oll o we d b y at leas t 
4 8 h o urs of was h o ut) a n d i nf usi o n of Le nti Gl o bi n B B [ADDRESS_205876] ( Da y 1)  
After t he tra ns d uce d cells are dis p ositi o ne d f or cli nical use, a n d t he s u bject's  
eli gi bilit y has bee n re -c o nfir me d ( b y cli nical la b orat or y tests, p h ysical 
e xa mi nati o n, perf or ma nce stat us, a d verse e ve nt ( A E) re vie w a n d ot her tests base d 
o n i nstit uti o nal re q uire me nts), t he s u bject will u n der g o m yel oa blati ve 
c o n diti o ni n g wit h b us ulfa n.  
After c o m pleti o n of t he [ADDRESS_205877] will be a d mi nistere d 
via i ntra ve n o us (I V) i nf usi o n at a d ose of ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g.  
St a ge 4:  F oll o w -u p, t hr o u g h e n graft me nt a n d u p t o [ADDRESS_205878] is c o nsi dere d 
me dicall y sta ble.  
T he g oal d uri n g t he f oll o w -u p peri o d is t o mai ntai n he m o gl o bi n ( H b) ≥ 9 g/ d L. 
Tra nsf usi o ns s h o ul d be a v oi de d f or H b ≥ 9 g/ d L u nless t he nee d is me dicall y 
j ustifie d (e. g., as a re q uire me nt f or s ur ger y). It is rec o m me n de d t hat s u bjects 
s h o ul d recei ve p R B C tra nsf usi o ns f or H b < 7 g/ d L, a n d f or cli nicall y s y m pt o matic 
a ne mia, irres pecti ve of H b le vel.  
S u bjects will be f oll o we d i n t his pr ot oc ol f or a peri o d of [ADDRESS_205879] i nf usi o n. T hereafter s u bjects will be e x pecte d 
t o e nr oll i n a se parate l o n g -ter m f oll o w -u p pr ot oc ol ( L T F -3 0 3) t hat will assess 
safet y a n d efficac y be y o n d M o nt h [ADDRESS_205880] 
i nf usi o n.  
D at a M o nit ori n g 
C o m mittee:  A n i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C) c o m prise d of me m bers wit h 
a p pr o priate scie ntific a n d me dical e x pertise t o m o nit or t he st u d y will be 
c o n ve ne d.  
T he D M C will be c har ge d wit h re vie w of all safet y data f or t his s t u d y, i ncl u di n g 
A Es, seri o us a d verse e ve nts ( S A Es) a n d rele va nt la b orat or y val ues. T he D M C 
will ha ve t he ri g ht t o rec o m me n d t hat t he S p o ns or st o p t he st u d y at a n y ti me d ue 
t o c o ncer ns f or t he safet y of t he s u bjects.  
C CI 
Pr ot oc ol H G B - [ADDRESS_205881] a n ne d:  A p pr o xi matel y [ADDRESS_205882] be ≥ 1 2 a n d ≤ 5 0 years of a ge (at least [ADDRESS_205883] be ≥ 1 2 a n d 
< 1 8), a n d at least [ADDRESS_205884] be < [ADDRESS_205885] i nf usi o n.  
N o m ore t ha n 7 s u bjects ≥ 1 2 a n d ≤ 5 0 years of a ge a n d 4 s u bjects < 1 2 years of a ge 
w h o are treate d ca n ha ve a β E allele (i.e., a p pr o xi matel y 5 0 % of s u bjects).  
I ncl usi o n Criteri a:  1.  S u bjects ≤ 5 0 years of a ge at t he ti me of c o nse nt or asse nt (as a p plica ble), a n d 
a ble t o pr o vi de writte n c o nse nt (a d ults, or le gal g uar dia ns, as a p plica ble) or 
asse nt (a d olesce nts or c hil dre n). Pe diatric s u bjects ( < 1 2 y ears of a ge) ma y 
o nl y be e nr ol le d at a gi ve n site if a p pr o ve d b y t he rele va nt re g ulat or y 
a ut h orit y. Pr o vi de d t hat t he D M C has a p pr o ve d e nr olli n g s u bjects y o u n ger 
t ha n [ADDRESS_205886] 1 0 0 m L/ k g/ year of p R B Cs i n t he 
2 years prece di n g e nr oll me nt (all s u bjects), or be ma na ge d u n der sta n dar d 
t halasse mia g ui deli nes (e. g., T halasse mia I nter nati o nal Fe derati o n, 2 0 1 4; see 
A p pe n di x  1 0. 4 ) wit h ≥ 8 tra nsf usi o ns of p R B Cs per year i n t he 2 years 
prece di n g e nr oll me nt (s u bjects ≥ 1 2 years; Rac h mile witz a n d Giar di na, 2 0 1 1 ). 
3.  Cli nicall y sta ble, ha ve a Kar n ofs k y perf or ma nce stat us of ≥ 8 0 f or a d ults 
( ≥ 1 6  years of a ge) or a La ns k y perf or ma nce stat us of ≥ 8 0 f or a d olesce n ts or 
c hil dre n ( < 1 6  years of a ge), a n d eli gi ble t o u n der g o H S C T.  
4.  Treate d a n d f oll o we d f or at least t he past 2 years i n a s pecialize d ce nter t hat 
mai ntai ne d detaile d me dical rec or ds o n R B C tra nsf usi o ns (i ncl u di n g v ol u me 
a n d u nits of R B Cs a n d ass ociate d pre -tra nsf usi o n H b val ues, retic ul oc yte 
c o u nts a n d rele va nt bl o o d ba n k details as a vaila ble), i n -patie nt 
h os pi[INVESTIGATOR_1314] o n, a n d ir o n c helati o n hist or y.  
E xcl usi o n Criteri a:  1.  Prese nce of a m utati o n c haracterize d as β 0 o n b ot h H B B  alleles. F or t he 
p ur p ose of scree ni n g, I V S I -1 1 0 ( G A) [ H G V S n o me nclat ure: H B B :c. 9 3 -
2 1 G > A] will be c o nsi dere d e q ui vale nt t o a β 0 m utati o n.  
2.  P ositi ve f or prese nce of h u ma n i m m u n o deficie nc y vir us t y pe 1 ( HI V -1) or 2 
( HI V -2), he patitis B vir us ( H B V), or he pa titis C vir us ( H C V). S y p hilis (ra pi d 
plas ma rea gi n [ R P R]) testi n g is als o re q uire d a n d a p ositi ve test f or s y p hilis is 
e xcl usi o nar y w here ma n date d b y re gi o nal dr u g pr o d uct ma n ufact uri n g 
practices. N ote t hat s u bjects w h o ha ve bee n vacci nate d a gai nst he patit is B 
( he patitis B s urface a nti b o d y -p ositi ve) w h o are ne gati ve f or ot her mar kers of 
pri or he patitis B i nfecti o n (e. g., ne gati ve f or he patitis B c ore a nti b o d y) are 
eli gi ble. S u bjects wit h past e x p os ure t o H B V ( H Bc A b p ositi ve a n d/ or H Be 
A b p ositi ve) are als o  eli gi ble f or t he st u d y pr o vi de d t he y are ne gati ve b y 
assess me nt f or H B V D N A. Als o n ote t hat s u bjects w h o are p ositi ve f or a nti -
he patitis C a nti b o d y are eli gi ble as l o n g as t he y ha ve a ne gati ve H C V viral 
l oa d. W here cli nicall y a n d/ or re gi o nall y i n dicate d, ot her tests ma y be 
perf or me d, i n w hic h case p ositi ve res ults w o ul d e xcl u de t he s u bject fr o m 
partici pati n g: f or e xa m ple, h u ma n T -l y m p h otr o pic vir us -1 ( H T L V -1) or -2 
( H T L V -2), t u berc ul osis, t o x o plas m osis, Tr y pa n os o ma cr uzi, West Nile 
Vir us, or Zi ka Vir us.  
3.  Cli nicall y si g nifica nt a n d acti ve bacterial, viral, f u n gal, or parasitic i nfecti o n 
as deter mi ne d b y t he cli nical i n vesti gat or.  
4.  A w hite bl o o d cell ( W B C) c o u nt < 3 × 1 0 9/ L, a n d/ or platelet c o u nt < 1 0 0 × 1 0 9/ L 
n ot relate d t o h y pers ple nis m.  
5.  U nc orrecte d blee di n g dis o r der.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 6 6.  A n y pri or or c urre nt mali g na nc y ( wit h t he e xce pti o n of a de q uatel y treate d 
c o ne‑ bi o psie d i n sit u carci n o ma of t he cer vi x uteri a n d basal or s q ua m o us cell 
carci n o ma of t he s ki n) or m yel o pr oliferati ve or si g nifica nt i m m u n o deficie nc y 
dis or der.  
7.  I m me diate  fa mil y me m ber (i.e. pare nt or si bli n gs) wit h a k n o w n Fa milial 
Ca ncer S y n dr o me (i ncl u di n g b ut n ot li mite d t o here ditar y breast a n d o varia n 
ca ncer s y n dr o me, here ditar y n o n -p ol y p osis c ol orectal ca ncer s y n dr o me a n d 
fa milial a de n o mat o us p ol y p osis).  
8.  Pri or H S C T.  
9.  A d va nce d li ver disease, defi ne d as:  
a.  Persiste nt as partate tra nsa mi n ase, ala ni ne tra nsa mi nase, or direct 
bilir u bi n val ue > 3 ×  t he u p per li mit of n or mal ( U L N), or  
b.  Baseli ne pr ot hr o m bi n ti me or partial t hr o m b o plasti n ti me > 1. 5 ×  U L N, 
s us pecte d of arisi n g fr o m li ver disease, or  
c.  Ma g netic Res o na nce I m a gi n g ( M RI) of t he li ver de m o nstrati n g clear 
e vi de nce of cirr h osis, or  
d.  M RI fi n di n gs s u g gesti ve of acti ve he patitis, si g nifica nt fi br osis, 
i nc o ncl usi ve e vi de nce of cirr h osis, or li ver ir o n c o nce ntrati o n ≥ 1 5 m g/ g 
re q uire f oll o w -u p li ver bi o ps y i n s u bjects ≥ 1 8 years of a ge. I n s u bjects 
< 1 8 years of a ge, t hese M RI fi n di n gs are e xcl usi o nar y, u nless i n t he 
o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, a li ver bi o ps y c o ul d pr o vi de a d diti o nal data 
t o c o nfir m eli gi bilit y a n d w o ul d be safe t o perf or m. If a li ver bi o ps y is 
perf or me d base d o n M RI fi n di n gs, a n y e vi de nce of cirr h osis, bri d gi n g 
fi br osis, or si g nifica nt acti ve he patitis will be e xcl usi o nar y.  
1 0.  Baseli ne esti mate d gl o mer ular filtrati o n rate < 7 0 m L/ mi n/ 1. 7 3 m 2, as 
deter mi ne d usi n g t he C hr o nic Ki d ne y Disease E pi [INVESTIGATOR_32450] o g y C olla b orati o n 
creati ni ne e q uati o n f or ≥ 1 8 years of a ge, a n d Be dsi de Sc h wartz e q uati o n 
calc ulat or f or < 1 8 years of a ge (see 
htt p:// w w w ki d ne y. or g/ pr ofessi o nals/ k d o qi/ gfr _calc ulat or.cf m).  
1 1.  U nc o ntr olle d seiz ure dis or der.  
1 2.  Diff usi o n ca pacit y of car b o n m o n o xi de ( D Lc o) < 5 0 % of pre dicte d (c orrecte d 
f or H b a n d/ or al ve olar v ol u me, as cli nicall y i n dicate d). If D Lc o ca n n ot be 
assesse d d ue t o a ge or c o g niti o n -relate d restricti o ns, t here m ust be a n or mal 
res pi[INVESTIGATOR_1305] y e xa m, c hest ra di o gra p h wit h o ut p ul m o nar y i nfiltrates, a n d o x y g e n 
sat urati o n b y p ulse o xi metr y > 9 2 % o n r o o m air. I n t he prese nce of cli nicall y 
si g nifica nt a b n or mal fi n di n gs o n c hest ra di o gra p h, cli nicall y si g nifica nt 
a b n or mal fi n di n gs o n t he res pi[INVESTIGATOR_1305] y e xa m, or o x y ge n sat urati o n b y p ulse 
o xi metr y ≤ 9 2 % o n r o o m air, t h e s u bject will be e xcl u de d.  
1 3.  A car diac T 2 * < 1 0 ms b y M RI.  
1 4.  A n y ot her e vi de nce of se vere ir o n o verl oa d t hat, i n t he i n vesti gat or’s o pi [INVESTIGATOR_9384] o n, 
warra nts e xcl usi o n.  
[ADDRESS_205887] i nf usi o n. If 
s u bjects are tr ul y se x uall y a bsti ne nt ( w here tr ue se x ual a bsti ne nce is defi ne d 
C CI 
Pr ot oc ol H G B - [ADDRESS_205888]), n o 
sec o n d met h o d is  re q uire d.  
[ADDRESS_205889] u d y pr oce d ures o utli ne d i n t he pr ot oc ol.  
2 1.  A k n o w n a n d a vaila ble h u ma n le u k oc yte a nti ge n ( H L A) -matc he d fa mil y 
d o n or. If re q uire d b y re gi o nal re g ulat or y a ut h orit y, patie nts wit h a k n o w n a n d 
a vaila ble matc he d u nrelate d d o n or will be e xcl u de d fr o m t he st u d y.  
[ADDRESS_205890] 
P artici p ati o n:  Ti me bet wee n Scree ni n g a n d dr u g pr o d uct i nf usi o n will be varia ble a n d is 
esti mate d ge nerall y t o be bet wee n 3 t o 5 m o nt hs (e. g., u p t o [ADDRESS_205891] i nf usi o n). T hereafter t he s u bject is pla n ne d t o re mai n o n st u d y f or 
a p pr o xi matel y [ADDRESS_205892]‑ dr u g 
pr o d uct i nf usi o n.  
Test Pr o d uct, D ose a n d 
M o de of A d mi ni str ati o n:  Le nti Gl o bi n B B [ADDRESS_205893] is a n a ut ol o g o us C D 3 4 + cell -e nric he d 
p o p ulati o n t hat c o ntai ns he mat o p oietic ste m cells tra ns d uce d wit h B B [ADDRESS_205894] o n Da y  1 
via I V i nf usi o n at a d ose of ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g.  
Effic ac y e n d p oi nts:  Pri m ar y E n d p oi nt  
T he pr o p orti o n of s u bjects w h o meet t he defi niti o n of “tra nsf usi o n i n de pe n de nce” 
( TI). TI is defi ne d as a wei g hte d a vera ge H b ≥ 9 g/ d L wit h o ut a n y p R B C 
tra nsf usi o ns f or a c o nti n u o us peri o d of ≥ [ADDRESS_205895] i nf usi o n.  
Sec o n d ar y E n d p oi nts  
• C haracterizati o n of s u bjects ac hie vi n g TI:  
− Pr o p orti o n of s u bjects w h o meet t he de fi niti o n of TI at 
M o nt h  2 4  
− D urati o n of TI  
− Ti me fr o m dr u g pr o d uct i nf usi o n t o ac hie ve me nt of TI  
− Wei g hte d a vera ge H b d uri n g TI  
• C haracterizati o n of tra nsf usi o n re d ucti o n ( T R):  
− Pr o p orti o n of s u bjects wit h a re d ucti o n i n t he a n n ualize d m L/ k g 
p R B Cs tra nsf use d f r o m [ADDRESS_205896] i nf usi o n 
t hr o u g h M o nt h 2 4 (a p pr o xi matel y a 1 2 -m o nt h peri o d) of at least 
5 0 %, 6 0 %, 7 5 %, 9 0 % or 1 0 0 % c o m pare d t o t he a n n ualize d 
m L/ k g p R B C tra nsf usi o n re q uire me nt d uri n g t he 2 years pri or 
t o e nr oll me nt  
− A n n ualize d n u m ber a n d v ol u me of p R B C tra nsf usi o ns fr o m 
[ADDRESS_205897] i nf usi o n t hr o u g h M o nt h 2 4 
c o m pare d t o t he a n n ualize d n u m ber a n d v ol u me of tra nsf usi o ns 
d uri n g t he 2  years pri or t o e nr oll me nt  
− Ti me fr o m dr u g pr o d uct i nf usi o n t o last p R B C t ra nsf usi o n  
− Ti me fr o m last p R B C tra nsf usi o n t o M o nt h 2 4  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 8 • Wei g hte d a vera ge na dir H b d uri n g t he [ADDRESS_205898] i nf usi o n t hr o u g h M o nt h 2 4  
• U ns u p p orte d t otal H b le vels o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, 
M o nt h 1 2, M o nt h 1 8, a n d M o nt h 2 4  
• U ns u p p orte d t otal H b le vels ≥ 1 0  g/ d L, ≥ 1 1  g/ d L, ≥ 1 2  g/ d L, 
≥ 1 3  g/ d L, ≥ 1 4  g/ d L o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 
1 2, M o nt h 1 8, a n d M o nt h 2 4  
• C haracterizati o n of use of ir o n c helati o n a n d/ or t hera pe utic 
p hle b ot o m y a m o n g all s u bjects:  
− Pr o p orti o n of s u bjects w h o ha ve n ot recei ve d ir o n c helati o n 
t hera p y f or at least [ADDRESS_205899] i nf usi o n  
− Ti me fr o m last ir o n c helati o n use t o last f oll o w -u p  
− Pr o p orti o n of s u bjects usi n g t hera pe utic p hle b ot o m y a n d 
a n n ualize d fre q ue nc y of p hle b ot o m y use per s u bject f oll o wi n g 
dr u g pr o d uct i nf usi o n  
• E val uati o n of t he c ha n ge i n ir o n b ur de n o ver ti me, as meas ure d b y:  
− C ha n ge i n li ver ir o n c o nte nt b y M RI at baseli ne t o M o nt h 1 2 
a n d M o nt h 2 4  
− C ha n ge i n car diac T 2 * o n M RI at baseli ne t o M o nt h 1 2 a n d 
M o nt h  2 4  
− C ha n ge i n ser u m ferriti n at baseli ne t o M o nt h  1 2 a n d M o nt h 2 4  
• E val uati o n of healt h -relate d q ualit y of life ( H R Q o L) o ver ti me 
i ncl u di n g M o nt h 1 2 a n d M o nt h 2 4 as c o m pare d t o baseli ne, usi n g 
t he f oll o wi n g vali date d t o ols:  
− Pe diatrics: Pe diatric Q ualit y of Life I n ve nt or y ( Pe ds Q L; pare nt 
ge neral c ore a n d ge neral c ore)  
− A d olesce nts: Pe ds Q L ( pare nt ge neral c ore a n d ge neral c ore) a n d 
E ur o Q ol -5 D ( Y o ut h versi o n) ( E Q -5 D -Y)  
− A d ults: E ur o Q ol -5 D ( E Q -5 D) F u ncti o nal Asses s me nt of Ca ncer 
T hera p y -B o ne Marr o w Tra ns pla nt ( F A C T -B M T), a n d 
S h ort  F or m‑ 3 6 ( S F -3 6) v [ADDRESS_205900] or at or y E n d p oi nts  
• Assess me nt of gr o wt h a n d p u bert y para meters (a ge a p pr o priate), 
b o ne de nsit y, dia betes, e n d ocri ne e val uati o ns, a n d ne ur oc o g niti ve 
de vel o p me nt ( pe d iatric s u bjects < 1 8 years of a ge)  
• Assess me nt of c ha n ge i n d yser yt hr o p oiesis  
• C orrelati o ns of pre -treat me nt varia bles (e. g., dr u g pr o d uct vect or 
c o p y n u m ber [ V C N]) wit h res p o nse (e. g., peri p heral bl o o d V C N, 
H b A T 8 7 Q ) 
• Meas ures of healt h res o urce utilizati o n (i ncl u di n g c o m pari n g 
a n n ualize d n u m ber of tra nsf usi o ns, n u m ber of h os pi[INVESTIGATOR_1314] o ns, a n d 
n u m ber of da ys h os pi[INVESTIGATOR_18552] d, fr o m [ADDRESS_205901] 
i nf usi o n t hr o u g h M o nt h 2 4 wit h t he a n n ualize d c orres p o n di n g 
para meters d uri n g t he 2 years pri o r t o e nr oll me nt)  
• Le n gt h of i n -patie nt h os pi[INVESTIGATOR_70213] y fr o m i nitiati o n of c o n diti o ni n g t o 
disc har ge  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 1 9 S afet y e n d p oi nts:  Sec o n d ar y E n d p oi nts  
• S uccess a n d ki netics of H S C e n graft me nt  
• I nci de nce of tra ns pla nt -relate d m ortalit y t hr o u g h [ADDRESS_205902] i nf usi o n  
• O verall s ur vi val ( O S)  
• Detecti o n of vect or -deri ve d re plicati o n c o m pete nt le nti vir us ( R C L) 
i n a n y s u bject  
• M o nit ori n g of la b orat or y para meters  
• Fre q ue nc y a n d se verit y of cli nical A Es  
• I nci de nce of ac ute a n d/ or c hr o nic graft -vers u s- h ost disease ( G V H D)  
• T he n u m ber of s u bjects wit h i nserti o nal o nc o ge nesis 
( m yel o d ys plasia, le u ke mia, l y m p h o ma, etc.)  
E x pl or at or y E n d p oi nt  
• T he n u m ber of s u bjects wit h cl o nal pre d o mi na nce  
P h ar m ac o d y n a mic 
e n d p oi nts:  Sec o n d ar y E n d p oi nts  
• βA‑ T 8 7 Q ‑ gl o bi n e x pressi o n o ver ti me i ncl u di n g M o nt h 6, M o nt h 9, 
M o nt h 1 2, M o nt h 1 8, a n d M o nt h 2 4, as meas ure d b y assessi n g t he 
rati o of β A‑ T 8 7 Q ‑ gl o bi n t o all β -li ke -gl o bi ns, a n d α‑ gl o bi n t o all 
β‑li ke‑ gl o bi ns, i n w h ole bl o o d  
− C orrelati o n of β A- T [ADDRESS_205903]‑ dr u g pr o d uct i nf usi o n t o β A- T 8 7 Q -gl o bi n e x pressi o n at later 
ti me p oi nts, as well as cli nical o utc o mes.  
• V C N i n peri p heral bl o o d o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, 
M o nt h [ADDRESS_205904] or at or y E n d p oi nt  
• Relati o ns hi p bet wee n meas ures of m yel oa blati o n a n d 
p har mac o d y na mic a n d cli nical o utc o mes  
A d diti o nall y, e x pl orat or y met h o ds ma y be use d t o e val uate p har mac o d y na mic 
e n d p oi nts.  
St atistic al Met h o ds:  S a m ple size esti m ati o n:  
N o f or mal sa m ple size calc ulati o ns were perf or me d.  
A p pr o xi matel y [ADDRESS_205905] be ≥ 1 2 a n d ≤ 5 0 years of a ge ( C o h ort 1), a n d at 
least [ADDRESS_205906] be < 1 2 years of a ge ( C o h ort 2). T he pr o p ose d s a m ple size i n 
C o h ort [ADDRESS_205907] of < 3 0 % wit h a 
hi g h pr o ba bilit y is of val ue ( de m o nstrati n g wit h 9 7. 5 % c o nfi de nce t hat ≥ 3 0 % of 
s u bjects bec o me TI) a n d a p oi nt esti mate of t he pr o p orti o n of patie nts w h o bec o me  
TI of at least 6 0 % is c o nsi dere d cli nicall y mea ni n gf ul. A m o n g t he pr o p ose d sa m ple 
size of 1 5 treate d s u bjects ≥ 1 2 a n d ≤ 5 0 years of a ge i n C o h ort 1, a p oi nt esti mate 
f or s uccess of 6 0 % ( 9 o ut of 1 5 s u bjects), w o ul d yiel d a l o wer 1 -si de d 9 7. 5 % e xact 
c o nfi de nce b o u n d of 3 2. 3 %, e xcee di n g t he 3 0 % mi ni mal criteri o n. A m o n g t he 
pr o p ose d sa m ple size of 8 treate d s u bjects < 1 2 years of a ge i n C o h ort 2, a p oi nt 
esti mate f or s uccess of 6 2. 5 % ( 5 o ut of 8 s u bjects) w o ul d yiel d a l o wer 1 -si de d 
9 7. 5 % e xact c o nfi de nce b o u n d  of 2 4. 5 %.  
P o p ul ati o ns f or a n al ysis:  
• I nte nt -t o -Treat  (I T T)  p o p ulati o n:  All  s u bjects  w h o  i nitiat e  a n y  st u d y  
pr oce d ures,  be gi n ni n g  wit h  m o bilizati o n  b y  gra n ul oc yte  c ol o n y  
sti m ulati n g fact or ( G -C S F) a n d/ or pleri xaf or  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 2 0 
 • Tra ns pla nt P o p ulati o n ( T P): All s u bjects w h o recei ve Le nti Gl o bi n B B [ADDRESS_205908]  
• S uccessf ul  E n graft me nt  P o p ulati o n  ( S E P):  All  s u bjects  w h o  ha ve  
s uccessf ul ne utr o p hil e n graft me nt after Le nti Gl o bi n B B [ADDRESS_205909] 
i nf usi o n  
T he pri mar y p o p ulati o n f or a nal ysis of safet y will be t he I T T p o p ulati o n. T he 
pri mar y p o p ulati o n f or t he a nal ysis of efficac y, p har mac o d y na mic, a n d tra ns pla nt -
relate d e n d p oi nts will be t he T P. T he S E P will be use d t o pr o vi de s u p p orti ve data 
f or s u bjects w h o e n graft.  
A n al ysis of pri m ar y effic ac y e n d p oi nt:  
S uccess criteria f o r t his st u d y are tar gete d at ac hie ve me nt of TI i n 9 o ut of 1 5 
s u bjects ≥ 1 2 years of a ge a n d 5 o ut of 8 s u bjects < 1 2 years of a ge. A p oi nt -
esti mate of t he pr o p orti o n of s u bjects ac hie vi n g TI, wit h a 2 -si de d 9 5 % CI 
calc ulate d usi n g t he Cl o p per -Pears o n e xact bi n o mial met h o d will be e m pl o ye d.  
A n al ysis of s afet y:  
All A Es will be c ollecte d fr o m si g ni n g of i nf or me d c o nse nt/asse nt t hr o u g h M o nt h 
[ADDRESS_205910]. All A Es  will be liste d a n d descri pti ve statistics 
f or A Es will be s u m marize d f or t he f oll o wi n g ti me peri o ds: 1) fr o m i nf or me d 
c o nse nt/asse nt u p t o t he start of m o bilizati o n; 2) fr o m start of m o bilizati o n u p t o 
start of c o n diti o ni n g; 3) fr o m start of c o n diti o ni n g t hr o u g h ne utr o p hil 
e n graft me nt; 4)  fr o m ne utr o p hil e n graft me nt t hr o u g h M o nt h 2 4 Visit; 5) fr o m 
dr u g pr o d uct i nf usi o n t hr o u g h M o nt h 2 4 Visit; a n d 6) fr o m i nf or me d 
c o nse nt/asse nt t hr o u g h M o nt h 2 4 Visit.  
A d diti o nall y, s ur vi val stat us, la b orat or y res ults a n d i nserti o nal o nc o ge nesis 
(i nserti o nal m uta ge nesis res ulti n g i n o nc o ge nesis) e ve nts will be s u m marize d.  
T he pla n ne d statistical met h o d ol o g y details will be prese nte d i n t he Statistical 
A nal ysis Pla n ( S A P).  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 2 1 
 LI S T O F A B B R E VI A TI O N S  
A b bre vi ati o n  Defi niti o n  
A b  A nti b o d y  
A D L  Acti vities of dail y li vi n g  
A E  A d verse e ve nt  
All o -H S C T  All o ge neic he mat o p oietic ste m cell tra ns pla nt(ati o n)  
A N C  A bs ol ute ne utr o p hil c o u nt  
A U C  Area u n der t he c ur ve  
B F U -E B urst -f or mi n g u nits -er yt hr oi d  
C B C  C o m plete bl o o d c o u nt  
c/ d g  C o pi[INVESTIGATOR_176325] d ge n o me  
C M V  C yt o me gal o vir us  
C R F  Case re p ort f or m  
C T C A E  C o m m o n Ter mi n ol o g y Criteria f or A d verse E ve nts  
D Lc o  Diff usi o n ca pacit y of car b o n m o n o xi de  
D M C  Data M o nit ori n g C o m mittee  
D N A  De o x yri b o n ucleic aci d  
E B V  E pstei n -Barr vir us  
E C  Et hics C o m mittee  
E C G  Electr ocar di o gra m  
e C R F  Electr o nic case re p ort f or m  
E D C  Electr o nic data ca pt ure  
E P O  
E Q -5 D  
E Q -5 D -Y 
F A C T -B M T  Er yt hr o p oieti n  
E ur o Q o L -5 D  
E ur o Q ol -5 D ( Y o ut h versi o n)  
F u ncti o nal Assess me nt of Ca ncer T hera p y -B o ne Marr o w Tra ns pla nt  
F E V [ADDRESS_205911] disease  
H b  He m o gl o bi n  
H b A  
H b E  He m o gl o bi n A  
He m o gl o bi n E  
H B B  β‑ gl o bi n ge ne  
H Bs A b  He patitis B s urface a nti b o d y  
H B V  He patitis B vir us  
Hct  He mat ocrit  
H C V  
H G V S  He patitis C vir us  
H u ma n Ge n o me Variati o n S ociet y  
HI V -[ADDRESS_205912]  Hematopoietic stem cell transplant(ation)  
HSV  Herpes simplex virus  
HTLV -[ADDRESS_205913]  
IS Integration site  
ISA Integration site analysis  
ITT Intent -to-treat population  
IV Intravenous  
KM Kaplan -Meier  
LCR  Locus control region  
LH Luteinizing hormone  
LIC Liver iron concentration  
LVEF  Left ventricular ejection fraction  
MCH  Mean corpuscular hemoglobin  
MCHC  Mean corpuscular hemoglobin concentration  
MCV  Mean corpuscular volume  
MRI  Magnetic resonance imaging  
NK Natural killer  
OS Overall survival  
PBL Peripheral blood leukocyte  
PBMC  Peripheral blood mononuclear cell  
PedsQL  
PFTs  Pediatric Quality of Life Inventory  
Pulmonary function tests  
PK Pharmacokinetic  
PTH  Parathyroid hormone  
pRBC  Packed red blood cell(s)  
q6h Every 6 hours  
qPCR  Quantitative polymerase chain reaction  
RBC  Red blood cell(s)  
RCL  Replication competent lentivirus  
RNA  Ribonucleic acid  
RPR  Rapid plasma reagin  
RV Respi[INVESTIGATOR_176326] H G B - [ADDRESS_205914] Parti ci pati o n ............................................................................... 5 1  
5. 8.  Assess me nt of Treat me nt C o m plia nce  ....................................................................... 5 2  
5. 9.  Pri or a n d C o nc o mita nt Me dicati o ns ........................................................................... 5 2  
5. 9. 1.  Pri or Me dicati o ns ........................................................................................................ 5 2  
5. 9. 2.  C o nc o mita nt Me dicati o ns a n d T hera pi [INVESTIGATOR_014]: Ge neral ..................................................... 5 2  
5. 9. 3.  C o nc o mita nt Me dicati o ns a n d T hera pi [INVESTIGATOR_014]: Tra nsf usi o ns ............................................. 5 3  
5. 9. 4.  C o nc o mita nt Me dicati o ns a n d T hera pi [INVESTIGATOR_014]: Ir o n C h elati o n .......................................... 5 4  
5. 9. 5.  C o nc o mita nt Me dicati o ns: I nf ecti o n S ur veilla nce a n d Pr o p h yla xis .......................... [ADDRESS_205915] or y ........................................................................... 6 3  
6. 2. 1. 1.  Ge n ot y pe ..................................................................................................................... 6 3  
6. 2. 2.  Cli nical/ P h ysical E xa mi nati o n  .................................................................................... [ADDRESS_205916] Res ults ............................................... 6 9  
6. 2. 1 7.  I m m u n ol o gical T esti n g  ............................................................................................... 6 9  
6. 2. 1 8.  Assess me nt of Cl o nal Pre d o mi na nce a n d/ or S us pi[INVESTIGATOR_37180] o n of Mali g na nc y ..................... [ADDRESS_205917] u d y Fi n di n gs a n d Use of I nf or mati o n .................. 8 6  
9.  R E F E R E N C E S  ........................................................................................................... 8 7  
1 0.  A P P E N DI C E S  ............................................................................................................ 9 0  
1 0. 1.  Gl o mer ular Filtrati o n Rate Calc ulati o n  ...................................................................... 9 0  
1 0. 2.  Kar n ofs k y Perf or ma n ce Stat us Scale  .......................................................................... 9 1  
1 0. 3.  La ns k y Perf or m a nce Stat us Scale  ............................................................................... 9 1  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 2 8 
 1 0. 4.  G ui deli nes f or Tr a nsf usi o n V ol u me ........................................................................... 9 2  
I N V E S TI G A T O R S T A T E M E N T  ................................................................................................. 9 3  
 
LI S T O F T A B L E S  
Ta ble  1:  D ose of Le nti Gl o bi n B B [ADDRESS_205918] or Bac k- u p Cells .................................... 3 8  
Ta ble  2:  M o bilizati o n f or S u bjects w h o ha ve a n I ntact S plee n ................................................ 4 7  
Ta ble  3:  M o bilizati o n f or S u bjects w h o d o n ot ha ve a n I ntact S plee n ..................................... 4 7  
Ta ble  4:  Sc he d ule of E ve nts: Scr ee ni n g a n d C D 3 4 + Cell H ar vest ........................................... 5 6  
Ta ble  5:  Sc he d ule of E ve nts: C o n diti o ni n g a n d Dr u g Pr o d uct I nf usi o n .................................. 5 8  
Ta ble  6:  Sc he d ule of E ve nts: F oll o w- u p ................................................................................... 6 0  
Ta ble  7:  A ge -a p pr o priate Vali date d H R Q o L T o ols .................................................................. 6 7  
Ta ble  8:  He mat ol o g y, Ir o n St u dies, Ser u m C he mistr y, a n d Li ver F u n cti o n ............................ [ADDRESS_205919] er n, I n dia n, a n d S o ut h 
Asia n desce nt (C ola h et al., 2 0 1 0 ). It is ca use d b y t he a bse n ce or re d u ce d pr o d ucti o n of t he β -
c hai ns of he m o gl o bi n ( H b) A ( H b A), a heter otetra mer c o m prise d of 2 β -gl o bi n a n d 2 α - gl o bi n 
c hai ns ( α 2β2) t hat acc o u nts f or > 9 5 % of t he H b i n t he bl o o d of a d ults. O ver 2 0 0 m utati o ns i n t he 
ge ne  t hat  e nc o d es  β -gl o bi n ( H B B ) ha ve b ee n i d e ntifie d; t here are t w o H B B  alleles per di pl oi d 
ge n o me.  M utati o ns  t hat  res ult  i n  c o m plet e  a br o gati o n  of  pr o d ucti o n  of  β -gl o bi n  pr ot ei n  
(e. g., n o nse nse m utati o ns) are c ollecti vel y referre d t o as β 0 m utati o ns ( Ca o a n d Gala nell o, 2 0 1 0 ). 
M utati o ns t hat res ult i n re d ucti o n, b ut n ot c o m plete a bse n ce, of pr o d ucti o n of β -gl o bi n pr otei n 
(e. g., affecti n g s plici n g)  are c ollecti vel y ref err e d t o as β + m utati o ns. T her e are s o m e β + m utati o ns 
w hic h  pr o d uce  mi ni mal  β -gl o bi n;  i n  partic ular  t he  I V S  I -1 1 0  G A  m utati o n  ( H G V S  
n o me nclat ure: H B B :c. 9 3 -2 1 G > A)  c o nsiste ntl y  res ults  i n  dra maticall y  re d uce d  β - gl o bi n 
pr o d ucti o n, a n d is  c o m m o nl y gr o u pe d cli nicall y wit h β 0 m utati o ns (B or g na- Pi g natti a n d Gala nell o, 
2 0 0 9 ).  β E is a s p ecific H B B  m utati o n i n t he c o di n g re gi o n of t h e ge n e t hat res ults i n re d u ce d 
pr o d ucti o n  of  β -gl o bi n  beca use  of  alter n ate s plici n g,  as  w ell  as  a si n gle a mi n o  aci d  c h a n ge  
( misse nse m utati o n, gl uta mic aci d t o l ysi ne at  c o d o n 2 6), res ulti n g i n a n electr o p h oreticall y  
disti n g uis ha ble  heter otetra mer,  h e m o gl o bi n  E  ( H b E).  T he  β E m utati o n is c o m m o n i n S o ut heast 
Asia ( 1 5 % t o 3 0 % pr e val e nce of m utati o n i n t he t otal p o p ulati o n) ( Be nz,  2 0 1 5 ).  
A bs e nce or re d ucti o n i n β -gl o bi n pr o d ucti o n res ults i n a n acc u m ulati o n of e xcess u nc o m ple x e d α -
gl o bi n c hai ns i n er yt hr o blasts, w hic h pr eci pi[INVESTIGATOR_047], lea di n g t o pre mat ur e d eat h of t he cells a n d  
i neffecti ve er yt hr o p oiesis t hat ca uses t he a ne mi a c har acteristic of patie nts  wit h  β -t halasse mia 
(Gala nell o a n d Ori g a, 2 0 1 0 ).  T he  cli nical  i m plicati o ns  of  t he  α‑ gl o bi n/ β‑ gl o bi n  i m bala nce  are 
t w of o l d: 1) p atie nts lac k s ufficie nt r e d bl o o d cells ( R B Cs) a n d H b t o effecti vel y tra ns p ort o x y ge n 
t hr o u g h o ut t he b o d y; a n d 2)  ele vate d he m ol ysis ca n lea d t o m or bi dities via s ple n o me gal y, marr o w 
e x pa nsi o n, c o nc o mita nt b o ne def or mities, a n d ir o n o verl oa d. Patie nts w h o are h o m oz y g o us f or 
m utati o ns t hat are β 0 (i.e., β0/ β 0 ge n ot y pe) pr o d uce n o β -gl o bi n, a n d he nce us uall y cli nicall y prese nt 
wit h  se vere  tr a nsf usi o n -de pe n de nt  β -t halass e mia  ( T D T),  als o  calle d  β -t halasse mia  maj or.  I n  
c o ntrast, patie nts w h o are h o m oz y g o us f or β + allel es, or ar e c o m p o u n d heter oz y g o us f or β 0, β +, or 
βE (i.e., β 0/ β +, β 0/ β E, β +/ β E ge n ot y pes) ge n erall y pr o d uce s o me e n d o ge n o us β -gl o bi n, a n d ma y h a ve 
a s pectr u m of cli nical se v erit y, ra n gi n g fr o m se v er e T D T t o mil der f or ms of t halasse mia.  
C hr o nic bl o o d tra nsf usi o n re gi me ns are hi g hl y eff ecti ve at pre v e nti n g t he hall mar k s y m pt o ms of 
disease, b ut i ntr o d u ce a l ar ge ir o n o verl oa d (Ca o et al., 1 9 9 6 ) t hat o v er ti m e ca n lea d t o m ortalit y 
t hr o u g h ir o n ass o ciate d h eart a n d li ver t o xicit y ( Vic hi ns k y et al., 2 0 0 5a; Vi c hi ns k y et al., 2 0 0 5 b ) 
a n d m ust be ma na ge d usi n g ir o n c helati o n re gi m e ns ( Ca p pelli ni et al., 2 0 0 6 ). P o or c o m plia nce 
wit h c helati o n re gi me ns r e mai ns a ke y c halle n ge, a n d e ve n wit h c urre nt t her a pi[INVESTIGATOR_014], o verall s ur vi v al 
u ntil t he a ge of 3 0 y ears is o nl y 5 5 % f or patie nts wit h se vere T D T ( M o d ell et al. 2 0 0 0; Delea et 
al. 2 0 0 7) .  
All o ge neic he m at o p oieti c ste m cell tra ns pla nt (all o -H S C T) is c urre ntl y t he o nl y a vaila ble c urati ve 
treat me nt f or patie nts wit h T D T. H o we ver, beca use of t he si g nifica nt ris k of tra ns pla nt -relat e d 
m ortalit y, graft - vers us- h ost disease ( G V H D), a n d graft r ejecti o n wit h all o‑ H S C T, tra ns pla nts are 
i nfre q ue ntl y perf or me d, a n d are offere d pri maril y t o patie nts wit h  a vaila ble h u ma n le u k oc yte 
a nti ge n ( H L A)- matc h e d si bli n g d o n ors ( < 2 5 % of cases).  
C CI 
Pr ot oc ol H G B - [ADDRESS_205920] f or t he treat me nt of β -t halasse mia (I N N/ U S A N: beti be gl o ge ne a ut ote mcel ) 
i n s u bjects wit h T D T.  
T he B B [ADDRESS_205921] or e nc o des a si n gle a mi n o aci d varia nt of β -gl o bi n, β A‑ T 8 7 Q ‑ gl o bi n, w hic h 
c o nser ves t he pr otei n’s f u ncti o n w hile all o wi n g f or q ua ntificati o n relati ve t o ot her gl o bi n s pecies. 
E x pressi o n of β A‑ T 8 7 Q ‑ gl o bi n is dri ve n b y t h e er yt hr oi d li nea ge s p ecific gl o bi n l oc us c o ntr ol re gi o n 
( L C R) t o c o rrect t he β -gl o bi n/ α - gl o bi n i m bala nce i n er yt hr oc ytes. Treat me nt of t he s u bject’s o w n 
H S Cs wit h t he B B [ADDRESS_205922] u d y H G B- 2 0 7. Ei g ht s u bje cts wer e <  1 2 
years of a ge, 6 s u bjects w ere ≥  1 2 t o <  1 8 y ears of a ge, a n d 9 s u bjects wer e ≥  [ADDRESS_205923] u d y are pr o vi de d i n t he I n v esti gat or's Br oc h ure f or L e nti Gl o bi n 
B B [ADDRESS_205924]  is  c o nsiste nt  wit h  m yel oa blati ve  
c o n diti o ni n g use d f or a ut ol o g o us tra ns pla ntati o n (see I n vesti gat or’s Br oc h ure).  
Ta ke n t o get her, t hese dat a de m o nstrate t he p ot e ntial of treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205925] u d y O bjecti ves  
Pri m ar y:  e val u ate t he efficac y of treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205926] i n s u bjects 
≤ 5 0 years of a ge wit h T D T w h o d o n ot ha ve a β0/ β 0 ge n ot y pe at t he H B B  ge ne 
CC CI 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 1 
 Sec o n d ar y: e val uate t h e safet y of treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205927] i n s u bjects 
≤ 5 0 years of a ge wit h T D T w h o d o n ot ha ve a β0/ β [ADDRESS_205928] u d y E n d p oi nts  
2. 2. 1.  Effic ac y E n d p oi nts  
Pri m ar y E n d p oi nt  
T he pr o p orti o n of s u bj ects w h o meet t he defi niti o n of “tra nsf usi o n i n d e pe n de nce” ( TI). TI is 
defi ne d as a wei g hte d a v era ge H b ≥ 9  g/ d L wit h o ut a n y p R B C tra nsf usi o ns f or a c o nti n u o us peri o d 
of ≥ [ADDRESS_205929] i nf usi o n.  
Sec o n d ar y E n d p oi nts  
• C haracterizati o n of s u bjects ac hie vi n g TI:  
− Pr o p orti o n of s u bjects w h o meet t he defi niti o n of TI at M o nt h 2 4 
− D urati o n of TI 
− Ti me fr o m dr u g pr o d uct i nf usi o n t o ac hie ve me nt of TI 
− Wei g hte d a v era g e H b d uri n g TI  
• C haracterizati o n of tr a nsf usi o n re d ucti o n ( T R): 
− Pr o p orti o n of s u bjects wit h a re d u cti o n i n t he a n n u alize d m L/ k g p R B Cs tra nsf use d 
fr o m [ADDRESS_205930] i nf usi o n t hr o u g h M o nt h 2 4 (a p pr o xi matel y a 1 2 -
m o nt h peri o d) of at least 5 0 %, 6 0 %, 7 5 %, 9 0 % or 1 0 0 % c o m par e d t o t he a n n ualize d 
m L/ k g p R B C tra nsf usi o n re q uire me nt d uri n g t he 2 years pri or t o e nr oll me nt 
− A n n ualize d n u m ber a n d v ol u me of p R B C tra nsf usi o ns fr o m [ADDRESS_205931]  i nf usi o n  t hr o u g h  M o nt h  2 4  c o m pare d  t o  t he  a n n ualize d  n u m b er  a n d  
v ol u me of tra nsf usi o ns d uri n g t he 2 years pri or t o e nr oll me nt 
− Ti me fr o m dr u g pr o d uct i nf usi o n t o last p R B C tra nsf usi o n 
− Ti me fr o m last p R B C tra nsf usi o n t o M o nt h 2 4  
• Wei g hte d  a v era g e  na dir  H b  d uri n g  t he  [ADDRESS_205932]  i nf usi o n  t hr o u g h  
M o nt h 2 4 
• U ns u p p orte d t otal H b le v els o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 1 2, M o nt h 
1 8, a n d M o nt h 2 4 
• U ns u p p orte d t otal H b le vels ≥ 1 0  g/ d L, ≥ 1 1  g/ d L, ≥ 1 2  g/ d L, ≥ 1 3  g/ d L, ≥ 1 4  g/ d L o ver 
ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 1 2, M o nt h 1 8, a n d M o nt h 2 4 
• C haracterizati o n of use of ir o n c h elati o n a n d/ or t hera pe utic p hle b ot o m y a m o n g all 
s u bjects:  
− Pr o p orti o n of s u bjects w h o ha ve n ot recei ve d ir o n c helati o n t hera p y f or at least [ADDRESS_205933] i nf usi o n 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 2 
 − Ti me fr o m last ir o n c helati o n use t o last f oll o w - u p 
− Pr o p orti o n of s u bjects usi n g t hera pe utic p hle b ot o m y a n d a n n ualize d fr e q u e nc y of 
p hle b ot o m y use per s u bject f oll o wi n g dr u g pr o d u ct i nf usi o n 
• E val uati o n of t he c h a n ge i n ir o n b ur de n o ver ti me, as meas ure d b y:  
− C ha n ge i n li ver ir o n c o nt e n t b y ma g netic res o na n ce i ma gi n g ( M RI) at b as eli ne t o 
M o nt h 1 2 a n d M o nt h 2 4 
− C ha n ge i n car di ac T 2 * o n M RI at b aseli ne t o M o nt h 1 2 a n d M o nt h 2 4 
− C ha n ge i n ser u m ferriti n at baseli ne t o M o nt h 1 2 a n d M o nt h 2 4 
• E val uati o n of h ealt h -r elat e d q ualit y of life ( H R Q o L) o ver ti me i ncl u di n g M o nt h 1 2 a n d 
M o nt h 2 4 as c o m pare d t o baseli ne, usi n g t he f oll o wi n g vali date d t o ols: 
− Pe diatrics: Pe diatric Q ualit y of Life I n ve nt or y ( P e ds Q L; pare nt ge ner al c ore a n d 
ge neral c ore)  
− A d olesce nts:  Pe ds Q L  ( p are nt  ge n eral  c ore  a n d  ge neral  c or e)  a n d  E ur o Q ol -5 D 
( Y o ut h versi o n) ( E Q - 5 D- Y)  
− A d ults: E ur o Q ol -5 D ( E Q -5 D), F u ncti o nal Ass ess me nt of Ca ncer T hera p y - B o ne 
Marr o w Tra ns pla nt ( F A C T- B M T), a n d S h ort F or m- 3 6 ( S F- 3 6) v 2  
2. 2. 2.  S afet y E n d p oi nts  
Sec o n d ar y E n d p oi nts  
• S uccess a n d ki netics of H S C e n graft me nt  
• I n ci de nce  of  tra ns pla nt -relate d  m ortalit y  t hr o u g h  [ADDRESS_205934] i nf usi o n 
• O verall s ur vi val ( O S) 
• Detecti o n of vect or- d eri v e d re plicati o n c o m p ete nt le nti vir us ( R C L) i n a n y s u bject 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 3 
 • M o nit ori n g of la b orat or y para mete rs  
• Fre q u e nc y a n d se verit y of cli nical A Es  
• I n ci de nce of ac ute a n d/ or c hr o nic gr aft- vers us- h ost disease ( G V H D)  
• T he  n u m ber  of  s u bjects  wit h  i nserti o nal  o nc o ge nesis  ( m yel o d ys plasia,  le u ke mia,  
l y m p h o ma, etc.)  
E x pl or at or y E n d p oi nt 
• T he n u m ber of s u bjects wit h cl o nal pre d o mi na nce (see Secti o n  6. 2. 1 8  f or descri pti o n 
of criteria f or cl o n al pre d o mi na nce a n d cli nical w or k - u p of mali g na nc y)  
2. 2. 3.  P h ar m ac o d y n a mic E n d p oi nts 
Sec o n d ar y E n d p oi nts  
• βA‑ T 8 7 Q ‑ gl o bi n e x pressi o n o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 1 2, M o nt h  1 8, 
a n d M o nt h 2 4, as meas ure d b y assessi n g t he rati o of β A‑ T 8 7 Q ‑ gl o bi n t o all β -li ke - gl o bi ns, 
a n d α‑ gl o bi n t o all β‑li ke‑ g l o bi ns, i n w h ole bl o o d 
− C orrelati o n  of  β A- T [ADDRESS_205935] 
i nf usi o n  t o  β A- T 8 7 Q -gl o bi n  e x pressi o n  at  later  ti me  p oi nts,  as  well  as  cli nical  
o utc o mes. 
• V C N i n peri p h eral bl o o d o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h [ADDRESS_205936] or at or y E n d p oi nt 
• Relati o ns hi p bet wee n meas ures of m yel oa bl ati o n a n d p har mac o d y na mics a n d cli nical 
o utc o mes 
A d diti o nall y, e x pl orat or y met h o ds ma y be use d t o e val uate p h ar mac o d y n a mic e n d p oi nts. 
  
C CI 
Pr ot oc ol H G B - [ADDRESS_205937] u d y wit h 2 c o h orts of s u bjects wit h T D T 
w h o d o n ot ha ve a β 0 m utati o n at b ot h alleles of t he β - gl o bi n  (H B B ) ge ne  (i.e., n o n -β0/ β 0):  C o h ort [ADDRESS_205938] 1 5 s u bjects ≥ 1 2 a n d ≤ [ADDRESS_205939] 8  s u bjects 
< [ADDRESS_205940] u d y will e val uate t he efficac y a n d safet y of a ut ol o g o us he mat o p oietic ste m cell ( H S C) 
tra ns pla ntati o n  ( H S C T)  usi n g  Le nti Gl o bi n  B B [ADDRESS_205941],  a n  a ut ol o g o us  C D 3 4 +  
cell‑e nri c he d p o p ulati o n t hat c o ntai ns he mat o p oietic ste m cells tr a ns d uce d wit h B B [ADDRESS_205942] or e n c o di n g t he β A- T 8 7 Q - gl o bi n ge ne, s us pe n de d i n cr y o preser vati o n s ol uti o n. 
S u bjects  ≥ 1 2  a n d  ≤ [ADDRESS_205943] 
1 0 0 m L/ k g/ year of p R B Cs i n t he 2 y ears prece di n g e nr oll me nt, or  be m a na ge d u n der sta n dar d 
t halasse mia g ui deli nes (e. g., T halasse mia I nter nati o nal Fe derati o n, 2 0 1 4; see A p pe n di x 1 0. 4 ) wit h 
≥ 8  tra nsf usi o ns  of  p R B Cs  per  year  i n  t he  2  years  prece di n g  e nr oll me nt  (s u bjects  ≥ 1 2  years; 
Rac h mile witz a n d Giar di n a, 2 0 1 1 ). S u bjects < [ADDRESS_205944] 1 0 0  m L/ k g/ year of p R B Cs i n t he [ADDRESS_205945] 1 0 0  m L/ k g/ year of p R B Cs i n t he 2 years prece di n g e nr oll me nt, 
s u bjects < [ADDRESS_205946] uri n g pr o cess.  
Treat me nt will pr ocee d i n a sta g g ere d fas hi o n. After 2 s u bjects ≥ [ADDRESS_205947]  i nf usi o n  i n  C o h ort  1,  t he  
i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C) will re vie w t heir safet y data a n d deter mi ne 
w het her t he st u d y ca n saf el y pr ocee d wit h t he treat me nt of s u bjects ≥ 5 a n d < [ADDRESS_205948] 2 s u bjects ≥ 5 a n d < [ADDRESS_205949] u d y ca n safel y pr o cee d wit h t he treat me nt of s u bjects y o u n ger t h a n 5 years of a ge. S u bjects < [ADDRESS_205950] a ge 1: Scree ni n g t o deter mi ne eli gi bilit y f or treat me nt  
S u bjects wit h pre vi o usl y k n o w n β 0/ β 0 ge n ot y pes s h o ul d n ot e nter Scree ni n g.   
F or t he p ur p oses of s cree ni n g, t he H B B  m utati o n I V S I -1 1 0 ( G A) will be c o nsi dere d e q ui v ale nt 
t o a β 0 m utati o n. S u bjects wit h T D T w h o are d oc u me nte d t o ha ve ot her H B B  ge n ot y pes (i.e., 
n o n- β0/ β 0) ma y e nter Scree ni n g. T h e H B B  g e n ot y pe f or all s u bj ects will be c o nfir me d d uri n g 
Scree ni n g al o n g wit h a d diti o nal para meters of eli gi bilit y.  
St a ge 2:  A ut ol o g o us C D 3 4 + cell c ollecti o n, Le nti Gl o bi n B B [ADDRESS_205951] or ( G -C S F; 
e. g., fil grasti m, le n o grasti m) a n d pleri xaf or. Peri p heral bl o o d m o n o n uclear cells ( P B M Cs) will be 
c ollecte d b y a p her esis.  A t otal of [ADDRESS_205952]. A p h eresis pr o d ucts ca n als o be use d f or res c ue cells; alter nati vel y, a b o ne marr o w 
har vest is als o all o we d t o pr oc ure cells f or resc u e.  
St a ge 3: M yel oa blati ve c o n diti o ni n g ( [ADDRESS_205953] 4 8 h o urs of 
was h o ut) a n d i nf usi o n of Le nti Gl o bi n B B [ADDRESS_205954] ( Da y 1)  
After t he tra ns d uce d cells are dis p ositi o ne d f or cli nical use, a n d t he s u bject's eli gi bilit y has bee n 
re -c o nfir me d ( b y cli nical la b orat or y tests, p h ysical e xa mi nati o n, perf or ma nce stat us, A E r e vie w 
a n d ot her  tests  base d  o n  i nstit uti o nal  re q uire me nts),  t he  s u bject  will  u n der g o  m yel oa bl ati ve  
c o n diti o ni n g wit h b us ulfa n.  
After c o m pleti o n of t he [ADDRESS_205955] will be a d mi nistere d via i ntra ve n o us 
(I V) i nf usi o n at a d ose of ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g.  
St a ge 4:  F oll o w- u p, t hr o u g h e n graft me nt a n d u p t o [ADDRESS_205956] is c o nsi dere d me dicall y sta ble. 
T he g oal d uri n g t he f oll o w -u p peri o d is t o  mai ntai n H b ≥ 9 g/ d L. Tra nsf usi o ns s h o ul d be a v oi d e d 
f or H b ≥ 9 g/ d L u nless t he nee d is me dicall y j ustifie d (e. g., as a pre -re q uire me nt f or s ur ger y). It is 
rec o m me n de d t hat s u bjects s h o ul d recei ve R B C tra nsf usi o ns f or H b < 7 g/ d L, a n d f or cli nicall y 
s y m pt o ma tic a ne mia, irres pecti ve of H b le v el.  
S u bjects will be f oll o we d i n t his pr ot oc ol f or a peri o d of [ADDRESS_205957] i nf usi o n. T her eafter s u bjects will be e x pecte d t o e nr oll i n a se parat e l o n g‑ter m f oll o w‑ u p 
pr ot oc ol ( L T F -3 0 3) t hat will assess safet y a n d efficac y be y o n d M o nt h [ADDRESS_205958].  
3. 2.  D at a M o nit ori n g C o m mittee  
A n i n de pe n de nt Data M o nit ori n g C o m mittee ( D M C) c o m prise d of me m bers wit h a p pr o priate 
scie ntific a n d me di cal e x pertise t o m o nit or t he st u d y will be c o n ve n e d bef ore t he first patie nt is 
m o bilize d. A c harter d escri bi n g t he c o m p ositi o n a n d c o n d uct of t h e D M C will be iss ue d a n d a gree d 
t o b y all D M C me m bers pri or t o t he D M C’s i nitial safet y re vie w meeti n g.  
T he D M C will b e c h ar g e d wit h r e vie w of all saf et y data f or t his st u d y, i ncl u di n g A Es, seri o us 
a d verse e v e nts ( S A Es) a n d rele v a nt la b or at or y v al ues. I n a d diti o n, t he D M C will be c har g e d wit h 
re vie w of saf et y data t o d eter mi ne w h et her t he st u d y ca n safel y pr ocee d wit h treat me nt of s u bjects 
< 1 2 years a n d < 5 y ears of a ge (ref er t o Secti o n  3. 1 ).  
C CI 
Pr ot oc ol H G B - [ADDRESS_205959] u d y at a n y ti me d ue t o c o ncer ns f or t he 
safet y of t he s u bjects ( R efer t o Secti o n 3. 5. 2  f or t he e nr oll me nt s us pe nsi o n criteria), h o w e ver all 
fi nal decisi o ns re g ar di n g st u d y c o n d uct re mai n wit h t he S p o ns or. 
3. 3.  R ati o n ale f or t he St u d y Desi g n  
T D T re q uires lifel o n g treat me nt wit h c hr o nic bl o o d tra nsf usi o ns a n d d oes n ot s p o nta ne o usl y 
res ol ve. S uccessf ul treat me nt i n c hil d h o o d has t h e p ote ntial t o pr e ve nt m or bi dities ge nerall y s ee n 
later i n life. T he dia g n osis of T D T is fre q u e ntl y ma de i n t he first year of lif e w he n i nfa nts b ec o me 
s y m pt o matic, b ut re gar dl ess of w h e n t he dia g n osis is ma de, eac h s u bject s h o ul d e nter t his st u d y 
wit h a sta ble pr ofile of tra nsf usi o n de p e n de nc y. F oll o wi n g treat me nt wit h Le nti Gl o bi n B B [ADDRESS_205960]’s  o w n  pr e -treat me nt  tra nsf usi o n  pr ofile.  
T heref ore,  bec o mi n g  tra nsf usi o n  i n de pe n de nt  ( pri mar y  efficac y  e n d p oi nt),  or  e x perie nci n g  a  
si g nifica nt re d u cti o n i n t he v ol u me of tra nsf usi o ns (sec o n d ar y effi cac y e n d p oi nt),  is e x pecte d t o 
re pres e nt t he m ost cli nicall y mea ni n gf ul e ve nt i n patie nts wit h T D T. B ot h TI a n d si g nifica nt T R 
are li kel y t o res ult i n m ulti ple cli nical be nefits f or patie nts, i ncl u di n g m ost salie nt l y, l o n g -ter m 
re d ucti o n of ir o n b ur de n, as well as r e d uce d e x p os ure t o p ote ntial c o m plicati o ns of tra nsf usi o n 
t hera p y ( e. g. tra nsf usi o n reacti o ns, all o-i m m u nizati o n, i nfecti o n wit h bl o o d b or ne pat h o ge ns).  
Data fr o m P hase 1/ 2 St u dies H G B -2 0 4 a n d H G B -2 0 5 s u g geste d t hat s u bjects wit h T D T w h o  wer e 
n ot h o m oz y g o us f or β 0 alleles (i.e., h a d n o n -β0/ β 0 ge n ot y pes) w ere m ost li kel y t o ac hi e ve TI  aft er 
e n graft me nt. T h us, t he c urre nt pr ot oc ol, w hic h h as a pri mar y e n d p oi nt of TI, will o nl y e nr oll 
s u bjects w h o d o n ot h a v e  a β 0/ β 0 ge n ot y pe. T his ma y i ncl u de s u bjects wit h ge n ot y pes of β 0/ β +, 
β0/ β E, β +/ β +, a n d β +/ β E. Fr o m a p h ysi ol o gic pers pecti ve, s u bjects wit h at least o ne β + or β E allele 
pr o d uce s o me e n d o ge n o us β -gl o bi n, w hic h alt h o u g h b y itself is i ns ufficie nt t o s ustai n life, w he n 
s u p ple me nte d b y tra ns d uce d  ma y be s ufficie nt t o ac hi e ve TI. I n c o ntrast, tra ns d uce d 
 le vels  ac hie ve d  i n  St u dies  H G B -2 0 4  a n d  H G B -2 0 5  w ere  pre dicte d  t o  re d u ce  t he  
re q uire me nt  f or tra nsf us e d bl o o d i n patie nts  w h o d o n ot  pr o d uce a n y o f  t heir  o w n  β - gl o bi n 
(i.e., β0/ β 0), b ut ma y n ot s ustai n TI. Si milar t o β 0 alleles, t he β + allele I V S -I- 1 1 0 ( G A) is wi del y 
rec o g nize d as pr o d uci n g little t o n o β - gl o bi n ( B or g na- Pi g natti a n d Gala nell o, 2 0 0 9 ), t h us s u bjects 
wit h  β 0/I V S -I- 1 1 0 or I V S -I- 1 1 0/I V S-I- 1 1 0  ge n ot y pes  wer e  gr o u p e d  wit h  t he  β 0/ β [ADDRESS_205961] u die d f or e x pressi o n of β -gl o bi n a n d t heir cate g oriz ati o n i nt o β 0 or 
β+ m utati o ns ha ve bee n catal o g ue d i n m ulti ple c orr o b orati ve s o ur ces, s uc h as: 
• A Syll a b us of H u m a n He m o gl o bi n V ari a nts  ( H uis ma n et al., 1 9 9 6 ) 
• A Syll a b us of T h al asse mi a M ut ati o ns  ( H uis ma n et al., 1 9 9 7 ) 
• Cre ati n g a n I nter net -B ase d D at a b ase of Bet a T h al asse mi a M ut ati o ns , Sa n J ose State 
U ni versit y Master’s T h esis, Sc h olar W or ks. ( G e or ge, 2 0 0 8 ) 
T he  o n -li ne  catal o g u e  w hic h  will  be  utilize d  f or  t his  st u d y  is  t he  gl o bi n  ge ne  s er ver  
htt p:// gl o bi n. b x. ps u.e d u/  ( Har dis o n et al., 2 0 0 1 ). 
C CI C CI 
C CI 
Pr ot oc ol H G B - [ADDRESS_205962]’s p retreat me nt sta ble tra nsf usi o n pr ofile is t he m ost s uita ble c o m parat or f or 
cli nical i m pr o ve me nt after treat me nt, a n d beca us e meas uri n g  i n peri p her al bl o o d all o ws 
direc t  e val u ati o n  of  pr otei n  e x pressi o n  a n d  p ot e ntial  c orrel ati o n  wit h  cli nical  o utc o me,  n o  
u ntreate d c o ntr ol gr o u p is i ncl u de d i n t his st u d y. F urt her m ore, beca use of t he p ote ntial t o xicit y of 
b us ulfa n, it w o ul d n ot be et hical t o i ncl u de a c o ntr ol gr o u p t hat d oes n ot recei ve Le nti Gl o bi n 
B B [ADDRESS_205963] 2 0 1 6, a t otal of 2 2  s u bjects 
wit h T D T a g e d bet w ee n 1 2 a n d 3 5 y ears (i ncl u di n g 5 a d oles ce nts of 1 2, 1 6, 1 6, 1 6,  a n d 1 7 years 
of a ge) ha ve bee n i nf use d wit h Le nti Gl o bi n B B [ADDRESS_205964] 
relate d a d v erse e v e nts ( A Es), or dr u g pr o d uct- r elat e d A Es greater t ha n Gra d e 1. All s u bjects ha ve 
e n graft e d a n d e x pr ess  wit h varia ble re d u cti o n i n tra nsf usi o n -re q uire me nts a n d/ or TI. I n 
a d diti o n, it is i m p orta nt t o st u d y pe diatric s u bjects beca use p atie nts tra ns pla nte d at y o u n ger a g es 
bef ore  a d va n ce d  disease  s y m pt o ms  of  t halasse mia  are  ma nifeste d  are  h y p ot hesize d  t o  ha v e  
differe nt  rat es  of  tra ns pla nt -relate d  c o m plicati o ns,  differ e nt  l o n g -ter m  disease  o utc o m es,  a n d  
p ote ntiall y differe nt efficac y of ge n e tra ns d u cti o n t ha n a d ult patie nts. 
I n St u d y H G B -2 0 7, tr eat me nt of s u bjects y o u n ger t ha n 1 2 will be perf or m e d i n a sta g gere d fas hi o n 
wit h safet y m o nit ori n g.  
T he s h ort -ter m ris ks ass ociate d wit h m yel oa blati o n are li kel y of a lesser ma g nit u de i n pe diatric 
s u bjects as o p p ose d t o a d ults d ue t o t heir b etter or ga n f u ncti o ns a n d l o wer ir o n o verl oa d, a n d are 
als o  li kel y  t o  be  of  a  lesser  ma g nit u de  t ha n  t he  o ver all  ris ks  ass o ciate d  wit h  all o ge n eic  
tra ns pla ntati o n, w hic h is re g ularl y offer e d t o c hil dre n wit h T D T i n t his a ge gr o u p ( < 1 2 years of 
a ge) wit h a n H L A - matc h e d si bli n g d o n or. All o ge neic b o ne marr o w tra ns pla nt ( B M T) is c urre ntl y 
rec o m me n de d i n y o u n g c hil dre n bef or e t he de vel o p me nt of ir o n o verl oa d a n d ir o n relate d tiss ue 
da ma ge (A n gel u cci  a n d  Bar o ncia ni, 2 0 0 8 ).  Tra ns pla nt  relate d  m ortalit y ass ociate d wit h b ot h 
all o ge neic  a n d  a ut ol o g o us  B M T  is  l o wer  i n  y o u n ger  patie nts  d ue  t o  better  t olera nce  of  
m yel oa blati ve treat me nts (Ca h n et al., 1 9 9 5; Keati n g et al., 1 9 9 6 ).  
3. 4.  R ati o n ale f or D ose of St u d y Dr u g  
Le nti Gl o bi n B B [ADDRESS_205965] is a n a ut ol o g o us C D 3 4 + cell -e nric h e d p o p ulati o n t hat c o ntai ns 
he mat o p oietic  ste m  cells  tra ns d uce d  wit h  B B [ADDRESS_205966] or  e nc o di n g  t he  β A‑ T [ADDRESS_205967] is a d mi nistere d 
via I V i nf usi o n.  
T he  d ose  of  C D 3 4 +  cells  t o  be  a d mi nistere d  is  base d  o n  acce pte d  saf e  practice  t o  ac hie v e  
he mat o p oietic  r ec o nstit uti o n  wit h  l o n g‑ter m  e n graft me nt  after  a ut ol o g o us  tra ns pla ntati o n.  T h e 
mi ni m u m C D 3 4 + d ose ass ociate d wit h fa v ora ble e n graft me nt ki netics is a p pr o xi matel y 1. 5 × 1 0 6 t o 
3. 0 × 1 0 6 cells/ k g ( Be n der et al., 1 9 9 2; Jillella a n d Ust u n, 2 0 0 4; Mi ya m ot o et al., 2 0 0 4; Per ez - Si m o n 
et al., 1 9 9 8 ). Cli nical data fr o m o n g oi n g trials utilizi n g Le nti Gl o bi n B B [ADDRESS_205968] or -tr a ns d uce d cells ma y be ac hie ve d wit h 
C CI C CI 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 8 
 sli g htl y hi g her cell d oses, i.e., ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g.  It is als o n ota ble t hat i n ge neral t he 
har vest of C D 3 4 + cells fr o m a p her esis yiel ds m uc h hi g her n u m bers ( u p t o 2 1 -f ol d hi g her) of 
C D 3 4 + cells t ha n are o bt ai ne d fr o m a b o ne m arr o w pr oce d ure ( Be y er et al., 1 9 9 5; Mi ya m ot o et 
al., 2 0 0 4; Perez- Si m o n et al., 1 9 9 8; T o et al., 1 9 9 2 ). Gi ve n t hes e data, Ta bl e  [ADDRESS_205969] cells, usa g e, a n d mi ni mal d ose t o be a d mi nistere d.  
T a ble 1:  D ose of Le nti Gl o bi n B B [ADDRESS_205970] ( o btai ne d b y a p heresis)   ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g a 
Bac k -u p Cells ( o btai ne d b y a p heresis; f or resc ue)  ≥ 1. 5 × 1 0 6 C D 3 4 + cells/ k g  
Bac k -u p Cells ( o btai ne d b y b o ne marr o w har vest; f or 
resc ue)   > 1. 0 × 1 0 8 T N C/ k g  
T N C, t otal n ucleate d cells  
a   N ote t hat t his d ose re prese nts t he cell c o u nt after tra ns d ucti o n. If m ore t ha n [ADDRESS_205971] meet t his criteri o n.  
3. 5.  Tre at me nt Disc o nti n u ati o n a n d E nr oll me nt S us pe nsi o n C riteri a  
See Secti o n 4. 5  f or “s u bj ect wit h dra w al fr o m t he st u d y”. 
3. 5. 1.  St o p pi n g R ules f or B us ulf a n  
O nce m yel oa blati o n wit h b us ulfa n has be g u n, t here ar e n o st o p pi n g r ules f or b us ulfa n. I n t he 
a ntici pate d ver y r are e v e nt of c o nse nt wit h dra wal d uri n g c o n diti o ni n g or t he de vel o p me nt of a ne w 
me dical  c o n diti o n t hat, i n t he i n vesti gat or’s  o pi [INVESTIGATOR_9384] o n, p uts  t he s u bject  at  ris k wit h c o nti n ue d  
b us ulfa n treat me nt, t he Me dical M o nit or s h o ul d be c o ntacte d i m me diatel y. I n s uc h sit uati o ns i n 
w hic h b us ulfa n c o n diti o ni n g has n ot bee n c o m plete d per pr ot oc ol, L e nti Gl o bi n B B [ADDRESS_205972] o p p e d at a n y ti me f or saf et y r eas o ns. It will be t he res p o nsi bilit y 
of t he D M C t o deter mi ne if t here is reas o na ble ca use f or s us pe n di n g e nr oll me nt. T he S p o ns or or 
S p o ns or’s desi g nee will pr o m ptl y i nf or m t he re g ulat or y a ut h orities, i n vesti gat ors, I nstit uti o nal 
Re vie w B oar ds (I R Bs) / Et hics C o m mittees ( E Cs), a n d ot her a p pr o priate i nstit uti o nal re g ulat or y 
b o dies if a decisi o n t o s us pe n d e nr oll me nt is ma de. I n t he e ve nt e nr oll me nt is s us pe n de d, n o ne w 
m o bilizati o n/c o n diti o ni n g/ or dr u g pr o d uct i nf usi o n of s u bjects will be i nitiate d, b ut s u bjects w h o 
ha ve alrea d y bee n treate d wit h Le nti Gl o bi n B B [ADDRESS_205973] u d y. If 
m o bilizati o n has bee n i nitiate d, cell c ollecti o n will be c o m plete d at i n vesti gat or’s discreti o n. 
Li ke wise, if t h e st u d y is halte d w hile a s u bject is u n der g oi n g c o n diti o ni n g, c o n diti o ni n g will be 
c o m plete d at i n vesti gat or’s discreti o n, a n d e v er y eff ort will be ta ke n t o restart t he st u d y pri or t o 
t heir sc he d ule d i nf usi o n. H o we ver, a s u bject ma y be i nf use d wit h t heir resc ue cells f oll o wi n g 
c o n diti o ni n g if t he st u d y ca n n ot be r estarte d i n ti me.  
E nr oll me nt a n d treat me nt wit h dr u g pr o d uct will be te m p oraril y s us pe n de d f or a n y of t he f oll o wi n g 
reas o ns, a n d will res u m e after  re vie w a n d rec o m me n dati o ns fr o m t he D M C a n d (as  re q uir e d) 
a p pr o val fr o m t he rele v a nt re g ulat or y a g e nc y(ies): 
• Deat h, u ntil t he ca use of t he deat h is deter mi ne d *  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 3 9 
 • Detecti o n of le u k e mia/l y m p h o ma d ue t o vect or- m e diate d i nserti o nal o nc o g e nesis * * 
• Detecti o n of vect or- d eri v e d R C L i n a n y s u bject (c o nfir me d o n c o- c ult ure assa y)  
• Fail ure t o ac hie ve rec o nstit uti o n wit h tra ns d uce d cells i n > [ADDRESS_205974], r e q uiri n g use of 
bac k u p cells 
• Deter mi nati o n of u n e x p ecte d, cli nicall y si g nifica nt, or u nacce pt a ble ris k t o  s u bjects 
(e. g., de vel o p me nt of dr u g pr o d uct -r elate d, Gr a de [ADDRESS_205975]  3 s u bjects)  
• If a n y criteria f or cl o n al pre d o mi na nce or tri g gers f or cli nical w or k -u p f or mali g na nc y 
is  satisfie d  (refer  t o  Secti o n  6. 2. 1 8 ),  treat me nt  of  a n y  e nr olle d  s u bjects  will  be  
te m p oraril y s us pe n de d u ntil f urt her re vie w b y t he D M C. 
* A n y deat h of a s u bject wit h T D T i n a n y st u d y after recei vi n g Le nti Gl o bi n B B [ADDRESS_205976], t he n e nr oll me nt/treat me nt wit h dr u g pr o d uct ma y 
restart. If t he relati o ns hi p bet wee n t he deat h a n d t he dr u g pr o d uct is n ot clear, or it a p pears t hat t he deat h ma y be 
relate d t o t he st u d y dr u g, e nr oll me nt will be hel d u ntil t he D M C assess me nt a n d rec o m me n dati o ns as descri be d 
a b o ve.  I n  cases  i n  w hic h  t he  ca use  of  deat h  is  still  u n der  i n vesti gati o n,  s u bjects  t hat  ha ve  alrea d y  recei ve d  
c o n diti o ni n g ma y recei ve eit her bac k -u p cells or Le nti Gl o bi n B B [ADDRESS_205977] o n a case -b y -case basis i n 
c o ns ultati o n wit h t he D M C.  
* *If a s u bject is dia g n ose d wit h le u ke mia or l y m p h o ma after recei vi n g Le nti Gl o bi n B B [ADDRESS_205978] be 
≥ 1 2 a n d ≤ 5 0 years of a g e (at l east [ADDRESS_205979] be ≥ 1 2 a n d < 1 8), a n d at least [ADDRESS_205980] 
be < [ADDRESS_205981] i nf usi o n. 
N o m ore t ha n 7 s u bjects ≥ 1 2 a n d ≤ 5 0 y ears of a ge a n d 4 s u bjects < 1 2 y ears of a ge w h o are treat e d 
ca n ha v e a β E allele (i. e., a p pr o xi mate l y 5 0 % of s u bjects). 
4. 2.  I ncl usi o n Criteri a  
S u bjects m ust meet all of t he f oll o wi n g criteri a t o be c o nsi der e d eli gi ble f or e nr oll me nt i n t he 
st u d y. 
1.  S u bjects  ≤ 5 0  years  of  a ge  at  t he  ti me  of  c o nse nt  or  asse nt  ( as  a p plica bl e),  a n d  a ble  t o 
pr o vi de writte n c o nse nt ( a d ults, or le gal g uar dia ns, as a p plica ble) or asse nt (a d olesce nts or 
c hil dre n). Pe diatric s u bj ects ( < 1 2 y ears of a ge) ma y o nl y be e nr olle d at a gi ve n site if 
a p pr o ve d  b y  t he  rele va nt  re g ulat or y  a ut h orit y.  Pr o vi de d  t hat  t he  D M C  has  a p pr o ve d  
e nr olli n g s u bjects y o u n ger t ha n [ADDRESS_205982] 1 0 0 m L/ k g/ year of p R B Cs i n t he 2 years 
prece di n g e nr oll me nt (all s u bjects), or be ma na ge d u n der sta n dar d t halasse mia g ui deli nes 
(e. g., T halass e mia I nter n ati o nal Fe d erati o n, 2 0 1 4; see A p pe n di x 1 0. 4 ) wit h ≥ 8  tra nsf usi o ns 
of p R B Cs per year i n t he 2 years prece di n g e nr oll me nt (s u bjects ≥ 1 2  years; Rac h mile witz 
a n d Giar di na, 2 0 1 1 ). 
3.  Cli nicall y sta ble, ha ve a Kar n ofs k y  p erf or ma nce stat us of ≥ 8 0 f or a d ults ( ≥ 1 6 years of a g e) 
or a L a ns k y perf or ma n ce stat us of ≥ 8 0 f or a d olesce nts or c hil dre n ( < 1 6 years of a g e), a n d 
eli gi ble t o u n der g o H S C T. 
4.  Treate d a n d f oll o we d f or at least t he past 2 years i n a s pecialize d ce nter t h at mai ntai ne d 
detaile d me dical r ec or ds o n R B C tra nsf usi o ns (i ncl u di n g v ol u me a n d u nits of R B Cs a n d 
ass ociate d pr e -tra nsf usi o n H b val ues, retic ul oc yte c o u nts a n d rele va nt bl o o d ba n k details 
as a vaila ble), i n - patie nt h os pi[INVESTIGATOR_1314] o n, a n d ir o n c helati o n hist or y.  
4. 3.  Excl usi o n Criteri a  
S u bjects meeti n g a n y of t he f oll o wi n g criteria will be e xcl u de d fr o m t he st u d y. 
1.  Prese nce  of  a  m utati o n  c har acterize d  as  β 0 o n  b ot h  H B B  alleles.  F or  t he  p ur p ose  of  
scree ni n g, t he H B B  m utati o n I V S I -1 1 0 ( G A) [ H G V S n o me nclat ure: H B B :c. 9 3- 2 1 G > A] 
will be c o nsi dere d e q ui vale nt t o a β0 m utati o n.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 1 
 2.  P ositi ve f or prese n ce of h u ma n i m m u n o deficie n c y vir us t y pe 1 ( HI V -1) or 2 ( HI V -2), 
he patitis B vir us ( H B V), or he patitis C vir us ( H C V). S y p hilis (ra pi d plas ma rea gi n  [ R P R]) 
testi n g is als o re q uire d a n d a p ositi ve test f or s y p hilis is e xcl usi o nar y w here ma n date d b y 
re gi o nal  dr u g  pr o d uct  ma n ufact uri n g  practices.  N ote  t hat  s u bjects  w h o  ha ve  bee n  
vacci nat e d a gai nst he patitis B ( he patitis B s urface a nti b o d y - p ositi ve) w h o a re ne gati ve f or 
ot her mar kers of pri or h e patitis B i nfecti o n [e. g., ne gati ve f or h e patitis B c ore a nti b o d y] 
are  eli gi ble.  S u bjects  wit h  past  e x p os ure  t o  H B V  ( H Bc  A b  p ositi ve  a n d/ or  H Be  A b  
p ositi ve) are als o eli gi ble f or t he st u d y pr o vi de d t h e y ar e ne gati ve b y assess me nt f or H B V 
D N A. Als o n ote t hat s u bjects w h o are p ositi ve f or a nti- he patitis C a nti b o d y are eli gi ble as 
l o n g as t he y ha ve a ne gati ve H C V viral l oa d. W h ere cli nicall y a n d/ or re gi o nall y i n dicate d, 
ot her tests ma y be perf or me d, i n w hic h case p ositi ve res ults w o ul d e xcl u de t he s u bject fr o m 
partici pati n g: f or e x a m ple, h u ma n T -l y m p h otr o pic  vir us‑ 1  ( H T L V -1) or -2 ( H T L V - 2), 
t u berc ul osis, t o x o plas m osis, Tr y pa n os o ma cr u zi, West Nile Vir us, or Zi ka Vir us. 
3.  Cli nicall y si g nifica nt a n d acti ve bacterial, vir al, f u n gal, or par asitic i nfecti o n as deter mi ne d 
b y t he cli nical i n vesti gat or.  
4.  A w hite bl o o d cell ( W B C) c o u nt < 3 × 1 0 9/ L, a n d/ or platelet c o u nt < 1 0 0 × 1 0 9/ L n ot relate d 
t o h y pers ple nis m. 
5.  U nc orr ecte d blee di n g dis or der.  
6.  A n y pri or or c urre nt mali g na nc y ( wit h t he e xce pti o n of a de q uatel y treate d c o ne - bi o psie d 
i n  sit u carci n o ma of t he cer vi x uteri a n d basal or s q ua m o us cell carci n o ma of t he s ki n) or 
m yel o pr oliferati ve or si g nifica nt i m m u n o deficie n c y dis or der. 
7.  I m me diat e fa mil y me m ber (i.e. pare nt or si bli n gs) wit h a k n o w n Fa milial Ca ncer S y n dr o me 
(i ncl u di n g b ut n ot li mite d t o here ditar y br east a n d o varia n ca ncer s y n dr o me, here ditar y 
n o n- p ol y p osis c ol orectal ca ncer s y n dr o me a n d fa milial a de n o mat o us p ol y p osis). 
8.  Pri or H S C T.  
9.  A d va nce d li ver disease, defi ne d as: 
a.  Persiste nt  as partat e  tr a nsa mi nase,  al a ni ne  tr a ns a mi nase,  or  direct  bilir u bi n  val ue  
> 3  × t he u p per li mit of n or mal ( U L N), o r  
b.  Baseli ne  pr ot hr o m bi n  ti me  or  partial  t hr o m b o plasti n  ti me  > 1. 5 ×  U L N, s us pecte d of 
arisi n g fr o m li ver diseas e, or  
c.  M RI of t he li ver de m o nstrati n g clear e vi de nce of cirr h osis, or  
d.  M RI fi n di n gs s u g gesti ve of acti ve h e patitis, si g nifica nt fi br osis, i nc o ncl usi v e e vi de n ce 
of  cirr h osis,  or  li ver  ir o n  c o nce ntrati o n  ≥ 1 5  m g/ g  re q uire  f oll o w -u p li ver bi o ps y i n 
s u bjects  ≥  1 8  years  of  a ge.  I n  s u bjects  <  1 8  years  of a ge, t hese M RI fi n di n gs are 
e xcl usi o nar y, u nless i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or, a li ver bi o ps y c o ul d pr o vi de 
a d diti o nal data t o c o nfir m eli gi bilit y a n d w o ul d be safe t o perf or m. If a li ver bi o ps y is 
perf or me d base d o n M RI fi n di n gs, a n y e vi d e n ce of cirr h osis, bri d gi n g fi br osis, or 
si g nifica nt acti ve he p atitis will be e xcl usi o nar y.  
1 0.  Baseli ne esti mate d gl o mer ular filtrati o n r ate < 7 0 m L/ mi n/ 1. 7 3 m 2, as deter mi ne d usi n g t he 
C hr o nic Ki d ne y Disease E pi [INVESTIGATOR_32450] o g y C olla b orati o n creati ni ne e q uati o n f or ≥ 1 8  years o f 
a ge,  a n d  Be dsi de  Sc h wartz  e q uati o n  calc ulat or  f or  < 1 8  y ears  of  a g e  
(see  htt p:// w w w. ki d ne y. or g/ pr ofessi o nals/ k d o qi/ gfr _calc ulat or.cf m ) 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 2 
 1 1.  U nc o ntr olle d seiz ur e dis or der. 
1 2.  Diff usi o n ca pacit y of car b o n m o n o xi de ( D Lc o) < 5 0 % of pre dict e d ( c orr ecte d f or H b  a n d/ or 
al ve olar  v ol u me,  as  cli nicall y  i n dicate d).  If  D Lc o  ca n n ot  be  ass esse d  d ue  t o  a ge  or  
c o g niti o n- relate d r estricti o ns, t here m ust be a n or mal res pi[INVESTIGATOR_1305] y e x a m, c hest ra di o gra p h 
wit h o u t p ul m o nar y i nfiltrates, a n d o x y g e n sat ur ati o n b y p ulse o xi metr y > 9 2 % o n r o o m air. 
I n t he pres e nce of cli nicall y si g nifica nt a b n or mal fi n di n gs o n c hest ra di o gra p h, cli nicall y 
si g nifica nt  a b n or mal  fi n di n gs  o n t he res pi[INVESTIGATOR_1305] y e xa m, or o x y ge n sat ur ati o n b y p u lse 
o xi metr y ≤ 9 2 % o n r o o m air, t he s u bject will be e x cl u de d.  
1 3.  A car diac T 2 * < 1 0 ms b y M RI.  
1 4.  A n y ot her e vi de nce of s e vere ir o n o v erl oa d t hat, i n t he i n vesti gat or’s o pi [INVESTIGATOR_9384] o n, warr a nts 
e xcl usi o n. 
[ADDRESS_205983] i nf usi o n. If s u bjects are tr ul y se x uall y a bsti ne nt ( w here tr u e se x ual a bsti ne nce 
is defi ne d as bei n g i n li ne wit h t he pref err e d a n d us ual lifest yle of t he s u bject), n o sec o n d 
met h o d is re q uire d. ( See Secti o n 6. 2. 1 9. 7  f or m ore details) . 
[ADDRESS_205984] u d y, t he n t he site will be gi n t he c o nse nt a n d ass e nt 
(as  a p plica ble)  pr ocess  as  per  i nstit uti o nal  practices,  acc or di n g  t o  G o o d  Cli nical  Practice  
(I C H -G C P). Writte n i nf or me d c o nse nt a n d ass e nt (as a p plica ble) m ust be o btai ne d b ef or e t he 
c o n d uct of a n y Scree ni n g tests n ot perf or me d r o uti nel y i n t he treat me nt of t he s u bject.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 3 
 U p o n o btai ni n g t he si g ne d i nf or me d c o nse nt a n d asse nt (as a p plica ble), t he p ote ntial s u bject will 
be re gister e d a n d assi g ne d a u ni q ue s u bject n u m ber. O nce a s u bject n u m ber has bee n assi g ne d t o 
a s pecific s u bject, it ca n n ot be reassi g ne d t o a ne w s u bject. T he s u bject n u m ber will sta y wit h t he 
sa me s u bject e v e n if a s u bject is rescr ee n e d.  
S u bjects w h o fail s cree ni n g ma y n ot be re -s cree ne d wit h o ut pri or disc ussi o n wit h t he bl ue bir d bi o 
Me dical M o nit or. I n g e neral, s u bjects w h o fail scree ni n g f or p ote ntiall y re versi ble c o n diti o ns, s uc h 
as ir o n o v erl oa d, s h o ul d n ot be r e -scree n e d u ntil stri n ge nt ma na ge m e nt of t he c o n diti o n, s uc h as 
a g gressi ve ir o n c hel ati o n, has bee n i n place f or at least 3 m o nt hs fr o m t he ti me of scr ee n fail ure, 
a n d t he faile d i ncl usi o n/e xcl usi o n criteria has b ee n c o nfir me d t o ha v e bee n re me die d. 
4. 5.  S u bject Wit h dr a w al fr o m t he St u d y  
S u bjects ha ve t he ri g ht t o wit h dra w fr o m t he st u d y  at a n y ti me f or a n y reas o n. After gi vi n g 
i nf or me d c o nse nt a n d ass e nt (as a p plica ble), s u bjects ma y wit h dra w or be wit h dra w n fr o m st u d y 
relate d pr oce d ur es a n d treat me nts (e. g., a p h eresis, b us ulfa n c o n diti o ni n g) u n der t he f oll o wi n g 
c o n diti o ns: 
• wit h dra wal of c o nse nt or asse nt, 
• t he s u bject is u na ble t o c o m pl y wit h pr ot oc ol -defi ne d visits or ot her re q uir e me nts of 
t he pr ot oc ol,  
• a n y me dical c o n diti o n w hic h, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat ors, w o ul d p ut t he s u bject 
at ris k f or c o nti n ui n g treat me nt or f oll o w- u p st u dies, or 
• a de q uate cells are n ot c ollecte d d uri n g har vests, or fail ur e of tra ns d uce d cells t o be 
dis p ositi o ne d f or cli nical use.  
Alt h o u g h s u bjects ha ve t he ri g ht t o wit h dra w fr o m t he st u d y at a n y ti me, wit h dra wal aft er t he start 
of c o n diti o ni n g a n d bef or e a d mi nistrati o n of Le nti Gl o bi n B B [ADDRESS_205985]’s st ore d bac k- u p cells (rat her t ha n tra ns d uce d cells) will be i nf use d.  
F or  s u bjects w h o wit h dra w c o nse nt or asse nt (if rele va nt), n o f urt her data will be c ollecte d o n t he 
s u bject.  
F or s u bjects w h o wit h dr a w f or r eas o ns ot her t ha n wit h dra wal of c o nse nt, a n y S A Es o p e n at t he 
ti me of disc o nti n uati o n  s h o ul d be f oll o we d -u p u ntil res ol uti o n or are deter mi ne d t o be a sta ble or 
c hr o nic c o n diti o n. See als o Secti o n  6. 2. [ADDRESS_205986] u d y. 
• If wit h dra wal is bef ore dr u g pr o d uct i nf usi o n, s u bjects s h o ul d re mai n o n st u d y f or at 
least [ADDRESS_205987] u d y pr oce d ure ( e. g., m o bilizati o n, li ver bi o ps y) bef or e 
wit h dra wal a n d o n g oi n g A Es s h o ul d be f oll o we d f or t he [ADDRESS_205988] m yel oa blati o n a n d A Es s h o ul d be f oll o we d f or t he 3- m o nt h d urati o n.  
• If wit h dra wal i s after dr u g pr o d uct i nf usi o n, s u bjects will be as ke d t o c o m plete t he sa me 
assess me nts  as  s p ecifi e d  i n  t he  Sc h e d ule  of  E ve nts  ( S O E)  f or  M o nt h  2 4  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 4 
 ( Earl y  Ter mi nati o n Visit assess me nts) a n d will be e x pecte d t o e nr oll i n t he l o n g -ter m 
f oll o w- u p St u d y L T F‑ [ADDRESS_205989] or:  B B [ADDRESS_205990] or is a re plicati o n d efecti ve, self -i n acti vati n g 
( SI N), t hir d ge nerati o n HI V -[ADDRESS_205991] o matitis 
vir us gl yc o pr otei n  ( V S V -G)  e n vel o pe  pr otei n,  carr yi n g  t he  h u ma n  β‑ gl o bi n  ge ne  wit h  a  si n gle 
m o dificati o n at c o d o n 8 7 ( β A 8 7  T hr: Gl n [ β A‑ T 8 7 Q ]).  B B [ADDRESS_205992] or is n ot a d mi nistere d t o 
s u bjects; rat her, it is use d f or e x -vi v o tra ns d u cti o n of a ut ol o g o us C D 3 4 + h e mat o p oietic ste m cells.  
Le nti Gl o bi n  B B [ADDRESS_205993] :  Le nti Gl o bi n  B B [ADDRESS_205994]  is  a n  a ut ol o g o us  
C D 3 4 + cell -e nric he d p o p ulati o n t hat c o ntai ns he mat o p oietic ste m cells tra ns d uce d wit h B B [ADDRESS_205995]  f or  2  p ur p os es: 
1) tra ns d ucti o n  f or  Le nti Gl o bi n  B B [ADDRESS_205996]  a n d  2)  f or  r esc u e  cells  (t o  be  us e d  if  
t he s u bject  fails  t o e n gr aft  wit h tra ns d uce d cells  or is  u na ble t o r ecei ve Le nti Gl o bi n B B [ADDRESS_205997] aft er c o n diti o ni n g has c o m me nce d). 
A d diti o nal details are pr o vi de d i n t he f oll o wi n g s u bsecti o ns. 
5. 2. 1.  M o biliz ati o n a n d A p heresis Pr oce d ure  
H b  f or  t he  s u bject  is  rec o m me n d e d  t o  b e  ≥ 1 1  g/ d L  d uri n g  m o bilizati o n  a n d  a p h er esis 
(see  Secti o n  5. 9. 3  f or  d etails).  Eac h  s u bject  will  u n der g o  H S C  m o bilizati o n  wit h  a  G -C S F 
(e. g., fil grasti m, le n o gr asti m) a n d pleri xaf or. Peri p heral bl o o d m o n o n uclear cells ( P B M Cs) will be 
c ollecte d b y a p her esis. A se par ate ma n u al o n a p heresis r e q uire me nts a n d rec o m me n d ati o ns will 
be pr o vi de d. 
A t otal of [ADDRESS_205998]’s me dical c o n diti o n.  
Eac h m o bilizati o n c ycle ma y i ncl u de u p t o 3 a p heresis pr oce d ur e da ys, a n d m o bilizati o n re gi me n 
after  2  da ys  of  a p her esis  s h o ul d  be  disc usse d  wit h  t he  Me di cal  M o nit or.  N o  m ore  t ha n  
2 c o nsec uti ve a p her esis pr oce d ur e pr o d u cts ma y be se nt f or eac h tra ns d u cti o n; eac h tra n s d u cti o n 
pr o d uces a n i n di vi d ual dr u g pr o d uct l ot. A p h eresis pr oce d ur e pr o d u cts ar e als o t o be us e d f or 
resc ue cells a n d ma y c o me fr o m eit her a f ull or partial da y of c ollecti o n. N ote t hat a p heresis 
c ollecti o ns i nte n de d f or dr u g pr o d uct ma n ufact ure o n a gi v e n da y ma y be s plit t o re m o ve cells f or 
resc ue ( ≥1. 5 × 1 0 6 C D 3 4 + cells/ k g b ut < 4. 0 × 1 0 6 C D 3 4 + cells/ k g ) o nl y if ≥ 2 5 × 1 0 6 C D 3 4 + cells/ k g 
are pr oc ure d o n t he first da y of a p heresis, or a n a g gre gate of ≥ 1 6 × 1 0 6 C D 3 4 + cells/ k g are c ollecte d 
t hr o u g h s u bse q ue nt da ys of a p heresis . See t he a p heresis ma n ual f or f urt her details. N ote als o t hat 
ali q u ots of cells i nte n de d f or resc ue s h o ul d be fr o ze n a n d st ore d at t he e n d of eac h c ollecti o n da y 
(i.e., s h o ul d n ot be hel d o ver ni g ht t o be p o ole d wit h t he ne xt da y’s c ollecti o n, e ve n if nee d t o 
c ollect a d diti o nal cells f or c o m plete r esc u e d ose). M o bilizati o n c ycles m ust be se parate d b y at least 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 6 
 2 wee ks (i.e., fr o m last da y of cell c ollecti o n i n C ycle [ADDRESS_205999] da y of G- C S F i n C ycle 2). A b o ne 
marr o w har vest is als o all o we d, b ut o nl y t o pr oc ur e cells f or resc u e cells.  
If [ADDRESS_206000] e n o u g h H S Cs t o meet t he r e q uire me nt of a t otal d ose 
of ≥ 5. 0 × 1 0 6 C D 3 4 + cells/ k g, t he n [ADDRESS_206001] l ots i n t otal. 
T he har v este d cells t o be use d f or tra ns d ucti o n will be selecte d f or t he C D 3 4 + mar k er t o e nric h f or 
H S Cs, tra ns d uce d wit h B B [ADDRESS_206002] ore d i n t he va p or p hase of li q ui d nitr o ge n 
w hile rele as e testi n g is o n g oi n g. 
P ote ntial  ris ks  relate d  t o  G -C S F  (e. g.,  fil grasti m,  le n o grasti m),  pleri xaf or,  a n d  a p her esis  ar e  
i ncl u de d i n t he I nf or m e d C o nse nt f or ms a n d i n t he res pecti ve pr o d uct la b els (e. g., U S PI, S m P Cs). 
G- C S F will be use d wit hi n t he mar keti n g  a ut h orizati o n a n d f oll o wi n g t he prescri bi n g i nf or mati o n.  
5. 2. 1. 1.  M o biliz ati o n  
Rece nt  p u blis he d  data  i n dicate  t hat  t he  use  of  pleri xaf or  i n  p e diatric  patie nts  is  safe  a n d  
effecti ve  f or  t he  m o bilizati o n  of  p eri p her al  bl o o d  ste m  cells  f or  a ut ol o g o us  tra ns pla ntati o n  
(Te usi n k et al., 2 0 1 6 ). T he a d diti o n of pl eri xaf or t o G -C S F i n pe diatri c patie nts u n der g oi n g 
ste m  cell m o bilizati o n pri or t o tra ns pla ntati o n as part of treat me nt of m ali g na nt t u m ors has als o 
bee n s h o w n t o res ult i n s u ccessf ul m o bilizati o n of t he vast maj orit y of p atie nts w h o fail t o m o bilize 
wit h si n gle a ge nt G -C S F, as well as t o pr o d uce lar ger yiel ds of C D 3 4 + cells (Masc ha n  et al., 2 0 1 5 ). 
T o xicities o bser ve d i n t he st u d y  were Gra d e [ADDRESS_206003] 
a p pr o priate m o bilizati o n strate g y f or s u bjects wit h β -t halasse mia (Ya n n a ki et al., 2 0 1 3; Y a n na ki  et 
al., 2 0 1 2 ). T he m o bilizati o n a p pr oac h bel o w ( Ta bl e  2 , Ta b le  3 ) f oll o ws t his rece nt data, a n d  uses 
fil grasti m as a n e xa m ple of t he G -C S F. M o dificati o ns t o t his a p pr oac h are all o w e d o nl y after 
c o ns ultati o n wit h t he Me dical M o nit or. 
  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 7 
 T a ble 2: M o biliz ati o n f or S u bjects w h o h a ve a n I nt act S plee n  
M o biliz ati o n 
d a y  Fil gr asti m 
d ose a Pleri x af or d ose 
(e ve ni n g) C o m plete 
Bl o o d 
C o u nt 
( C B C)  Peri p her al 
C D 3 4 + c o u nt  A p heresis  
1 1 0 µ g/ k g   X c   
2 1 0 µ g/ k g   X c   
3 1 0 µ g/ k g   X c   
4 1 0 µ g/ k g  0. 2 4  m g/ k g  X Xd  
5 1 0 µ g/ k g  0. 2 4  m g/ k g  X Xd X 
6 (if nee de d)  b 1 0 µ g/ k g  b X Xd X 
7 (if nee de d)  b    Xd X 
a D osa ge of fil grasti m s h o ul d be decrease d if W B C > 1 0 0  × 1 0 9/ L pri or t o t he da y of a p heresis u nless disc usse d wit h 
Me dical M o nit or; H b is rec o m me n de d t o be mai ntai ne d ≥ 1 1 g/ d L d uri n g t he m o bilizati o n a n d a p heresis p hase.  
b M o bilizati o n re gi me n after 2 da ys of a p heresis s h o ul d be disc usse d wit h t he Me dical M o nit or.  
c Rec o m me n de d b ut ca n be deferre d i n case of diffic ult y i n o btai ni n g C B C (e. g., wee ke n d) at t he discreti o n of t he site 
i n vesti gat or.  
d C D 3 4 + c o u nt is d o ne b ot h o n t he da y pri or t o a p heresis, as well as o n t he da y of a p heresis  
T a ble 3: M o biliz ati o n f or S u bjects w h o d o n ot h a ve a n I nt act S plee n  
M o biliz ati o n 
d a y  Fil gr asti m 
d ose a Pleri x af or 
d ose 
(e ve ni n g)  C o m plete 
Bl o o d C o u nt 
( C B C)  Peri p her al 
C D 3 4 + c o u nt  A p heresis  
1 5 µ g/ k g   X c   
2 5 µ g/ k g   X c   
3 5 µ g/ k g   X c   
4 5 µ g/ k g  0. 2 4  m g/ k g  X Xd  
5 5 µ g/ k g  0. 2 4  m g/ k g  X Xd X 
6 (if nee de d)  b 5 µ g/ k g  b X Xd X  
7 (if nee de d) b    Xd X 
a D osa ge of fil grasti m s h o ul d be decrease d if W B C > 1 0 0  × 1 0 9/ L pri or t o t he da y of a p heresis u nless disc usse d wit h 
Me dical M o nit or; H b is rec o m me n de d be mai ntai ne d ≥ 1 1 g/ d L d uri n g t he m o bilizati o n a n d a p heresis p hase.  
b M o bilizati o n re gi me n after 2 da ys of a p heresis s h o ul d be disc usse d wit h t he Me dical M o nit or.  
c Rec o m me n de d b ut ca n be deferre d i n case of diffic ult y i n o btai ni n g C B C (e. g., wee ke n d) at t he discreti o n of t he site 
i n vesti gat or.  
d C D 3 4 + c o u nt is d o ne b ot h o n t he da y pri or t o a p heresis, as well as o n t he da y of a p heresis  
 
After c o m pleti o n of M o bilizat i o n a n d A p h eresis C ycle 1, if a d diti o nal H S Cs are nee de d eit her f or 
dr u g pr o d uct ma n ufact ur e, or f or res c ue cells (i.e., if < 1. 5 × 1 0 6 C D 3 4 + cells/ k g ha ve bee n c ollecte d 
a n d st ore d at t he site f or r esc ue cells), t he s u bject s h o ul d be gi n M o bilizati o n a n d A p he r esis C ycle  [ADDRESS_206004]’s  e x p erie n ce  fr o m  M o bilizati o n  a n d  A p heresis  C ycle  1.  At  least  1. 5 × 1 0 6  C D 3 4 + 
cells/ k g s h o ul d be st ore d f or res c ue cells at eac h p artici pati n g site’s la b orat or y. 
C CI 
Pr ot oc ol H G B - [ADDRESS_206005]’s  first  a p heresis  will  occ ur  o n  M o bilizati o n  Da y  5.  
H o we ver, after disc ussi o n wit h t he Me dical M o nit or, it ma y occ ur o n M o bilizati o n Da y [ADDRESS_206006] s h o ul d ha v e a c o m plete p h ysical e x a mi nati o n (i ncl u di n g wei g ht) a n d 
vital si g ns perf or me d pri or t o be gi n ni n g a p heresis, a n d a n a b bre vi ate d p h ysical e x a mi nati o n a n d 
vital si g ns a gai n after c o m pleti o n of a p heresis.  
5. 2. 2.  B o ne M arr o w H ar v est Pr oce d ure  
If s ufficie nt cells f or res c ue ar e n ot pr oc ure d aft er [ADDRESS_206007] will be perf or me d usi n g b us ulf a n.  
C o n diti o ni n g will o nl y be gi n after t h e f oll o wi n g criteria ar e met:  
1.  All Le nti Gl o bi n B B [ADDRESS_206008] 3 0 da ys pri or 
t o c o n diti o ni n g t o mai ntai n a pre -tra nsf usi o n H b of ≥ 1 1 g/ d L. Ir o n c helati o n will  li kel y 
nee d t o be a dj uste d t o c o m pe nsate f or t h e i ncr ease d ir o n l oa d, u ntil re q uire d disc o nti n uati o n 
per pr ot oc ol. See Secti o n  5. 9. [ADDRESS_206009] u g i nter acti o ns (S weiss et al., 2 0 1 2 ), disc o nti n uati o n of defer asir o x, a n d 
i nstit uti o n of a n alter nati ve ir o n c hel ati o n a ge nt, at least 2 5 da ys bef ore i nitiati n g b us ulfa n 
treat me nt ma y be c o nsi dere d; if t his is d o ne, t he alter nati ve c hel ati o n a ge nt s h o ul d be 
st o p pe d at least 7 da ys pri or t o starti n g b us ulfa n. 
5.  B us ulfa n will be a d mi nistere d via I V i nf usi o n f or 4  c o nsec uti ve da ys o n D a ys ‑ [ADDRESS_206010] arti n g d ose of 3. 2 m g/ k g as a 3 -h o ur i nf usi o n o nce dail y f or a t otal  of 4 d oses or 
0. 8 m g/ k g as a 2 -h o ur i nf usi o n e ver y 6 h o urs f or a t otal of 1 6  d os es. Please refer t o t h e 
b us ulfa n prescri bi n g i nf or mati o n f or details o n a p pr o priate met h o d f or  d eter mi nati o n of 
patie nt wei g ht. It is rec o m me n de d t hat b us ulfa n is a d mi nistere d at  0. 8 m g/ k g e ver y 6 h o urs 
i n  c hil dre n  a n d  a d olesce nts  t o  a v oi d  hi g her  pea k  c o nce ntr ati o ns  w hile  still  pr o vi di n g  
e q ui vale nt dail y e x p os ur e. A n y m o dificati o ns t o t he b us ulfa n r e gi me n s h o ul d be re vie w e d 
a n d  a p pr o v e d b y t he Me dical M o nit or pri or  t o  a d mi nistrati o n. Please n ote t hat t he ti mi n g 
of b us ulfa n p har mac o ki n etic ( P K)  s a m ple  c ollecti o n is base d o n w h et her a [ADDRESS_206011]  d ose  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 4 9 
 p har mac o ki netics ( a n d if a vaila ble, t hir d da y d ose p har mac o ki n etics) i n or der t o attai n 
tar gete d c o nce ntrati o n ( area  u n der t he c ur v e [ A U C]; see n e xt Secti o n  5. 2. 3. 2  f or tar gete d 
A U Cs). If nee d e d, t he Da y [ADDRESS_206012] d os e of b us ulfa n se v eral da ys b ef or e m yel oa blati o n t o pre -
deter mi ne t he b us ulfa n d ose ma y als o d o s o i n t his pr ot oc ol. A d diti o nal m o dificati o ns t o t he 
b us ulfa n c o n diti o ni n g re gi me n (e. g., s plitti n g d oses) ma y be c o nsi der e d  after disc ussi o n a n d 
a gree m e nt wit h t he Me di cal M o nit or.  
U nless  t he y  ha v e  a  c o ntrai n dicati o n,  all  s u bjects  ar e  t o  r ecei ve  pr o p h yla xis  f or  h e patic  
ve n o‑ occl usi ve  disease  ( V O D)/si n us oi dal  o bstr u cti o n  s y n dr o me  ( S O S)  pri or  t o  i nitiati o n  of 
c o n diti o ni n g, a n d t his s h o ul d be rec or de d i n t h e e C R F; urs o de o x yc h oli c aci d is preferre d a n d 
s h o ul d be a d mi nistere d per i nstit uti o nal g ui deli nes. If t her e are n o i nstit uti o nal sta n dar ds f or 
a d mi nistrati o n of urs o de o x yc h olic aci d, t he n t h e f oll o wi n g re gi me n s h o ul d be use d: 1 2 m g/ k g dail y 
di vi de d  i n  [ADDRESS_206013] 3 m o nt hs after c o m pleti o n of b us ulfa n c o n diti o ni n g ( R u ut u et al. 2 0 0 2, 
2 0 1 4) . A nti -seiz ur e pr o p h yla xis s h o ul d be gi n at least [ADDRESS_206014] d ose P K will be perf or me d i n all s u bjects re gar dless of b us ulfa n d osi n g sc he d ule. Dail y 
d osi n g will tar get a n A U C 0- 2 4 h  of 4 2 0 0 (ra n ge 3 8 0 0 t o 4 5 0 0) µ M * mi n. E ver y 6- h o ur ( q 6 h) d osi n g 
will tar get a n A U C 0- 6 h  of 1 0 5 0 (ra n ge 9 5 0 t o 1 1 2 5) µ M * mi n. 
Sa m ples f or P K a nal ysis of b us ulfa n d ose will als o be dr a w n o n t he t hir d da y of d osi n g (after 
c o m pleti o n of 3r d da y of o nce dail y d osi n g or after first d ose o n t hir d da y w h e n usi n g q 6 h re gi me n) 
usi n g g ui deli nes bel o w.  
Rec o m m e n d ati o ns f or o nce d aily d osi n g : Sa m ples f or b us ulfa n P K a nal ysis s h o ul d be c ollecte d at 
t he e n d of t he first 3 h o ur i nf usi o n ( 3 h o ur ti m e p oi nt), t he n at 3 h o urs 1 5 mi n utes, 3   h o urs 
3 0 mi n utes, 4 h o urs, 5 h o urs, 6 h o urs, a n d 8 h o urs ( +/ − 5 mi n ute wi n d o w u p t o a n d i ncl u di n g t he 
3 h o ur 3 0 mi n utes ti me p oi nt; +/ − 1 5 mi n ute wi n d o w f or all s u bse q ue nt c ollecti o ns ti mes) after t he 
start of t he first i nf usi o n. Sa m ples f or P K a nal ysis s h o ul d als o be dra w n o n t h e t hir d da y of b us ulf a n 
d osi n g, usi n g t he sa me sc he d ule.  
Rec o m m e n d ati o ns f or d osi n g every 6 h o urs ( q 6 h):  Sa m ples f or b us ulfa n P K a nal ysis s h o ul d be 
c ollecte d at t he e n d of t he first 2 h o ur i nf usi o n ( 2 h o ur ti me p oi nt), t he n at 2 h o urs 1 5 mi n utes, 
2 h o urs  3 0  mi n utes,  3  h o urs,  4  h o urs,  5  h o urs,  a n d  6  h o urs  ( +/ −  5  mi n ute  wi n d o w  u p  t o  a n d 
i ncl u di n g t he 2 h o ur 3 0 mi n utes ti me p oi nt; +/ − 1 5 mi n ute wi n d o w f or all s u bse q ue nt c ollecti o ns 
ti mes) after t he start of t he first i nf usi o n. Sa m ples f o r P K a nal ysis s h o ul d als o be dra w n o n t he 
t hir d da y of b us ulfa n d osi n g, usi n g t he sa me sc he d ule. 
N ote: Sa m ples s h o ul d n ot be dra w n fr o m t he l u me n use d t o i nf use b us ulfa n. 
C CI 
Pr ot oc ol H G B - [ADDRESS_206015] da y of d osi n g. Base d o n  b us ulfa n P K res ults f or da y  1 
a n d (if test d ose met h o d is n ot use d) da y [ADDRESS_206016] me nts will be ca pt ure d i n t he case re p ort f or m ( C R F).  
After c o m pleti o n of t he [ADDRESS_206017](s) m ust be t ha we d at a p pr o xi matel y 3 7° C a n d t he i nf usi o n 
of t he dr u g pr o d uct s h o ul d be c o m plete d i m me diatel y aft er t ha wi n g a n d wit hi n a ma xi m u m of [ADDRESS_206018] will be  a d mi nistere d o n Da y  1 via I V i nf usi o n at t he cli nical 
site.  T he  d ose  t o  be  a d mi nistere d  is  ≥ 5. 0 × 1 0 6 C D 3 4 +  cells/ k g.  S u bjects  w h o  u n der g o  
2 m o bilizati o n c ycles (a n d s u bse q ue nt tra ns d ucti o n of t h ose cells) t o ac hie ve a t otal d ose of 
≥ 5. 0 × 1 0 6 C D 3 4 +  cells/ k g  will  ha ve  [ADDRESS_206019] i nf usi o n.  A d diti o nall y, vital si g ns (e xcl u di n g E C G) s h o ul d be 
meas ure d f or t w o h o urs after i nf usi o n ( e. g. e v er y 3 0 t o 6 0 mi n utes). I nf usi o n reacti o ns, i ncl u di n g 
a na p h yla xis, will be m a n a ge d acc or di n g t o t he me dical j u d g me nt of t he p h ysicia n o vers eei n g t he 
i nf usi o n. Refer t o t he St u d y O perati o ns Ma n u al ( S O M) f or a d diti o nal det ail re gar di n g i nf usi o n. 
5. 3.  St or a ge a n d St a bilit y of Le nti Gl o bi n B B [ADDRESS_206020] uri n g Practice ( G M P) f oll o wi n g pr ocess -s pecific pr o ce d ures. T h e s u bject’s 
C D 3 4 + cell -e nric he d p o p ulati o n c o ntai ni n g cells tra ns d uce d wit h B B [ADDRESS_206021] is a n a ut ol o g o us C D 3 4 + cell -e nric h e d p o p ulati o n t hat c o ntai ns 
he mat o p oietic  ste m  cells  tra ns d uce d  wit h  B B [ADDRESS_206022] or  e nc o di n g  t he  β A‑ T [ADDRESS_206023] i nf usi o n will be varia ble a n d  is esti mate d ge ner all y t o 
be bet wee n 3 t o 5 m o nt hs (e. g., u p t o [ADDRESS_206024] i nf usi o n). T hereafter s u bject is pla n n e d t o re mai n o n st u d y 
f or a p pr o xi matel y 2 4 m o nt hs. Eli gi ble s u bjects will t he n be e x pecte d t o e nr oll i n a se parate 
l o n g‑ter m f oll o w - u p st u d y u ntil a p pr o xi matel y [ADDRESS_206025]‑ dr u g pr o d uct i nf usi o n.  
If t he s u bject is u na ble t o u n der g o m o bilizati o n wit hi n a p pr o xi matel y [ADDRESS_206026] u d y pr o ce d ures. I n p artic ular, p h ysical e x a m,  vital si g ns, 
perf or ma n ce  stat us,  H R Q o L,  electr o car di o gra m  ( E C G),  c o m plete  bl o o d  c o u nt,  c h e mistr y,  
uri nal ysis, a n d li ver f u ncti o n tests, a n d f or w o me n of c hil d -beari n g p ote ntial, tests f or  pre g n a nc y, 
m ust be perf or me d wit hi n 3 m o nt hs of  pr ocee di n g t o e val uati o n f or m o bilizati o n. F or s u bjects wit h 
e x p os ure ris ks f or HI V, H B V a n d H C V, t hese tests s h o ul d als o be re peat e d.  
S o me of t hese assess me nts ma y be perf or me d i m me diatel y pri or t o m o bilizati o n, as s pecifie d i n 
t he sc he d ule of e ve nts. W here cli nicall y a n d/ or re gi o nall y i n dicate d, ot h er tests f or i nfecti o us 
pat h o ge ns ma y be p erf or me d, as re q uir e d b y re gi o nal re g ulati o ns or at p h ysicia n discreti o n. Ot her 
bl o o d tests, i ncl u di n g t h ose f or i m m u ne s u bsets, h or m o nal or d ys er yt hr o p oiesis testi n g  o nl y nee d 
t o be re p eate d if m ore t h a n [ADDRESS_206027] (e. g. b or derli ne t h yr oi d f u ncti o n). Car diac M RI (if i nitial val ue ≥  1 5 ms, a n d 
n o cli nicall y si g nifica nt a b n or malit y o n E C G) a n d li ver M RI (if n o e vi de nce of fi br osis a n d LI C ≤ 
1 0 m g/ g o n i nitial M RI, a n d if n o ne w cli nicall y si g nifica nt li ver f u ncti o n a b n or malities) d o n ot 
nee d t o be re peate d if p erf or me d wit hi n t he p ast 1 year, a n d if ir o n c helati o n has bee n a d her e d t o 
i n t he i nter v e ni n g ti me; if t hese sti p ulati o ns are n ot met, t he n t hese tests s h o ul d be r e peate d if m ore 
t ha n 3 m o nt hs ha ve tra ns pi[INVESTIGATOR_1312] d. T he n ee d f or li ver bi o ps y s h o ul d be g ui d e d b y M RI fi n di n gs, as 
descri be d i n t he pr ot oc ol, u nless a bi o ps y perf or m e d wit hi n o ne year of m o bilizati o n e x hi bite d n o 
e vi de nce of fi br osis or he patitis. P ul m o nar y f u ncti o n tests a n d ec h ocar di o gr a p h y (if n o b or derli ne 
val ues o n i nitial testi n g of eit her test) als o d o n ot nee d t o be re peate d u nless m ore t ha n [ADDRESS_206028] u d y e nr oll me nt (si g ni n g of t he i nf or me d c o nse nt f or m [I C F]), as 
n ote d bel o w a n d i n Secti o n 6. 2. [ADDRESS_206029] or y.  
5. 9. 2.  C o nc o mit a nt Me dic ati o ns a n d T her a pi[INVESTIGATOR_014]: Ge ner al  
All c o nc o mita nt treat me nts, i ncl u di n g tra nsf usi o ns, will be d oc u me nte d. 
T he use of er yt hr o p oieti n -li ke sti m ulati n g a ge nts, h y dr o x y urea, a n d electi ve s ple nect o m y (f or 
s u bjects wit h i ntact s plee ns) will be pr o hi bite d fr o m Scree ni n g t hr o u g h e n d of st u d y. I n a d diti o n, 
use of a n y p ote ntiall y dis ease m o dif yi n g t hera p y ( e. g., l us pater ce pt) s h o ul d n ot be i nitiate d wit h o ut 
disc ussi o n wit h a n d e x plicit a p pr o val of t he S p o ns or’s Me dical M o nit or. 
Per mitte d c o nc o mita nt treat me nts ma y i ncl u de:  
• H y drati o n, be gi n ni n g 1 2 h o urs b ef or e i nitiati n g c o n diti o ni n g a n d c o nti n ui n g t hr o u g h 
2 4 h o urs t hereafter 
• Pre ve nti o n or treat me nt of na usea a n d v o miti n g b y pr o p h ylactic a d mi nistrati o n of a nti -
na usea me dicati o ns  
• Seiz ure  pr o p h yla xis.  All  dr u gs  ot her  t ha n  p h e n y t oi n  are  all o we d  f or  a nti -seiz ure 
pr o p h yla xis d uri n g c o n diti o ni n g.   
• Urs o de o x yc h olic  aci d  s h o ul d  be  a d mi nistere d  pr o p h ylacticall y  f or  pre ve nti o n  of  
he patic ve n o -o ccl usi ve disease ( V O D)/si n us oi dal o bstr ucti o n s y n dr o me ( S O S), u nless 
t he s u bject has a c o ntrai n dicati o n t o use of urs o de o x yc h olic aci d. Defi br oti de ma y be 
use d i n lie u of urs o de o x yc h olic aci d as pr o p h yla xis a n d s h o ul d be a d mi nistere d per 
i nstit uti o nal sta n dar ds f or pre ve nti o n a n d/ or treat me nt of V O D/ S O S. If t here ar e n o 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 3 
 i nstit uti o nal sta n dar ds f or a d mi nistrati o n of urs o d e o x yc h olic aci d, t he n t he f oll o wi n g 
re gi me n s h o ul d be use d: 1 2 m g/ k g dail y di vi de d i n [ADDRESS_206030]  3  m o nt hs  after  
c o m pleti o n of b us ulfa n c o n diti o ni n g ( R u ut u et al. 2 0 0 2, 2 0 1 4) . 
• Tra nsf usi o ns s h o ul d be gi ve n acc or di n g t o H b a n d platelet c o u nts base d o n i nstit uti o nal 
g ui deli nes d uri n g t he h os pi[INVESTIGATOR_1314] o n t o s u p p ort e n graft me nt. All bl o o d pr o d ucts will 
be filt ere d a n d irra diat e d.  
• G- C S F s h o ul d n ot be use d pri or t o Da y 2 1 wit h o ut e x plicit a p pr o val fr o m t he bl ue bir d 
bi o Me dical M o nit or. After Da y 2 1, G -C S F ma y be use d acc or di n g t o i nstit uti o nal 
g ui deli nes.  
• S u bjects will be is olate d a n d a p pr o priate pr eca uti o ns will be ta ke n if t he p ol y n uclear 
le u k oc yte  c o u nt  is  < 0. 5  × 1 0 9/ L.  Br oa d -s pectr u m  a nti bi otic  treat me nt  will  be  
a d mi nistere d  acc or di n g  t o  sta n dar d  pr oce d ures  f or  t he  ma na ge me nt  of  fe brile  
ne utr o pe nia. 
F or t h e p ur p os es of t his st u d y, vacci n es ( e. g., C O VI D -1 9 vac ci nes) are c o nsi dere d c o nc o mita nt 
me dicati o ns. Alt h o u g h i nteracti o ns bet w ee n a vacci ne a n d L e nti Gl o bi n B B [ADDRESS_206031] are 
n ot  e x pecte d,  t he  pr ot oc ol  i ncl u des  use  of  i m m u n o m o d ulat or y  ( pleri xaf or)  a n d  
i m m u n os u p pressi ve  me dicati o n  ( b us ulfa n).  L ocal  g ui deli nes  s h o ul d  be  f oll o we d  re gar di n g  a  
mi ni m u m  ti me  peri o d  bet wee n  a n y  me dicati o n  t o  be  pr o vi de d  as  part  of  treat me nt  wit h  
Le nti Gl o bi n B B [ADDRESS_206032] a n d a n y vacci ne; it is rec o m me n de d t hat vacci nes are n ot 
a d mi nistere d t o s u bjects wit hi n [ADDRESS_206033] 
i nf usi o n s h o ul d be c o nsi dere d p er I n v esti gat or's discreti o n d ue t o p ote ntial l oss of i m m u nit y after 
m yel oa blati ve c o n diti o ni n g a n d ma y be a d mi nistere d f oll o wi n g l ocal g ui deli nes. 
T he pr escri bi n g i nf or mati o n of t he v acci n e a d mi nistere d s h o ul d be  referre d t o  f or  t he lat est  
i n dicat i o n,  c o ntrai n dicati o ns  a n d  safet y  i nf or m ati o n  as  well  as  t he  l atest  ge ner al  cli nical  
rec o m me n dati o ns o n vacci ne a d mi nistrati o n i n t he c o u ntr y or re gi o n. 
All vacci nati o ns d uri n g t he st u d y peri o d s h o ul d be d oc u me nte d i n t he C R F. 
See ne xt secti o ns f or tra nsf u si o ns ( Secti o n  5. 9. 3 ), ir o n c helati o n ( Secti o n  5. 9. 4 ), a n d i nfecti o n 
pr o p h yla xis ( Secti o n  5. 9. 5 ) rec o m me n d ati o ns.  
5. 9. 3.  C o nc o mit a nt Me dic ati o ns a n d T her a pi[INVESTIGATOR_014]: Tr a nsf usi o ns  
Tra nsf usi o ns f or t he [ADDRESS_206034] u d y will be d oc u me nte d. 
Rec o m me n dati o ns f or tra nsf usi o ns are ma d e f or 4 se parat e peri o ds d uri n g tr eat me nt:  
1.  Pri or t o a p heresis: tra nsf usi o ns are rec o m me n de d t o o btai n H b ≥ 1 1 g/ d L.  
2.  It is rec o m me n de d t hat, if p ossi ble, pre -tra nsf usi o n H b ≥ 1 1 g/ d L be mai ntai ne d f or at least 
o ne  m o nt h  pri or  t o  i nitiati o n  of  c o n diti o ni n g.  Ir o n  c helati o n  s h o ul d  be  a dj uste d  
a p pr o priatel y t o mi ni mize t he effects of t h e a d diti o nal ir o n l oa d.  
3.  D uri n g  c o n diti o ni n g  a n d  h os pi[INVESTIGATOR_1314] o n  s u p p orti n g  e n graft me nt:  f oll o w  i nstit uti o nal  
g ui deli nes.  
C CI 
Pr ot oc ol H G B - [ADDRESS_206035] -disc har ge f oll o w -u p: It is rec o m me n de d t hat s u bjects s h o ul d recei v e R B C 
tra nsf usi o ns f or a n y H b < 7  g/ d L, a n d f or cli nicall y s y m pt o matic a ne mia, irres pecti ve of H b 
le vel.  Decisi o ns  re g ar di n g  tra nsf usi o n  i n  as y m pt o matic  s u bjects  ( wit h o ut  cli nicall y  
s y m pt o matic a ne mia) s h o ul d be base d o n ce ntral la b orat or y H b val ues a n d n ot l ocall y 
dra w n H b. Tra nsf usi o ns s h o ul d be a v oi de d f or H b ≥ 9  g/ d L, u nless t he nee d is me dicall y 
j ustifie d (e. g., as a pre -re q uire me nt f or s ur ger y), or if t he s u bject h as a n ac q uire d c o n diti o n 
re q uiri n g hi g her bas eli ne H b (e. g. pr e g na nc y).  
5. 9. 4.  C o nc o mit a nt Me dic ati o ns a n d T her a pi[INVESTIGATOR_014]: Ir o n C hel ati o n 
Ir o n c hel at ors f or t he [ADDRESS_206036] u g i nteracti o ns (S weiss 
et al., 2 0 1 2 ), disc o nti n uati o n of deferasir o x a n d i nstit uti o n of a n alter nati ve ir o n c helati o n a ge nt at 
least 2 5 da ys bef ore i nitiati n g b us ulfa n treat me nt m a y be c o nsi d ere d; if t his is d o ne, t he alter nati ve 
c helati o n a g e nt s h o ul d b e st o p pe d at least [ADDRESS_206037]-tra ns pla nt. Deferi pr o ne ma y be us e d n o s o o ner t ha n 6 m o nt hs after tra ns pla nt d u e t o 
t he  p ote ntial  ris k  of  m yel os u p pressi o n  (as  per  prescri bi n g  i nf or mati o n  f or  Def eri pr o n e),  a n d  
alter nati ve c h e lati o n re gi me ns s h o ul d be e m pl o ye d i n t he i nteri m. Starti n g d ose of c helat or is 
rec o m me n de d b ase d o n i nstit uti o nal pr ot oc ols. D oses ma y nee d t o be a dj uste d c o nti n u o usl y base d 
o n ser u m ferriti n le vels t o pre ve nt t o xicit y. 
P hle b ot o m y ca n be use d i n lie u of c helati o n i n s u bjects w h o ha ve H b c o nsiste ntl y ≥ 1 1 g/ d L a n d 
w h o  are  n o  l o n ger  recei vi n g  re g ular  tra nsf usi o ns.  T o  a v oi d  t o xicit y,  o nce  ser u m  ferriti n  is  
≤ 1 0 0 0  n g/ m L,  d o w n war d  a dj ust me nt  of  d ose  of  c helat or  a n d  d ecreasi n g  t he  fre q u e nc y  of  
p hle b ot o m y is a d vise d, as per i nstit uti o nal pr ot oc ols. C helati o n s h o ul d be disc o nti n ue d if s u bjects 
bec o me TI, LI C is < 5 m g/ g, a n d ser u m ferriti n is < 5 0 0 n g/ m L. S u bjects w h o are n ot ta ki n g c helat ors 
s h o ul d be c o nti n uall y r eassesse d f or c hel ati o n nee ds p ost -H S C T base d o n t he S O E of t h e r ele va nt 
pr ot oc ol. 
5. 9. 5.  C o nc o mit a nt Me dic ati o ns: I nfecti o n S ur veill a nce a n d Pr o p h yl a xis 
T he Le nti Gl o bi n B B [ADDRESS_206038] is a C D 3 4 + cell -e nric he d p o p ulati o n a n d is f u ncti o nall y 
T cell -de plete d.  T h us,  o p p ort u nistic  i nfecti o n  s ur veilla nce  a n d  pr o p h yla x is  is  rec o m me n de d.  
Bel o w is a s u g geste d a p pr oac h t o i nfecti o n s ur veilla nce a n d pr o p h yla xis. Alter nati ves t hat f oll o w 
i nstit uti o nal practices ma y be e m pl o ye d.  
• I n s u bjects wit h past e x p os ure t o H B V, re g ular m o nit ori n g of H B V de o x yri b o n ucleic 
aci d ( D N A) f or u p t o [ADDRESS_206039] i nf usi o n is a d vise d, wit h pre -e m pti ve 
la vi m u di ne rec o m me n d e d f or a n y i ncreas e i n H B V D N A titer ( H B V reacti vati o n). 
Si milarl y, s u bjects wit h past e x p os ure t o H C V will u n der g o re g ular m o nit ori n g of H C V 
D N A f or u p t o [ADDRESS_206040] i nf usi o n. 
• Her pes si m ple x vir us ( H S V) pr o p h yla xis: Ac ycl o vir pr o p h yla xis is rec o m me n de d f or 
at least [ADDRESS_206041] i nf usi o n f or p atie nts w h o are s er o -p ositi v e f or H S V 
or varicella z oster vir us ( V Z V).  
• P ne u m oc ystis  p ne u m o nia  pr o p h yla xis:   Tri met h o pri m -s ulfa met h o xaz ole  or  a n  
e q ui vale nt dr u g is rec o m me n de d f or at least [ADDRESS_206042] i nf usi o n.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 5 
 • F u n gal  pr o p h yla xis:  A nti -f u n gal  pr o p h yla xis  is  rec o m me n de d wit h a ge nts  s uc h as 
fl uc o naz ole f or at least [ADDRESS_206043] i nf usi o n.  
• I ntr a ve n o us i m m u n o gl o b uli n (I g G) ma y be a d mi nistere d f or 3 m o nt hs t o mai ntai n I g G 
le vels per i nstit uti o nal g ui deli nes.  
• F oll o w i nstit uti o nal p ost -tra ns pla ntati o n g ui deli nes f or re- i m m u nizati o n of s u bjects.  
• S u bjects s h o ul d n ot use me dicati o ns wit h a nti -r etr o viral acti vit y (s uc h as t h ose use d f or 
HI V pr e -e x p os ure pr o p h yla xis) fr o m at least o ne m o nt h pri or t o m o bilizati o n u ntil at 
least [ADDRESS_206044] sta ges, as f oll o ws. 
• Sta ge 1:  Scree ni n g  
• Sta ge 2:  A ut ol o g o us C D 3 4 + cell c ollecti o n a n d L e nti Gl o bi n B B [ADDRESS_206045] ur e a n d dis p ositi o n 
• Sta ge 3:  M yel oa blati ve c o n diti o ni n g (a p pr o xi matel y Da y -6 t hr o u g h Da y   - 3) a n d 
i nf usi o n of Le nti Gl o bi n B B [ADDRESS_206046] ( D a y 1) 
• Sta ge 4:   F oll o w- u p t hr o u g h M o nt h [ADDRESS_206047] a w n c o nc urr e ntl y f or a nal ysis b y b ot h ce ntral a n d 
l ocal la b orat ories; t hese will be s pecifie d i n t he S O M. It will be at t he I n v esti gat or's discreti o n t o 
dra w l ocal la b or at or y ass a ys base d o n t he ur ge nc y nee de d f or t he r es ults. Assa ys re q uir e d d uri n g 
h os pi[INVESTIGATOR_1314] o n peri o ds (i.e., m o bilizati o n/a p heresis, c o n diti o ni n g t hr o u g h tra ns pla nt, a n d p ost -
tra ns pla nt) will n ot be perf or me d ce ntrall y u nless i n dicate d b y t he Me dical M o nit or.  
S u bjects will be as ke d t o c o m pl y wit h t he pr ot oc ol s pecifie d assess me nts acc or di n g t o t he ti me 
peri o ds e n u merat e d i n t he S O E. If t he ti mi n g of assess me nts is s hifte d d ue t o sc he d uli n g c o nflicts 
(e. g.,  li mite d  be d  a v aila bilit y  at  t he  h os pi[INVESTIGATOR_307],  dela ys  i n  scr ee ni n g  assess me nts,  re p eate d  
m o bilizati o ns, dela ys i n sc he d uli n g c o n diti o ni n g a n d Le nti Gl o bi n B B [ADDRESS_206048] i nf usi o n), 
t hese will n ot be c o nsi der e d pr ot oc ol de viati o ns.  
E val uati o ns a n d pr oce d ures i de ntifie d i n t he S O E ma y be perf or me d at u nsc he d ule d visits, as 
cli nicall y i n dicate d, at t he i n vesti gat or’s discreti o n i n c o ns ultati o n wit h t he S p o ns or as a p pr o pri ate.  
If a s u bject is n ot a ble t o visit t he st u d y site d ue t o f orce of nat ure (e. g., C O VI D -1 9 p a n de mic), 
t he n a tele healt h visit s h o ul d be c o nsi dere d t o e ns ure a p pr o priate o versi g ht a n d safet y m o nit ori n g. 
I n a d diti o n t o t his, if t he s u bject is a ble t o visit a l ocal d oct or a n d/ or la b orat or y, t he n pre - defi ne d 
assess me nts ma y b e p erf or me d at a l o cal la b orat or y or d oct or’s offi ce, p er I n v esti gat or discreti o n.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 6 
 T a ble 4: Sc he d ule of E ve nts: Scree ni n g a n d C D 3 4 + Cell H ar vest 
Pr oce d ure  Scree ni n g  
( U p t o 9 0 d a ys bef ore m o biliz ati o n)  M o biliz ati o n [ADDRESS_206049]  
Si g ni n g of i nf or me d c o nse nt f or m (I C F)/asse nt  X   
De m o gra p hics a n d me dical hist or y 2 X   
P h ysical e xa mi nati o n  X3 X3 X3 
Vital si g ns  X X4 X4 
Bl o o d f or cli nical la b orat or y tests  X5 X6 X6 
Esti mate d Gl o mer ular Filtrati o n Rate ( G F R)  X   
Uri nal ysis  X   
Bl o o d f or ser ol o g y  X7   
Bl o o d f or i m m u n ol o gical testi n g  X8   
Bl o o d f or ser u m β -h u ma n c h ori o nic g o na d otr o pi n  f or w o me n of 
c hil d‑ beari n g p ote ntial (ser u m pre g na nc y test)   X X9  
Bl o o d f or h or m o nal a n d d yser yt hr o p oiesis testi n g  X1 0    
Bl o o d f or re plicati o n c o m pete nt le nti vir us ( R C L) [ADDRESS_206050] or c o p y n u m ber 
( V C N), gl o bi n H P L C, a n d gl o bi n i n a ut ol o g o us cells  X   
Bl o o d f or t halasse mia ge n ot y pi n g [ADDRESS_206051] ora ge: p ote ntial bi o mar ker a nal ysis ( o pti o nal)  X   
Peri p heral bl o o d C D 3 4 + cell c o u nt    X1 3  
S per m / testic ular tiss ue or o oc yte ba n ki n g, if re q ueste d  X1 4    
Li ver bi o ps y (if re q uire d)  X   
B o ne marr o w ( m or p h ol o g y st u dies)  X1 5    
1 2 -lea d E C G  X   
I ma gi n g: C hest X -ra y, car diac D o p pler ec h ocar di ol o g y (i ncl. L V E F), 
car diac a n d li ver T 2 * M RI, S O C li ver a n d s plee n M RI, b o ne i ma gi n g 
( X  ra y a n d/ or D E X A sca n) 1 6  X   
P ul m o nar y f u ncti o n tests  X1 7    
Tra nsf usi o n re gi me n   X1 8   
Healt h -relate d Q ualit y of Life ( H R Q o L) Assess me nt  X   
A d verse e ve nt c ollecti o n  C o nti n u o us fr o m I C F si g ni n g  
Pri or a n d c o nc o mita nt me dicati o ns (i ncl. ir o n c helat ors f or t he pri or 2 
years)  C o nti n u o us fr o m I C F si g ni n g 
[ADDRESS_206052] or y (see Secti o n  6. 2. 1  f or details  re q uire d) a n d i n -patie nt 
h os pi[INVESTIGATOR_1314] o n; i ncl u des ge n ot y pe ( m utati o ns at H B B  ge ne).  
3 I ncl u des wei g ht, hei g ht, ne ur oc o g niti ve de vel o p me nt e val uati o n (f or s u bjects < 1 8 years of a ge), perf or ma nce  stat us 
a n d Ta n ner sta gi n g (if rele va nt) at Scree ni n g. A c o m plete p h ysical e xa mi nati o n (i ncl u di n g wei g ht) s h o ul d be 
perf or me d wit hi n [ADDRESS_206053] a n d t he n a gai n 
pri or t o disc har ge.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 7 
 5 I ncl u des he mat ol o g y ( C B C, platelets, retic ul oc ytes, n ucleate d R B Cs), ir o n st u dies (ir o n, ferriti n, tra nsferri n, ser u m 
tra nsferri n rece pt or), ser u m c he mistr y (i ncl u di n g fasti n g gl uc ose/i ns uli n a n d H o me ostasis M o del Assess me nt i n de x), 
li ver f u ncti o n tests, pr ot hr o m bi n a n d partial t hr o m b o plasti n ti me. Oral gl uc ose t olera nce test is re q uire d f or a n y 
a b n or mal fasti n g gl uc ose.  
[ADDRESS_206054] ors or cli nical e vi de nce of i nfecti o n wit h ot her c o m m u nica ble disease a ge nts 
or disease. Tests s h o ul d be d o ne acc or di n g t o c o u ntr y -s pecific a n d i nstit uti o nal g ui deli nes  
8 T cell s u b sets ( C D 4, C D 8), B cells ( C D 1 9), nat ural killer cells ( C D 1 6 a n d/ or C D 5 6); i m m u n o gl o b uli ns (I g G, I g M, 
a n d I g A)   
9 S h o ul d be c o nfir me d ne gati ve pri or t o m o bilizati o n  
1 0  H or m o nal testi n g i ncl u des t h yr oi d f u ncti o n (free T 4, T S H), P T H. F or s u bjects after p u bert y, als o i ncl u des L H, F S H 
a n d estra di ol (fe males o nl y); test oster o ne ( males o nl y). F or s u bjects < 1 8 years of a ge, i ncl u des gr o wt h h or m o ne 
(I G F -1 a n d I G F B P -3).  
1 1  T w o sa m ples re q uire d t o be arc hi ve d f or p ote ntial R C L testi n g: o ne f or t he R C L scree ni n g test, a n ot her f or R C L 
P B L c oc ult ure test  
1 3  Peri p heral bl o o d C D 3 4 + c o u nt s h o ul d be perf or me d o n t he da y pri or t o a p heresis, as well as o n t he da y of a p heresis.  
1 4  Ma y occ ur a n y ti me bef ore c o n diti o ni n g; h or m o nal treat me nt, if a p plica ble as part of ba n ki n g, s h o ul d st o p at least 7 
da ys pri or t o c o n diti o ni n g.  
1 5  B o ne marr o w c ollecti o n f or m or p h ol o g y, cell ularit y, cell c o u nt a n d ir o n stai ns. F or s u bjects u n der g oi n g re -scree ni n g, 
b o ne marr o w c ollecti o n d oes n ot nee d t o be perf or me d. If s ufficie nt sa m ple is a vaila ble, sa m ple ma y be arc hi ve d 
a n d/ or ot her researc h tests (e. g., ge netic testi n g) ma y be perf or me d.  
1 6  A ge a p pr o priate  b o ne i ma gi n g ( b o ne a ge/ mi neral de nsit y) t o be d o ne base d o n i n vesti gat or’s j u d g me nt.  
1 7  I ncl u di n g o x y ge n sat urati o n; c orrecte d % pre dicte d F V C, % pre dicte d F E V 1; % pre dicte d R V; a n d % pre dicte d  
D Lc o (c orrecte d f or H b a n d/ or al ve olar v ol u me, as cli nicall y i n dicate d). If s u bject ca n n ot perf or m t hese p ul m o nar y 
f u ncti o n tests d ue  t o  a ge  or  c o g niti o n -relate d  restricti o ns, t he n  res pi[INVESTIGATOR_1305] y  e xa m,  c hest  ra di o gra p h,  a n d  p ulse 
o xi metr y will s u bstit ute f or  t hese assess me nts.  
1 8  T o mai ntai n H b ≥ 1 1 g/ d L pri or t o m o bilizati o n  
C CI C CI 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 5 8 
 T a ble 5: Sc he d ule of E ve nts: C o n diti o ni n g a n d Dr u g Pr o d uct I nf usi o n  
 Prec o n diti o ni n g  C o n diti o ni n g  I nf usi o n  P ost -i nf usi o n 
u ntil 
e n gr aft me nt  
A p pr o xi m atel y [ADDRESS_206055] o p ir o n c helati o n   X7    
H y pertra nsf usi o n t o pre -tra nsf usi o n H b 
≥ 1 1 g/ d L  X8     
Bl o o d f or cli nical la b orat or y tests 9  X X X X41 0  
Bl o o d f or ser u m β -h u ma n c h ori o nic 
g o na d otr o pi n  f or fe male s u bjects of c hil d -
beari n g p ote ntial (ser u m pre g na nc y test)   X    
Bl o o d f or ser u m tra nsferri n rece pt or   X  X X1 1  
Bl o o d f or retic ul oc yte c o u nt   X  X X1 1  
Re -c o nfir mati o n of eli gi bilit y   X1 2     
A nti -seiz ure a n d V O D/ S O S pr o p h yla xis    X1 [ADDRESS_206056]     X  
A d verse e ve nt c ollecti o n   C o nti n u o us fr o m I C F si g ni n g  
C o nc o mita nt me dicati o n c ollecti o n   C o nti n u o us fr o m I C F si g ni n g  
1 Pla n ne d Da ys relati ve t o Da y 1, b ut ma y var y de pe n di n g o n le n gt h of was h -o ut ( 4 8 h o ur mi ni m u m) bef ore dr u g pr o d uct i nf usi o n  
[ADDRESS_206057] i nf usi o n.  A d diti o nall y, vital 
si g ns (e xcl u di n g E C G) s h o ul d be meas ure d f or t w o h o urs after i nf usi o n (e. g. e ver y 3 0 t o 6 0 mi n utes)  
[ADDRESS_206058] 7 da ys bef ore i nitiati n g c o n diti o ni n g. See Secti o n  5. 9. 4  f or disc o nti n uati o n of deferasir o x  
8 Pre -c o n diti o ni n g h y pertra nsf usi o n is rec o m me n de d, b ut n ot re q uire d. Ir o n c helati o n s h o ul d be ma na ge d a p pr o priatel y t o mi ni mize a d diti o nal ir o n o verl oa d.  
Pre‑tra nsf usi o n he m o gl o bi n, a n d if a vaila ble, ser u m ferriti n a n d ser u m tra nsferri n rece pt or s h o ul d be rec or de d as u nsc he d ule d la bs.  
9 C B C; ser u m c he mistr y; li ver f u ncti o n tests; a n d a n y ot her tests t hat are cli nicall y i n dicate d or re q uire d b y i nstit uti o nal g ui deli nes, i ncl u di n g f or e xa m ple testi n g 
f or c yt o me gal o vir us ( C M V), E pstei n Barr vir us ( E B V), H S V a n d V Z V I g G. O n Da y 1 la bs are t o be c ollecte d pri or t o i nf usi o n. Cli nical la b orat or y tests s h o ul d 
be o btai ne d o n a m ore fre q ue nt basis if cli nicall y i n dicate d (e. g. m o nit ori n g & e val uati o n of A Es).  
1 0  C B Cs are perf or me d dail y d uri n g h os pi[INVESTIGATOR_1314] o n u ntil A N C e n graft me nt is de m o nstrate d  
1 1  R etic ul oc ytes a n d ser u m tra nsferri n rece pt or s h o ul d be m o nit ore d dail y fr o m Da y 1 t hr o u g h Da y + [ADDRESS_206059] or y; ser u m β -h u ma n c h ori o nic g o na d otr o pi n f or w o me n 
of c hil d -beari n g p ote ntial (ser u m pre g na nc y test); verificati o n t hat Le nti Gl o bi n B B [ADDRESS_206060] has bee n cli nicall y dis p ositi o ne d,  is a vaila ble o n site a n d 
t hat resc ue cells are a vaila ble. N ot e t hat if Scree ni n g Visit a n d Prec o n diti o ni n g Visits are > [ADDRESS_206061] be re peate d: P F Ts, esti mate d  
G F R, a n d car diac D o p pler ec h ocar di ol o g y (i ncl. L V E F).  
[ADDRESS_206062] 2 4 h o urs after c o m pleti o n of 4 da y  b us ulfa n c o urse; V O D/ S O S 
pr o p h yla xis as ma n date d i n Secti o n  5. 9. [ADDRESS_206063] a n d t hir d da y of d osi n g is re q uire d.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 0 
 T a ble 6: Sc he d ule of E ve nts: F oll o w -u p  
Pr oce d ure  F oll o w -U p: D a y ( D), M o nt h ( M)  ( Visit Wi n d o w, d a ys) P ost -Dr u g Pr o d uct I nf usi o n  
D 3 0  D 6 0  D 9 0  D 1 2 
0 D 1 5 0  D 1 8 
0 D 2 1 0  D 2 4 
0 D 2 7 0  D 3 0 0  D 3 3 0  D 3 6 0  D 4 2 0  D 4 5 0  D 4 8 
0 D 5 4 0  D 6 0 0  D 6 6 0  D 7 2 0  
M 1  
( ± 7)  M 2  
( ± 7)  M 3  
( ± 7)  M 4  
( ± 1 4 
) M 5  
( ± 1 4)  M 6  
( ± 1 4)  M 7  
( ± 1 4)  M 8  
( ± 1 4 
) M 9  
( ± 1 4)  M 1 0  
( ± 1 4)  M 1 1  
( ± 1 4)  M 1 2  
( ± 3 0)  M 1 4  
( ± 3 0)  M 1 5  
( ± 3 0)  M 1 6  
( ± 3 0 
) M 1 8  
( ± 3 0)  M 2 0  
( ± 3 0)  M 2 2  
( ± 3 0)  M 2 4  
( ± 3 0)  
P h ysical e xa mi nati o n 1 X X X X X X   X   X  X  X   X 
Vital si g ns  X X X X X X   X   X  X  X   X 
Bl o o d f or ser u m β -h u ma n 
c h ori o nic  g o na d otr o pi n  
f or  w o me n  of  c hil d -
beari n g  p ote ntial  (ser u m  
pre g na nc y test) 2   X   X              
Bl o o d  f or  cli nical  
la b orat or y tests 3 X X X X X X   X   X  X  X   X 
Bl o o d f or C B C o nl y        X X  X X  X  X  X X X 
Bl o o d  f or  fasti n g  
Gl uc ose/I ns uli n le vels [ADDRESS_206064] u dies 5   X   X      X  X  X   X 
Bl o o d f or i m m u n ol o g y 6   X   X      X       X 
Bl o o d  f or  h or m o nal  a n d 
 
testi n g 7             X       X 
Bl o o d  f or  gl o bi n  i n  
a ut ol o g o us cells             X       X 
Bl o o d  f or  gl o bi n  H P L C  
& V C N    X X   X   X   X    X   X 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 1 
 T a ble 6: Sc he d ule of E ve nts: F oll o w -u p  
Pr oce d ure  F oll o w -U p: D a y ( D), M o nt h ( M)  ( Visit Wi n d o w, d a ys) P ost -Dr u g Pr o d uct I nf usi o n  
D 3 0  D 6 0  D 9 0  D 1 2 
0 D 1 5 0  D 1 8 
0 D 2 1 0  D 2 4 
0 D 2 7 0  D 3 0 0  D 3 3 0  D 3 6 0  D 4 2 0  D 4 5 0  D 4 8 
0 D 5 4 0  D 6 0 0  D 6 6 0  D 7 2 0  
M 1  
( ± 7)  M 2  
( ± 7)  M 3  
( ± 7)  M 4  
( ± 1 4 
) M 5  
( ± 1 4)  M 6  
( ± 1 4)  M 7  
( ± 1 4)  M 8  
( ± 1 4 
) M 9  
( ± 1 4)  M 1 0  
( ± 1 4)  M 1 1  
( ± 1 4)  M 1 2  
( ± 3 0)  M 1 4  
( ± 3 0)  M 1 5  
( ± 3 0)  M 1 6  
( ± 3 0 
) M 1 8  
( ± 3 0)  M 2 0  
( ± 3 0)  M 2 2  
( ± 3 0)  M 2 4  
( ± 3 0)  
Bl o o d f or R C L  a nal yses 8   X   X      X       X9 
Bl o o d f or I S A       X      X    X   X 
B o ne marr o w 1 0             X       X 
Li ver  a n d  s plee n  S O C  
M RI             X       X 
P ul m o nar y  f u ncti o n  
tests 1 1              X       X 
Car diac  a n d  li ver  
T 2 * M RI  &  
ec h ocar di ol o g y 1 2             X       X 
1 2 -lea d E C G             X       X 
B o ne  i ma gi n g  ( X -ra y 
a n d/ or De xa Sca n) [ADDRESS_206065] i nf usi o n disc har ge  
A d verse e ve nt c ollecti o n  C o nti n u o us fr o m I C F si g ni n g  
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 2 
 T a ble 6: Sc he d ule of E ve nts: F oll o w -u p  
Pr oce d ure  F oll o w -U p: D a y ( D), M o nt h ( M)  ( Visit Wi n d o w, d a ys) P ost -Dr u g Pr o d uct I nf usi o n  
D 3 0  D 6 0  D 9 0  D 1 2 
0 D 1 5 0  D 1 8 
0 D 2 1 0  D 2 4 
0 D 2 7 0  D 3 0 0  D 3 3 0  D 3 6 0  D 4 2 0  D 4 5 0  D 4 8 
0 D 5 4 0  D 6 0 0  D 6 6 0  D 7 2 0  
M 1  
( ± 7)  M 2  
( ± 7)  M 3  
( ± 7)  M 4  
( ± 1 4 
) M 5  
( ± 1 4)  M 6  
( ± 1 4)  M 7  
( ± 1 4)  M 8  
( ± 1 4 
) M 9  
( ± 1 4)  M 1 0  
( ± 1 4)  M 1 1  
( ± 1 4)  M 1 2  
( ± 3 0)  M 1 4  
( ± 3 0)  M 1 5  
( ± 3 0)  M 1 6  
( ± 3 0 
) M 1 8  
( ± 3 0)  M 2 0  
( ± 3 0)  M 2 2  
( ± 3 0)  M 2 4  
( ± 3 0)  
C o nc o mita nt  me dicati o n  
(i ncl.  ir o n  c helat ors  &  
p hle b ot o m y)  C o nti n u o us fr o m I C F si g ni n g  
[ADDRESS_206066] i nf usi o n. Ta n ner sta gi n g s h o ul d be perf or me d e ver y 6 m o nt hs 
d uri n g p u bert y, if rele va nt. F or s u bjects < 1 8 years of a ge, will be e val uate d e ver y 6 m o nt hs.  
2 S h o ul d be c o nfir me d pri or t o m o bilizati o n  
3 He mat ol o g y ( C B C, platelets, retic ul oc ytes, n ucleate d R B Cs); ser u m c he mistr y a n d li ver f u ncti o n tests, a n d a d diti o nal cli nical la b orat or y tests as cli nicall y 
i n dicate d. Cli nical la b orat or y tests s h o ul d be o btai ne d o n a m ore fre q ue nt basis if cli nicall y i n dicate d (e. g. m o nit ori n g & e val uati o n of A Es). If t he res ults fr o m 
bl o o d tests are n ot as e x pecte d, a d diti o nal testi n g ma y nee d t o be perf or me d a n d ma y i ncl u de a p h ysical e xa m, bl o o d tests, i ma gi n g tests, or a b o ne marr o w bi o ps y 
t o all o w f or f urt her i n vesti gati o n of ste m cells.  
4 Fasti n g gl uc ose a n d i ns uli n le vels ( H O M A i n de x) at least e ver y [ADDRESS_206067] u dies (ir o n, ferriti n, ser u m tra nsferri n rece pt or, tra nsferri n) s h o ul d als o be perf or me d pri or t o restarti n g ir o n c helati o n/ p hle b ot o m y.  
6 T cell s u bsets [ C D 4, C D 8], B cells ( C D 1 9), a n d nat ural killer cells ( C D 1 6 a n d/ or C D 5 6); i m m u n o gl o b uli ns (I g G, I g M, a n d I g A)   
7 H or m o nal testi n g i ncl u des t h yr oi d f u ncti o n (free T 4, T S H); P T H. F or s u bjects after p u bert y, als o i ncl u des L H, F S H a n d estra di ol (fe males o nl y); test oster o ne 
( males o nl y). F or s u bjects < 1 8 years of a ge, i ncl u des gr o wt h h or m o ne (I G F -1 a n d I G F B P -3).    
[ADDRESS_206068]’s pre vi o us R C L tests were all ne gati ve, t he [ADDRESS_206069] u dies (retic ul oc ytes, n ucleate d R B C, ser u m tra nsferri n rece pt or, he pci di n, a n d er yt hr o p oieti n), as well as m or p h ol o g y, 
cell ularit y, cell c o u nt, a n d ir o n c o nte nt; if s ufficie nt s a m ple is a vaila ble, sa m ple ma y be arc hi ve d a n d/ or ot her researc h tests (e. g., V C N, I S A, H P L C, ge netic 
testi n g) ma y be perf or me d.  
1 1  I ncl u di n g o x y ge n sat urati o n; c orrecte d % pre dicte d F V C, % pre dicte d F E V 1; % pre dicte d R V; a n d % pre dicte d D Lc o (c orrecte d f or H b a n d/ or al ve olar v ol u me, 
as cli nicall y i n dicate d). If s u bject ca n n ot perf or m t hese p ul m o nar y f u ncti o n tests d ue t o a ge or c o g niti o n -relate d restricti o ns, t he n res pi[INVESTIGATOR_1305] y e xa m, c hest 
ra di o gr a p h, a n d p ulse o xi metr y will s u bstit ute f or t hese assess me nts. If s u bject bec o mes a ble t o perf or m s pir o metr y a n d l u n g diff usi o n ca pacit y test, t hese 
p ul m o nar y f u ncti o n tests s h o ul d be perf or me d per S O E a n d/ or at a n u nsc he d ule d ti me p oi nt.  
1 2  A n n ual ec h ocar di o gra p h y is o nl y re q uire d if cli nicall y si g nifica nt a b n or malit y is o bser ve d o n t he Scree ni n g ec h ocar di o gra m, or a n y s u bse q ue nt ec h ocar di o gra m, 
or if t here is e vi de nce of ir o n o verl oa d (car diac T 2 * ≤ 2 0 ms) or ot her cli nicall y si g nifica nt a b n or malit y o n car diac T 2 * M RI  
1 3  A ge a p pr o priate b o ne i ma gi n g ( b o ne a ge/ mi neral de nsit y) t o be d o ne base d o n i n vesti gat or j u d g me nt.  
[ADDRESS_206070] tra nsf usi o n, a n d a g e w he n fre q ue nc y of tr a nsf usi o ns was esta blis he d (i.e., a ge 
at w hic h tra nsf usi o n nee ds t o be sta bilize d t o a p pr o xi matel y bet wee n o n ce e ver y 3 -8 wee ks). 
Tra nsf usi o n hist or y (i ncl u di n g date, a m o u nt tra nsf use d, n u m ber of u nits, a vera ge v ol u me of u nits 
a n d a ver a ge c o n ce ntr ati o n of he mat ocrit [ Hct] of R B Cs tra nsf use d), al o n g wit h t he ass ociate d 
ret ic ul oc yte a n d H b val u es ta ke n pri or t o t he tra nsf usi o n w here a vaila ble, s h o ul d als o be c ollect e d 
f or t he [ADDRESS_206071] u d y e nr oll me nt. 
All i n -patie nt h os pi[INVESTIGATOR_1314] o ns ( da ys) f or t he [ADDRESS_206072] or y (c h elati o n a ge nt, d ose/ u nit, r o ute, fre q ue n c y, dates a n d reas o n f or st o p pi n g) 
f or t he [ADDRESS_206073] was ma n a ge d wit h s pecific tr a nsf usi o n g oals (i.e., H b a n d/ or s y m pt o m tri g ger f or 
tra nsf usi o n) w hic h wer e a d here d t o f or a mi ni m u m of [ADDRESS_206074]’s  me dical  r ec or ds  a n d us e d t o det er mi ne i nitial  
eli gi bilit y t o e nter Scree ni n g. I n a d diti o n, m utati o n at eac h allele of t he β -gl o bi n l oc us ( H B B ge ne) 
as deter mi ne d b y se q ue n ci n g a n d n otate d acc or di n g t o t he precise ge netic m utati o n i de ntifie d per 
rec o m me n dati o n of t he H u ma n Ge n o me Variati o n S ociet y ( w w w. H G V S. or g ) will be assesse d b y 
a  ce ntr alize d  la b orat or y  pri or  t o  s u bjects  be gi n ni n g  m o bilizati o n  a n d  a p her esis  t o  c o nfir m  
eli gi bilit y.  M utati o ns  will  be  classifie d  as  β +,  β 0 or  β E base d  o n  t h e  gl o bi n  ge ne  s er ver  
( htt p:// gl o bi n. b x. ps u.e d u/ ),  a n  a n n otate d  o nli ne  c o m pre he nsi ve  d ata  bas e  of  H B B  m utati o ns. 
S u bjects w h ose g e n ot y pi n g d oes n ot c o nfir m t he m as eli gi ble will be dis c o nti n ue d fr o m t his st u d y 
pri or t o be gi n ni n g m o bilizati o n a n d a p h eresis. 
A n a d diti o nal bl o o d sa m ple ta ke n at t he Scr ee ni n g Visit will be ar c hi ve d f or p ote ntial a n al yses of 
ge nes i m p orta nt i n T D T at a ce ntr al la b orat or y, w hic h ma y i ncl u de:  
• Al p ha- gl o bi n ge ne c o p y n u m ber 
• H G B 2  S N Ps  
• H B S 1 L- M Y B  S N Ps  
• B C L [ADDRESS_206075]. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 4 
 6. 2. 2.  Cli nic al/ P h ysic al E x a mi n ati o n  
A  c o m plete  p h ysical  e xa mi nati o n  ( ge ner al  a p peara n ce;  hea d  e y es,  ears,  n ose,  a n d  t hr o at;  
car di o vas c ular; der mat ol o gic, a b d o mi nal; ge nit o uri nar y; l y m p h n o des; he patic; m usc ul os keletal; 
res pi[INVESTIGATOR_1305] y; ne ur ol o gical) is t o be c o n d ucte d as per t he S O E.  I n a d diti o n, at scree ni n g, a n d e ver y 
[ADDRESS_206076] i nf usi o n,  will be assesse d f or s u bjects 
< [ADDRESS_206077]’s wei g ht is t o be meas ure d at e ver y visit t hat i ncl u des a c o m plete p h ysical e xa mi nati o n.  
A n  a b bre vi ate d  p h ysical  e xa mi nati o n  i ncl u des  ge neral  a p peara n ce  a n d  e xa mi nati o n  of  
s y m pt o matic or ga n s yste ms a n d d oes n ot i ncl u de wei g ht. 
T he s u bject’s hei g ht is t o be meas ur e d at t he Scree ni n g Visit a n d at e ver y [ADDRESS_206078]’s perf or ma nce stat us is t o be m eas ur e d at t he Scree ni n g Visit, at t he Pre - c o n diti o ni n g 
Visit, a n d at e ver y [ADDRESS_206079] olic/ diast olic bl o o d press ure, p ulse, res pi[INVESTIGATOR_1313] o n rate, a n d 
te m perat ur e, a n d will be perf or me d i n acc or da n ce wit h i nstit uti o nal sta n dar ds, as per t he S O E .  
6. 2. 4.  Electr oc a r di o gr a m  
A 1 2 -lea d el ectr o car di o gra m ( E C G) will be o btai n e d as per t h e  S O E.  
6. 2. 5.  I m a gi n g 
Sta n dar d cli nical practice g ui deli nes will be use d t o perf or m t he f oll o wi n g i ma gi n g assess me nt at 
t he ti me p oi nts s pecifie d i n t he S O E:  
• A c hest X -ra y will be o bt ai ne d at Scree ni n g. 
• B o ne i ma gi n g ( X -ra y a n d/ or  [ D E X A] sca n) s h o ul d als o be d o ne base d o n 
s u bject’s a ge, as per S O E.  
• Car diac  D o p pler  ec h o car di o gra p h y,  i ncl u di n g  t he  assess me nt  of  left  ve ntric ular  
ejecti o n fr acti o n ( L V E F) will be perf or me d as per S O E.  
• Li ver a n d s plee n i ma gi n g b y M RI. 
• Car diac M RI a n d li ver M RI f or deter mi nati o n of T 2 * a n d LI C, r es pecti v el y, will be 
perf or me d as defi ne d b y t he i ma gi n g c ore la b orat or y at t he ti mes s pecifie d i n t he S O E.  
A  Bli n de d  I n d e pe n d e nt  Ce ntral  Re vie w  C o m mittee  ( BI C R)  will  e v al uate  M RI  i ma ges  f or  
deter mi nati o n of LI C a n d car di ac a n d li ver T 2 * i n acc or d a nce wit h a n i ma gi n g c hart er. Dr y wei g ht 
of LI C will be meas ur e d. T he M RI i ma ges will be ac q uire d at t he cli nical site i n acc or d a nce wit h 
t he i ma ge ac q uisiti o n g ui deli nes. Li ver a n d s plee n v ol u mes as well as i nci de ntal cli nical fi n di n gs 
C CI C CI 
C CI 
Pr ot oc ol H G B - [ADDRESS_206080] u dies. Li ver 
bi o ps y will be perf or me d i n a d ult s u bjects ( ≥ 1 8 years of a ge) if M RI of t he li ver s u g gests acti ve 
he patitis, si g nifica nt fi br osis, i nc o ncl usi ve e vi de nce of  cirr h osis, or LI C is ≥ 1 5 m g/ g. Li ver bi o ps y 
is c urre ntl y t he preferre d met h o d f or e val uati o n of t he e xte nt of fi br osis  (C a p pelli ni et al., 2 0 1 4 ). 
Li ver bi o ps y will o nl y be perf or me d i n a d ol esce nt a n d pe diatric s u bj ects ( < 1 8 years of a ge), if 
a d diti o nal data be y o n d t h e M RI is f elt t o be a bs ol utel y necessar y b y t he i n v esti gat or t o c o nfir m or 
ref ute M RI data, a n d if t he pr oce d ure is c o nsi der e d t o be safe t o perf or m. Li ver bi o ps y s h o ul d n ot 
be perf or me d o n t hr o m b oc yt o pe nic patie nts if i nc o nsiste nt wit h i nstit uti o nal g ui deli nes. 
6. 2. 6.  P ul m o n ar y F u ncti o n Tests  
P ul m o nar y f u ncti o n testi n g will be perf or me d as per t he S O E. Para m eters t o be meas ure d i ncl u d e 
o x y ge n  sat urati o n  meas ure d  b y  p ulse  o xi metr y,  %  pre dicte d  f orce d  vital  ca pacit y  ( F V C),  
% pre dicte d f or ce d e x pir at or y v ol u me i n 1 s ec o n d ( F E V 1), % pr e dicte d res pi[INVESTIGATOR_1305] y v ol u me ( R V), 
a n d % pr e dicte d D Lc o ( c orrect e d f or H b a n d/ or al ve olar v ol u me, as cli nicall y i n dicate d). If  s u bject 
ca n n ot perf or m t hese p ul m o nar y f u ncti o n tests d ue t o a ge or c o g niti o n -rel ate d restricti o ns, t he n 
res pi[INVESTIGATOR_1305] y e xa m, c h est r a di o gra p h, a n d p ulse o xi metr y will s u bstit ute f or t hese assess me nts. If 
s u bject bec o m es a ble t o perf or m s pir o metr y a n d l u n g diff usi o n ca pacit y test, t hese p ul m o nar y 
f u ncti o n tests s h o ul d be perf or me d p er S O E a n d/ or at a n u nsc he d ule d ti me p oi nt. 
6. 2. 7.  Tr a nsf usi o ns  
I nter val tra nsf usi o ns re q uire d ar e t o be d oc u me nt e d as per t he S O E. 
6. 2. 8.  I n - p atie nt H os pit aliz ati o ns 
All i n -patie nt h os pi[INVESTIGATOR_1314] o ns are t o be d oc u me nte d, w here i n -p atie nt h os pi[INVESTIGATOR_1314] o n is defi ne d as 
d urati o n of h os pi[INVESTIGATOR_1314] o n f or at least 2 4 h o urs. 
6. 2. 9.  He m o gl o bi n o p at h y M ar kers i n Bl o o d 
Bl o o d  sa m ples  are  t o  be  c ollecte d  f or  gl o bi n  pr otei n  a nal yses  b y  hi g h -press ur e  li q ui d  
c hr o mat o gra p h y ( H P L C) per t he S O E f or deter mi nati o n of t he r ati o of β A- T [ADDRESS_206081] u d y t halasse mia a n d/ or 
ge ne t her a p y, ar e o pti o nal. 
C ollecti o n a n d st ora ge of t he sa m ples des cri be d a b o ve will be s u bject t o discreti o nar y a p pr o val 
fr o m eac h ce nter’s I R B/ E C a n d t he s u bject’s s p ecific writte n c o nse nt. Sa m pl es will be la bele d wit h 
a u ni q ue i de ntificati o n n u m ber t hat i ncl u des n o s u bject i de ntif yi n g i nf or mati o n. 
6. 2. 1 4.  Fertilit y Preser v ati o n  
Fertilit y preser vati o n ( e. g., s per m  or t estic ular tiss ue ba n ki n g f or m ales  or o oc yte  as pi[INVESTIGATOR_1313] o n 
f oll o wi n g o varia n sti m ulati o n a n d cr y o preser vati o n f or fe males) will be d o ne as a p pr o priate at t he 
discreti o n of t he s u bject, t heir le gal g uar dia n (as a p plica ble) a n d t he I n vesti gat or. 
6. 2. 1 5.  He alt h -Rel ate d Q u alit y of Life Assess m e nt  
E val uati o n of healt h -relat e d q ualit y of life ( H R Q o L) o ver ti me usi n g t he f oll o wi n g vali date d t o ols * 
(as s h o w n i n Ta ble  7 , acc or di n g t o t he S O E): 
*W her e vali date d tr a nslati o ns of H R Q o L i nstr u me nts are a v aila ble  
• Pe diatrics: Pe ds Q L ( par e nt ge neral c ore a n d ge ner a l c ore)  
• A d olesce nts: Pe ds Q L ( p are nt ge neral c or e a n d g e n eral c ore) a n d E Q - 5 D- Y 
• A d ults: E Q -5 D, F A C T - B M T, a n d S F- 3 6 v 2  
T a ble 7: A ge - a p pr o pri ate V ali d ate d H R Q o L T o ols 
A ge  Pe ds Q L  
Ge ner al C ore  Pe ds Q L P are nt  
Ge ner al C ore  E Q -5 D -Y 
( y o ut h)  E Q - 5 D S F - 3 6 v 2 F A C T -B M T  
0-4 
5- 1 1 
1 2 -1 7   
X 
X X 
X 
X  
X ( 1 1 o nl y) 
X    
[ADDRESS_206082] u d y. 
6. 2. 1 6.  Cli nic al L a b or at or y Tests 
Cli nical  la b orat or y  tests  will  be  perf or m e d  as  s pecifie d  b el o w,  a n d  i n  t he  S O E.  A d diti o nal  
la b orat or y tests s h o ul d b e perf or me d as cli nicall y i n dicate d ( e. g. o n g oi n g m o nit ori n g of A Es). A n y 
a d diti o nal la b orat or y par a meters t hat are perf or m e d w hile a s u bject is o n st u d y s h o ul d be e ntere d 
as s uc h i nt o t he cli nical st u d y data base. 
Cli nical la b orat or y tests are t o be perf or m e d a n d re vie we d b y t he i n vesti gat or or q ualifie d desi g nee 
(e. g.,  p h ysicia n’s  assista nt,  n urse  practiti o ner).  All  la b orat or y  assess me nts  will  be  a nal yze d  
ce ntrall y u nless ot her wise n ote d i n t he S O E or S O M.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 8 
 6. 2. 1 6. 1.  He m at ol o g y a n d Cli nic al C he mistr y 
Bl o o d sa m ples f or all he mat ol o g y para meters, a n d cli nical c h e mistries, ar e t o be c ollecte d as p er 
t he S O E.  
T he f oll o wi n g cli nical la b orat or y par a meters ( Ta ble  8 ) ar e t o be deter mi ne d: 
T a ble 8:  He m at ol o g y, Ir o n St u dies, Ser u m C he mistr y, a n d Li ver F u ncti o n 
He m at ol o g y   Ir o n St u dies  
C o m plete bl o o d c o u nt ( C B C) wit h differe ntial a Ir o n  
Platelet c o u nt  Ferriti n  
Retic ul oc yte c o u nt  Ser u m tra nsferri n rece pt or  
N ucleate d R B Cs  Tra nsferri n  
Ser u m C he mistr y a n d Li ver F u ncti o n   
S o di u m  Bl o o d urea nitr o ge n  
P otassi u m  Creati ni ne  
C hl ori de  Gl uc ose b 
Bicar b o nate  Calci u m  
Al b u mi n  P h os p hate  
T otal pr otei n  Bilir u bi n (t otal a n d direct)  
Ala ni ne tra nsa mi nase  Al kali ne p h os p hatase  
As partate tra nsa mi nase  Lactic de h y dr o ge nase  
Ga m ma gl uta m yl tra nsferase   
a C B C  R B C  e val uati o n  s h o ul d  i ncl u de  R B C  c o u nt,  H b,  he mat ocrit,  mea n  c or p usc ular  v ol u me  ( M C V),  mea n  
c or p usc ular H b ( M C H), a n d mea n c or p usc ular H b c o nce ntrati o n ( M C H C).  
b Fasti n g gl uc ose/i ns uli n a n d H o me ostasis M o del Assess me nt i n de x testi n g s h o ul d be d o ne at  least e ver y [ADDRESS_206083] is re q uire d f or a n y a b n or mal fasti n g gl uc ose.  
I n a d diti o n, t he G F R will be esti mate d as per t he S O E. See Secti o n 1 0. 1  f or t he f or m ula f or 
calc ulati o n of G F R.  
Pr ot hr o m bi n ti me (re p orte d as t he i nter nati o nal n or malize d rati o [I N R]) a n d partial t hr o m b o plasti n 
ti me will als o be deter mi ne d at t he Scree ni n g Visit as per t he S O E . 
6. 2. 1 6. 3.  Uri n al ysis  
A uri nal ysis will be perf or me d at Scree ni n g.  
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 6 9 
 6. 2. 1 6. 4.  Pre g n a nc y Testi n g  
F or f e male s u bj ects of c hil d -beari n g p ote ntial o nl y, ser u m pre g n a nc y t ests ( β-h u ma n c h ori o nic 
g o na d otr o pi n) will be o btai ne d as per t he S O E. 
6. 2. 1 6. 5.  Ser ol o g y 
Scree ni n g ser ol o g y will be e val uate d usi n g sta n d ar d met h o ds as per t he S O E, testi n g f or prese n ce 
of HI V -1, HI V -2, H B V, or H C V. S y p hilis (ra pi d plas ma rea gi n [ R P R]) testi n g is als o re q uire d, 
a n d s u bjects testi n g p ositi ve will be e xcl u de d ( u nless n o l o n ger ma n d ate d b y ce ntral dr u g pr o d uct 
ma n ufact uri n g  practices).  W here  cli nicall y  a n d/ or  re gi o nall y  i n dicat e d,  ot her  tests  ma y  be  
perf or me d,  i n  w hic h  case  p ositi ve  res ults  w o ul d  e xcl u de  t he  s u bject  fr o m  partici pati n g:  f or  
e xa m ple, H T L V -[ADDRESS_206084] ’s 
hist or y a n d/ or t he c haract eristics of t he s u bject’s cells (e. g., malaria). 
See als o i nfecti o n s ur v eilla nce ( Secti o n 5. 9. 5 ).  
6. 2. 1 6. 6.  H or m o n al Testi n g 
H or m o nal testi n g, i ncl u di n g t h yr oi d f u ncti o n (free t h yr o xi ne [ T 4], t h yr oi d sti m ulati n g h or m o ne 
[ T S H]) a n d p ar at h yr oi d h or m o ne ( P T H), f or all s u bjects is t o be perf or m e d as per t he S O E. I n 
a d diti o n  f or  s u bjects  aft er  p u bert y,  l utei nizi n g  h or m o ne  ( L H,  fe m ale  s u b jects  o nl y),  f ollicle  
sti m ulati n g h or m o ne ( F S H, fe male s u bjects o nl y), estra di ol (fe male s u bjects o nl y), test oster o ne 
( male s u bjects o nl y), s h o ul d be perf or me d acc or di n g t o t he S O E.  Gr o wt h h or m o ne (I ns uli n -li ke 
gr o wt h fact or 1[I G F -1] a n d I ns uli n -li ke gr o w t h fact or -bi n di n g pr otei n 3 [I G F B P -3]) s h o ul d b e 
assesse d i n a d oles ce nts.  
6. 2. [ADDRESS_206085] e d, a d diti o nal testi n g ma y nee d t o be perf or me d t o 
all o w f or f urt h er i n vesti g ati o n  of ste m cells a n d m a y i ncl u de:  
• P h ysical e xa m  
• Bl o o d tests 
• I ma gi n g tests  
• B o ne marr o w bi o ps y a n d/ or as pi[INVESTIGATOR_1313] o n ( ma y als o b e ar c hi ve d f or a d diti o nal a nal ysis i n 
t he f ut ure, see Secti o n  6. 2. 1 0 ) 
6. 2. 1 7.  I m m u n ol o gic al Testi n g  
I m m u n ol o gical testi n g, i ncl u di n g T cell s u bsets ( C D 4, C D 8), B cells ( C D 1 9), a n d nat ur al killer 
( N K) cells ( C D 1 6 a n d/ or C D 5 6), will be perf or me d as per t he S O E. 
Q ua ntitati o n of i m m u n o gl o b uli ns (I g G, I g M, a n d I g A) is t o be perf or me d as per t he S O E. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 0 
 C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 1 
 C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 2 
 6. 2. 1 8. 2.  Cli nic al W or k - u p f or P ote nti al M ali g n a nc y 
I n t he e ve nt of cl o nal pr e d o mi na nce, p ersiste nt cl o nal pre d o mi na n ce, or a n y cli nical s us pi[INVESTIGATOR_37180] o n of 
m yel o d ys plasia, le u ke mi a, or l y m p h o ma, t he Me dical M o nit or will be n otifie d a n d a w or k -u p will 
be perf or me d t hat ma y  o cc ur i n sta ges a n d ma y i n cl u de s o me of t he f oll o wi n g at eac h sta g e:  
• P h ysical e xa m  
• C B C wit h differe ntial  
• L y m p h oc yte s u bsets 
• St u dies t o r ule o ut i nfecti o us ca use 
• St u dies t o r ule o ut a ut oi m m u ne disease 
• I ma gi n g st u dies 
• B o ne marr o w a nal ysis 
• C yt o ge netic a n d m olec ul ar a nal ys es  
If t he cli nical w or k -u p i n dicates n o e vi de nce of m yel o d ys plasia, le u ke mia, or l y m p h o ma, t he 
s u bject will c o nti n ue t o be m o nit ore d as p er t he pr ot oc ol -defi n e d S O E, or m ore fre q u e ntl y at 
discreti o n  of  t he  I n v esti gat or  a n d  S p o ns or.  If  t he  c li nical  w or k -u p  i n dicates  a  dia g n osis  of  
m yel o d ys plasia,  le u ke mia,  or  l y m p h o ma,  t he  S p o ns or  will  c o n ve ne  a n  ur ge nt  safet y  re vi e w  
meeti n g. F urt her a n al yses will be deter mi ne d b y t he S p o ns or, i n c o ns ultati o n wit h t he D M C. It 
s h o ul d be n ote d t hat it ma y n ot be p ossi ble t o disti n g uis h t he s o urce of mali g na nc y (e. g., arisi n g 
fr o m u n derl yi n g p at h o p h ysi ol o g y of t he diseas e, tra ns pla nt -r elate d me di cati o ns or pr oce d ures, or 
fr o m e x pa nsi o n of ge n e -m o difie d cells d ue t o i ns erti o nal o nc o ge n esis), a n d all eff orts s h o ul d  be 
ma de t o c o nfir m t he s o ur ce of mali g na n c y.  
F or cli nical w or k -u p after i de ntificati o n of a persiste nt pre d o mi na nt cl o ne a n d c o nfir me d pres e nce 
of a b n or mal C B C, b o ne marr o w a n al ysis is rec o m me n de d if n ot pre vi o usl y perf or me d as p art of 
t he cli nical w or k - u p. 
6. 2. [ADDRESS_206086] u d y  
M o nit ori n g of A Es will be c o n d u cte d fr o m t he si g ni n g of i nf or me d c o ns e nt. A Es f or all s u bjects 
(e xcl u di n g scr ee n fail ur es) will be rec or d e d i n t he C R Fs starti n g fr o m t he ti me i nf or me d c o nse nt 
is si g ne d t hr o u g h t he M o nt h  2 4 Visit. All S A Es (i ncl u di n g scree n f ail ures) will be re p ort e d fr o m 
t he si g ni n g of i nf or me d c o nse nt/asse nt o n t he S A E re p ort f or m. 
All A Es s h o ul d be m o nit ore d u ntil t he y are r es ol ve d or ar e clearl y deter mi ne d t o be d ue t o a 
s u bject’s sta ble or  c hr o nic c o n diti o n or i nter -c urr e nt ill ness(es). F or s u bjects w h o wit h dra w f or 
reas o ns ot her t ha n wit h dr a wal of c o ns e nt, a n y S A Es o pe n at t he ti me of disc o nti n uati o n s h o ul d be 
f oll o we d- u p u ntil res ol uti o n or are d eter mi ne d t o b e a sta ble or c hr o nic c o n diti o n.  
If wit h dra wal is bef or e dr u g pr o d uct i nf usi o n, s u bjects s h o ul d re mai n o n st u d y f or at least [ADDRESS_206087] u d y pr oce d ur e ( e. g., m o bilizati o n, li ver bi o ps y) bef ore wit h dra wal a n d o n g oi n g 
A Es  s h o ul d  be  m o nit ore d  f or  t he  [ADDRESS_206088]  i nf usi o n,  s u bjects  will  be  as ke d  t o  c o m plete  t h e  sa m e  
assess me nts as s pecifie d i n t he S O E f or M o nt h 2 4 ( Earl y Ter mi nati o n Visit assess me nts) a n d will 
be e x pecte d t o e nr oll i n t he l o n g- ter m f oll o w - u p St u d y L T F‑ [ADDRESS_206089] u d y ( L T F -3 0 3), t hat will m o nit or t he s afet y of s u bjects (i ncl u di n g dr u g pr o d uct -relat e d 
A Es) t hr o u g h a t otal of [ADDRESS_206090] u d y H G B - 2 0 7 (e. g., M o nt h [ADDRESS_206091] u d y visit) a n d partici p ati o n i n 
t he L T F -[ADDRESS_206092] u d y (i. e. si g nat ure o n I C F), all S A Es t hat start d uri n g t hat ga p s h o ul d be re p orte d 
o n t he St u d y H G B- [ADDRESS_206093] u g relate d.  A n A E ma y i ncl u de a c ha n ge i n p h ysical si g ns, s y m pt o ms, a n d/ or 
cli nicall y si g nifica nt la b orat or y c ha n g e occ urri n g i n a n y p hase of a cli nical st u d y. T his defi niti o n 
i ncl u des i nterc urre nt ill nesses or i nj uries, a n d e x acer b ati o n of pre -e xisti n g c o n diti o ns. A pre -
e xisti n g c o n diti o n is a cli nical c o n diti o n (i ncl u di n g a c o n diti o n bei n g treate d) t hat is dia g n ose d 
bef ore t he s u bject si g ns t he i nf or me d c o nse nt f or m a n d is d oc u m e nte d as part of t he s u bj ect’s 
me dical hist or y.  
F or t he p ur p oses of t his st u d y, e n graft me nt fail ur e is defi ne d  as a n S A E a n d is t o be re p orte d as 
s uc h. ( F or t his pr ot oc ol, e n graft me nt f ail ure is defi ne d as fail ure t o ac hie ve a n A N C ≥ 5 0 0  cells/ µ L 
f or 3 c o nsec uti ve da ys b y Da y 4 3 or recei vi n g bac k -u p cells at a n y ti me d uri n g t he ne utr o p e nic 
p hase).  
6. 2. [ADDRESS_206094] refere nce saf et y i nf or mati o n w hic h 
is c o ntai ne d i n t he c urr e nt I n vesti gat or’s Br oc h ur e.  
6. 2. [ADDRESS_206095] u g t hat ca us es pr of o u n d m yel os u p pressi o n. Acc or di n gl y, s u bjects will 
e x perie n ce  i nte n de d  he mat ol o gic  e ve nts  (e. g.,  ne utr o pe nia,  t hr o m b oc yt o pe nia,  a ne mia)  a n d  
e x pecte d n o n- he mat ol o gi c e ve nts ( e. g., m uc ositis, na usea, v o miti n g, al o peci a, p yre xia) as a res ult 
of recei vi n g b us ulfa n I V. F or t he p ur p oses of t his pr ot oc ol, t hese e ve nts, w hic h are f a miliar t o 
tra ns pla nt p h ysicia ns a n d are descri be d i n t he b us ulfa n pres cri bi n g i nf or mati o n, are c o nsi dere d 
c o n diti o ni n g- relate d e v e nts ( C R Es).  
T he i nte n de d pr of o u n d m yel os u p pressi o n ( ma nif este d b y ne utr o pe nia, t hr o m b oc yt o pe nia, a n d/ or 
a ne mia)  a n d  e x pecte d  e ve nts  t hat  occ ur  after  t he  i nitiati o n  of  b us ulfa n  I V  c o n diti o ni n g  are  
c o nsi dere d t o be t he direct c o nse q ue nce of b us ulfa n c o n diti o ni n g a n d are t o be re p orte d as A Es 
b ut s h o ul d be attri b ute d t o c o n diti o ni n g a ge nt o n t he A E e C R F, as a p plica ble. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 4 
 6. 2. 1 9. 2. 4.  Seri o us A d verse E ve nts  
A n S A E  is a n y A E t hat: 
• Res ults i n deat h. 
• Is i m me diatel y life -t hr eate ni n g; i.e. t he s u bject was a t i m me diate ris k of deat h at t he 
ti me of t he e ve nt. It d o es n ot i ncl u de a n A E t hat, h a d it occ urr e d i n a m or e s e vere f or m, 
mi g ht ha ve ca use d d eat h.  
• Re q uires  i n -patie nt  h os pi[INVESTIGATOR_1314] o n  or  pr ol o n gati o n  of  e xisti n g  h os pi[INVESTIGATOR_1314] o n.  
H os pi[INVESTIGATOR_1314] o n a d missi o ns occ urri n g d uri n g t he st u d y peri o d t hat are f or pr oce d ur es 
pl a n ne d pri or t o st u dy e ntry  d o n ot meet t his criteria, u nless t here is a c o m plicati o n 
res ulti n g fr o m pr oce d ure t hat pr ol o n gs h os pi[INVESTIGATOR_1314] o n. 
• Res ults i n persiste nt or si g nifica nt disa bilit y/i nca pac it y; or a s u bsta ntial disr u pti o n of a 
s u bject’s a bilit y t o c o n d uct n or mal life f u ncti o ns. 
• Is a c o n ge nital a n o mal y/ birt h defect. 
• Is a n i m p orta nt me dical e ve nt. A n i m p orta nt me dical e ve nt is a n A E t hat ma y n ot res ult 
i n deat h, be lif e t hreate ni n g, or re q uir e  h os pi[INVESTIGATOR_1314] o n b ut ma y be c o nsi der e d seri o us 
w he n, base d u p o n a p pr o priate me dical j u d g me nt, it ma y je o par dize t he s u bject a n d ma y 
re q uire me di cal or s ur gical i nter ve nti o n t o pre ve nt o ne of t he o utc o mes liste d a b o ve. 
• F or t he p ur p os es of t his st u d y, a n y ne w mali g na nc y or ne w dia g n osis of a n e ur ol o gic, 
r he u mat ol o gic, or he mat ol o gic dis or der t h at, i n t h e i n vesti gat or’s o pi [INVESTIGATOR_9384] o n, is cli nicall y 
si g nifica nt a n d re q uires me dical i nter ve nti o n will be c o nsi dere d me dicall y i m p orta nt 
a n d t heref ore s eri o us. 
6. 2. [ADDRESS_206096] pr o vi de assess me nts of r elati o ns hi p a n d 
seri o us criteria at t he ti me of S A E re p ort s u b missi o n t o t he S p o ns or. 
Se verit y will be assesse d b y t he i n vesti gat or usi n g t he f oll o wi n g criteria per Nati o nal Ca ncer 
I nstit ute C o m m o n Ter mi n ol o g y Criteria f or A d v erse  E ve nts ( C T C A E), versi o n 4. 0 3, i ncl u di n g f or 
A Es t hat are a res ult of a la b orat or y a b n or malit y:  
• Gr a de 1 : Mil d, as y m pt o matic or mil d s y m pt o ms; cli nical or dia g n ostic o bser vati o ns 
o nl y; i nter ve nti o n n ot i n dicate d. 
• Gr a de 2:  M o derate; mi ni mal, l ocal or n o ni n vasi ve i nter ve nti o n i n dicate d; li miti n g a ge -
a p pr o priate i nstr u me nt al acti vities of dail y li vi n g ( A D L).  
• Gr a de  3 :  Se vere  or  me dicall y  si g nifica nt  b ut  n ot  i m me diatel y  life -t hreate ni n g; 
h os pi[INVESTIGATOR_1314] o n or pr ol o n gati o n of h os pi[INVESTIGATOR_1314] o n i n dicate d; disa bli n g; li miti n g self -
care A D L.  
• Gr a de 4:  Life -t hr eate ni n g c o nse q ue nces; ur ge nt i nter ve nti o n i n dicate d. 
• Gr a de 5:  Deat h r elate d t o A E.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 5 
 If t he Gr a de c h a n ges wit hi n a da y, t he ma xi m u m Gra de s h o ul d be rec or de d.  
Rel ati o ns hi p:  T he  I n v esti gat or  is  re q uire d  t o  pr o vi de  a n  assess me nt  of  t he  relati o ns hi p  of  
Le nti Gl o bi n B B [ADDRESS_206097] t o a n A E: 
• N ot Rel ate d : E x p os ure t o t he st u d y treat me nt di d n ot occ ur, or t he occ urr e nce of t he 
A E is n ot reas o na bl y rel ate d i n ti me, or t he A E is c o nsi dere d n ot r elate d t o t he st u d y 
treat me nt.  
• Unli kel y Rel ate d :  T he st u d y treat me nt a n d t he A E were n ot cl osel y relate d i n ti me, 
a n d/ or t he A E c o ul d be e x plai ne d m ore c o nsiste ntl y b y ca uses ot her t ha n e x p os ure t o 
t he st u d y treat me nt pr o d uct. 
• P ossi bl y Rel ate d :  T he st u d y treat me nt a n d t he A E wer e reas o na bl y relate d i n ti me, 
a n d t he A E c o ul d be e x plai ne d e q uall y w ell b y ca uses ot her t ha n e x p os ure t o t he st u d y 
treat me nt pr o d uct. 
• Rel ate d :  T h e st u d y tr eat me nt a n d t he A E w er e r eas o na bl y r elate d i n ti me, a n d t he A E 
was m ore li kel y e x plai ne d b y e x p os ure t o t he st u d y pr o d uct t ha n b y ot her ca uses, or 
t he st u d y treat me nt was t he m ost li kel y ca use of t he A E. 
F or t he p ur p ose of safet y a nal yses a n d safet y re p orti n g, all A Es t hat are classifie d as p ossi bl y 
relate d or relate d will be c o nsi dere d tr eat me nt -r elate d e ve nt s.  
6. 2. [ADDRESS_206098] be caref ull y m o nit ore d f or t he de vel o p me nt of a n y A Es. T his i nf or mati o n s h o ul d 
be o btai ne d i n t he f or m of n o n -lea di n g q uesti o ns (e. g., “ H o w ar e y o u feeli n g?”) a n d fr o m si g ns 
a n d s y m pt o ms detecte d d uri n g eac h e x a mi nati o n, la b orat or y assess me nts, o bser vati o ns of st u d y 
pers o n nel, a n d s p o nta n e o us re p orts fr o m s u bjects. 
A Es f or all eli gi ble s u bjects (i.e., e x cl u di n g scree n fail ures) will be rec or de d i n t he C R F. A n y 
cli nicall y si g nifica nt la b orat or y a b n or malit y or ot h er cli nicall y si g nifica nt fi n di n g is c o nsi dere d a n 
A E a n d t he A E m ust be r ec or de d o n t he a p pr o priat e pa ges of t he C R F. T he dia g n osis / u n derl yi n g 
eti ol o g y rat her t ha n t he si g ns/s y m pt o ms s h o ul d be r e p orte d as t he A E, w he n p ossi ble.  If n o 
dia g n osis is a vaila ble, re p ort o nl y t he si g ns a n d s y m pt o ms t hat met A E criteria as i n di vi d ual A E 
ter ms.  
6. 2. [ADDRESS_206099] be i m me diatel y re p orte d o n t he S A E 
re p ort f or m t o t he S p o ns or ( or desi g nee) wit hi n 2 4 h o urs of t he I n vesti gat or ( or desi g nee) b ec o mi n g 
a war e of t he S A E. All S A Es m ust be r e p orte d w h et her or n ot t he y are c o nsi dere d ca usall y r elate d 
t o Le nti Gl o bi n B B [ADDRESS_206100] u d y O per ati o ns Ma n ual ( S O M). All f oll o w -u p i nf or mati o n o n S A Es m ust als o be 
i m me diatel y re p orte d t o t he S p o ns or (i.e. wit hi n 2 4 h o urs). 
C o pi[INVESTIGATOR_3951] S A E re p orts a n d ass ociate d d oc u me ntati o n s u b mitte d t o t he S p o ns or will be ke pt i n 
t he I n v esti gat or's st u d y site file.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 6 
 Please  refer  t o  t he  S A E  re p ort  f or m  a n d  ass o ciate d  g ui deli nes  f or  i nf or mati o n  o n  h o w  t o  
i m me diatel y s u b mit S A E re p orts t o t he S p o ns or. 
6. 2. 1 9. 6.  S afet y Re p orti n g t o Re g ul at or y A ut h orities, Et hics C o m mittees, a n d I n vesti g at ors  
If t here  are s us p ecte d, u n e x pecte d s eri o us a d verse reacti o ns ( S U S A Rs) ass o ciate d wit h t he use of 
Le nti Gl o bi n B B [ADDRESS_206101] or pleri xaf or, bl ue bir d bi o, I n c., will n otif y t he a p pr o priate 
re g ulat or y a g e nc y(ies) a n d all partici pati n g i n vesti gat ors o n a n e x p e dite d b asis a n d i n acc or da n ce 
wit h a p plica ble re g ul ati o ns.  
T he I n vesti gat or or S p o ns or will n otif y t he I R B/ E C a n d ot her a p pr o pri ate i nstit uti o nal re g ulat or y 
b o dies of a n y S U S A Rs or u na ntici pate d pr o bl e ms, i n acc or d a nce wit h l ocal re q uire me nts. 
Re p orti n g of S U S A Rs t o re g ulat or y a g e ncies will be perf or me d wit hi n 7 or 1 5 da ys as i n dicate d 
b y t he e ve nt a n d i n acc or da nce wit h l ocal re g ulati o ns. A n n ual re p orti n g of safet y i nf or mati o n will 
als o be perf or me d b y bl u e bir d bi o, I nc., as re q uire d b y l ocal re g ulati o n.  
6. 2. 1 9. 7.  Pre g n a nc y a n d C o ntr ace pti o n 
Pre g na nc y is neit her a n A E n or a n S A E, u nless a c o m plicati o n relati n g t o t he pre g na n c y occ urs 
(e. g.,  s p o nta ne o us  a b orti o n,  w hic h  re q uir es  re p orti n g  as  a n  S A E).  H o we ver,  all  pre g n a ncies  
occ urri n g d uri n g t his st u d y (i n s u bjects or fe male part ners of male s u bjects) are t o be r e p orte d i n 
t he sa me ti me fra me as S A Es usi n g t he Pre g na nc y F or m. S A Es e x perie nce d b y s u bject or fe male 
part ner of m ale s u bject d uri n g t he c o urse of t h e pr e g na nc y are r e q uire d t o b e i m me diatel y re p orte d 
(i.e. wit hi n 2 4 h o urs) o n t he S A E re p ort f or m. 
T he c o urse of all * pre g n a ncies, i ncl u di n g peri nat al a n d ne o natal o utc o me, re gar dless of w h et her 
t he s u bject has disc o nti n ue d partici pati o n i n t h e st u d y, will be f oll o we d u ntil o utc o me, i ncl u di n g 
f oll o w- u p of t he h ealt h st at us of t he ne w b or n at 6  wee ks of a ge a n d a n n u all y t hereafter f or 2  years. 
S A Es e x perie n ce d b y ne w b or n wit hi n 6 wee ks of a ge are r e q uire d t o be i m me diatel y re p ort e d (i.e. 
wit hi n 2 4 h o urs) o n t he S A E re p ort f or m. 
* E xce pti o ns i ncl u de: 
I n cases w h er e t he M A L E was t he st u d y s u bject, pre g na nci es r es ulti n g fr o m s per m b a n ki n g pri or 
t o recei pt of dr u g pr o d uct will n ot be f oll o we d. 
I n cases w here t he F E M A L E was t he st u d y s u bject, pre g na n cies res ulti n g fr o m o oc yte ba n ki n g 
pri or t o recei pt of dr u g pr o d uct i n w hic h t he pre g na nc y is carri e d t o ter m b y s urr o gac y will n ot be 
f oll o we d. 
B us ulfa n has bee n s h o w n i n a ni mal st u dies t o be terat o ge nic (see pac ka g e i nsert f or a d diti o nal 
details). T he eff ects of a d mi nistrati o n of Le nti Gl o bi n B B [ADDRESS_206102]  o n t he pre g na nt fe male 
or t he de vel o pi n g fet us are u n k n o w n. Fe mal e s u bjects of c hil d -beari n g p ote ntial a n d males are 
re q uire d  t o  use  t w o  differe nt  effecti ve  met h o ds  of  c o ntr ace pti o n  (e. g.,  i m pla nts,  i njecta bles,  
c o m bi ne d oral c o ntr ace pti ves, s o me i ntra uteri ne de vices, barrier m et h o ds of c o ntrace pti o n wit h 
s per mici de, vasect o mise d part ner, f or fe m ales; barrier met h o ds of c o ntrace pti o n wit h s per mici de, 
vasect o m y, f or males) fr o m Scree ni n g t hr o u g h at least [ADDRESS_206103] i nf usi o n. If 
s u bjects are  tr ul y se x uall y a bsti ne nt ( w here tr ue s e x ual a bsti ne nce is defi n e d as bei n g i n li ne wit h 
t he pref err e d a n d us u al lifest yle of t he s u bject), n o sec o n d met h o d is re q uire d. ( Peri o dic a bsti ne n ce 
[cale n d ar, s y m pt ot her mal, p ost -o v ulati o n met h o ds], wit h dra w al [c oit us i nt err u pt us], s p er mici des 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 7 
 o nl y, a n d lactati o nal a me n orr hea met h o d ar e n ot acce pta bl e met h o ds of c o ntrace pti o n) . Be y o n d [ADDRESS_206104] u d y w he ne ver necessar y t o assess 
f or or t o f oll o w -u p o n A Es or as dee m e d necessar y b y t he i n vesti gat or. E val u ati o ns a n d pr oce d ures 
t o be perf or me d at u nsc h e d ule d visits will be at t he i n vesti gat or’s discreti o n i n c o ns ultati o n wit h 
t he S p o ns or as a p pr o pri ate a n d m a y be b ase d o n t h ose liste d i n t he S O E. U nsc he d ule d visits, 
i ncl u di n g a n y u nsc he d ul e d assess me nts or pr oce d ures perf or me d at t he visit, s h o ul d be pr o m ptl y 
e ntere d i nt o t he C R F. 
6. 2. [ADDRESS_206105] i nf usi o n u n der t his pr ot oc ol. S u bjects 
are e x p ecte d t o be f oll o we d -u p f or a n a d diti o nal 1 3  years u n der a se par at e l o n g -ter m f oll o w - u p 
pr ot oc ol ( L T F -3 0 3), w hi c h will f oc us o n l o n g -ter m safet y, wit h a n e m p hasis o n I S A, i nserti o nal 
o nc o ge nesis,  a n d  l o n g -ter m  efficac y.  A p pr o priate  c o nse nt  will  be  o bt ai ne d  at  t he  ti me  of  
e nr oll me nt i n t he L T F -[ADDRESS_206106] u d y. T his f oll o w -u p i ncl u des r ec or di n g of S A Es a n d arc hi vi n g of 
peri p her al b l o o d le u k oc yte cell sa m ples f or R C L a n d cl o nalit y testi n g.  
  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 7 8 
 7.  S T A TI S TI C A L P R O C E D U R E S  
Details of t he statistical a nal ysis will be pr o vi de d i n a se par ate d oc u me nt (t he Statistical A nal ysis 
Pla n [ S A P]). T his secti o n pr o vi des a ge n eral o ver vie w of t hese pla ns. 
7. 1.  S a m ple Size Esti m ati o n  
N o f or mal sa m ple size calc ulati o ns were d o n e.  
C o n versi o n t o TI f or p atie nts wit h T D T is ver y u nli kel y t o ha p pe n s p o nta ne o usl y. T heref ore, t he 
c o n versi o n of a n y s u bject i n t he st u d y t o TI w o ul d be attri b uta ble t o t he t hera p e utic eff ect of 
Le nti Gl o bi n B B [ADDRESS_206107] be ≥ 1 2 a n d 
≤ 5 0 years of a ge ( C o h ort 1; wit h at least 5 s u bjects ≥ 1 2 a n d < 1 8 years of a ge), a n d at least [ADDRESS_206108] be < 1 2 years of a ge ( C o h ort 2). Re place me nt s u bjects ma y b e a d de d if s u bjects are 
scree n fail ures or wit h dra w pri or t o dr u g pr o d uct i nf usi o n. 
T he pr o p ose d sa m ple size i n C o h ort [ADDRESS_206109] of 
< 3 0 % wit h a hi g h pr o ba bilit y is of val ue ( de m o nstrati n g  wit h  9 7. 5 %  c o nfi de nce  t hat  ≥ 3 0 %  of 
s u bjects bec o me TI). M ore o ver, a p oi nt esti mate of t he pr o p orti o n of s u bjects w h o bec o me TI of 
at least 6 0 % is c o nsi der e d cli nicall y mea ni n gf ul. T his p oi nt esti mate was selecte d b ase d o n t h e 
mi ni mal criteri o n t o be met i n t he st u d y a n d was s u p p orte d as t he mi ni mal tar get base d o n 
disc ussi o ns wit h ke y o pi [INVESTIGATOR_9384] o n lea ders wit h e x pertise i n t he tr eat me nt of β -t halasse mia. T heref ore, 
a m o n g t he pr o p ose d s a m ple size of 1 5 treat e d s u bjects ≥ 1 2 a n d ≤ 5 0 years of a ge i n C o h ort 1, a 
s uc cess criteri o n of 6 0 % is pr o p ose d ( 9 o ut of 1 5 s u bjects), w hic h w o ul d yiel d a l o wer 1 -si de d 
9 7. 5 % e x act  c o nfi de nce  b o u n d of  3 2. 3 %,  e xcee di n g t he 3 0 % mi ni mal  criteri o n.  A m o n g t he  
pr o p ose d sa m ple size of 8 treate d s u bjects < 1 2 y ears of a ge i n C o h ort 2, a s uc cess criteri o n of 
6 2. 5 % ( 5 o ut of 8 s u bjects) w o ul d yiel d a l o wer 1-si de d 9 7. 5 % e xact c o nfi d e nce b o u n d of 2 4. 5 %. 
T he p oi nt esti mate of C o h ort 2 ( 6 2. 5 %) is si milar t o t he p oi nt esti mate of C o h ort 1 ( 6 0 %), a n d 
b ot h p oi nt esti mates are c o nsi dere d cli nicall y m ea ni n gf ul.  
7. 2.  P o p ul ati o ns f or A n al ysis  
T he f oll o wi n g s u bject p o p ulati o ns will be e val uat e d a n d us e d f or pres e ntati o n a n d a nal ysis of t he 
data:  
• I nte nt- t o -Treat  (I T T)  p o p ulati o n:  All  s u bjects  w h o  i nitiate  a n y  st u d y  pr oce d ur es,  
be gi n ni n g wit h m o bilizati o n b y G- C S F a n d/ or pleri xaf or. 
• Tra ns pla nt  P o p ulati o n  ( T P):  All  s u bjects  w h o  recei v e  L e nti Gl o bi n  B B [ADDRESS_206110]. 
• S uccessf ul E n gr aft me nt P o p ulati o n ( S E P): All s u bjects w h o ha ve s u ccessf ul ne utr o p hil 
e n graft me nt after L e nti Gl o bi n B B [ADDRESS_206111] i nf usi o n. 
T he I T T p o p ulati o n is t he pri mar y p o p ulati o n f or t he a nal ysis of saf et y par a meters. T h e T P is t h e 
pri mar y  p o p ulati o n  f or  t he  a nal ysis  of  effi cac y,  p har mac o d y na mic,  a n d  tra ns pla nt  para meter  
e n d p oi nts (i.e., s uccess a n d ki netics of e n graft me nt, a n d i nci de nce of tr a ns pla nt- relate d m ortalit y 
C CI 
Pr ot oc ol H G B - [ADDRESS_206112] i nf usi o n). T he S E P will be use d t o pr o vi de s u p p orti ve data f or 
s u bjects w h o e n gr aft. 
7. 3.  Pl a n ne d A n al yses  
7. 3. 1.  I nteri m A n al yses  
I nteri m a nal yses are pla n ne d i n s u p p ort of re g ulat or y s u b missi o ns. T he ti mi n g of t hese a nal yses 
a n d t he n u m b er of s u bjects i ncl u de d i n eac h a nal ysis will ta ke i nt o acc o u nt i n p ut fr o m r e g ulat or y 
a ge ncies a n d a p plica bl e r e g ulat or y g ui da nce. T he rati o nale f or eac h a nal ysis will be d oc u me nte d. 
7. 3. 2.  Fi n al A n al yses 
A fi nal a nal ysis will be perf or me d w he n all s u bjects treate d wit h Le nti Gl o bi n B B [ADDRESS_206113] atistic al Met h o ds  
7. 4. 1.  Ge ner al Met h o ds  
Ta b ulati o ns  will  be  pr o d uce d  f or  a p pr o priat e  de m o gra p hic,  bas eli ne,  effi cac y,  a n d  saf et y  
para meters. F or cate g ori cal  varia bles, s u m mar y ta b ulati o ns  of t he n u m ber a n d perce nta ge of  
s u bjects wit hi n eac h cate g or y of t he para meter will be pres e nte d. F or c o nti n u o us varia bles, t he 
n u m ber of s u bjects, mea n, me dia n, sta n dar d de vi ati o n ( S D), mi ni m u m, a n d ma xi m u m val ues will 
be prese nt e d. Descri pti ve s u m mar y statistics as well as 2 -si de d, 9 0 % or 9 5 % or 1 -si de d 9 7. 5 % 
c o nfi de nce i nte r vals, as a p pr o priate, will be pr ese nte d o n selecte d p ara met ers . 
L o n git u di nal data (c ollecte d seriall y o ver ti me) will be prese nte d b y a p pr o priate ti me i nter vals, 
s uc h as m o nt hl y, q uarterl y a n d s o f ort h, de p e n di n g o n t he nat ure of t h e data. 
7. 4. 2.  B aseli ne Defi ni ti o ns  
T w o years of retr os p ecti ve pre -tra ns pla nt a n d bi ol o gical data will be c ollecte d f or eac h s u bj ect 
i n  t he  st u d y,  s o  t hat  eac h  s u bject  ma y  ser ve  as  his/ her  o w n  c o ntr ol  f or  t he  para meters  of  
p R B C  tra nsf usi o n  re q uire me nts,  wei g hte d  a ver a ge  na dir  H b  c o nce ntr ati o ns,  a n d  i n -patie nt 
h os pi[INVESTIGATOR_1314] o n ( n u m ber a n d d urati o n). F or t hes e para meters, w her e a p plica ble, baseli ne will be 
a n n ualize d o v er t h e [ADDRESS_206114] u d y e ntr y ( d ate of  i nf or me d c o nse nt). F or p R B C tra nsf usi o n 
C CI 
Pr ot oc ol H G B - [ADDRESS_206115] ors will be s u m marize d: a ge ( at ti me 
of e nr oll me nt, at  dia g n osis, at  ti me of first  tra nsf usi o n, w he n fre q ue n c y  of tra nsf usi o ns  was  
esta blis he d, w he n ir o n c h elati o n be ga n, a n d at dr u g pr o d uct i nf usi o n), ge n ot y pe, c o u ntr y of birt h, 
race a n d et h nicit y, hist or y of s ple nect o m y a n d s pl ee n size f or s u bjects wit h a s plee n. 
A d diti o nal scree ni n g res ults t o be s u m marize d will i ncl u de t he f oll o wi n g: ec h ocar di o gra m stat us 
( n or mal, a b n or mal, n ot d o ne ), L V E F %, a n d  li ver ir o n c o nce ntr ati o n ( LI C) ( m g/ g dr y wei g ht ).  
I n  a d diti o n,  baseli ne  data  fr o m  t he  2 -year  retr os pecti ve  c ollecti o n  will  als o  be  s u m marize d,  
i ncl u di n g p R B C v ol u me ( m L/ k g/ year), n u m b er of p R B C tra nsf usi o ns ( n u m ber per year), a n d i n -
patie nt h os pi[INVESTIGATOR_1314] o n da ys a n d d urati o n ( per year). 
7. 4. 5.  Effic ac y A n al ysis 
7. 4. 5. 1.  A n al ysis of Pri m ar y Effic ac y E n d p oi nt 
T he pri mar y efficac y e n d p oi nt is defi ne d as t he pr o p orti o n of s u bjects w h o meet t he d efi niti o n of 
“tra nsf usi o n i n de pe n de n ce” ( TI). TI is defi ne d as a wei g hte d  a vera g e  H b  ≥ 9  g/ d L  wit h o ut  a n y 
p R B C tra nsf usi o ns f or a c o nti n u o us peri o d of ≥ [ADDRESS_206116] i nf usi o n, w her e: 
• Calc ulati o n of ti me peri o d  of TI will start w he n s u bjects ac hie v e a H b ≥ 9 g/ d L wit h n o 
tra nsf usi o ns i n t he prece di n g 6 0 da ys. 
• T o meet t he i nitial TI criteria, t he wei g hte d H b m ust be ≥ 9 g/ d L at t he e n d of t he 1 2 -
m o nt h peri o d 
• T o re mai n i n t he TI stat e be y o n d t he [ADDRESS_206117] nee ds t o 
mai ntai n a w ei g hte d H b of ≥ 9 g/ d L fr o m t hat p oi nt f or war d, wit h o ut r ecei vi n g a p R B C 
tra nsf usi o n. 
• A  p R B C  tra nsf usi o n  f or  a  si n gle  ac ut e  e v e nt  (e. g.,  s ur g er y,  tr a u ma,  par v o vir us  
i nfecti o n, or se psis) will n ot be c o u nte d t o war ds t he defi niti o n of TI. F or t he calc ulati o n 
C CI 
Pr ot oc ol H G B - [ADDRESS_206118] ual H b dra w n 
w o ul d a gai n be use d i n t he calc ul ati o n of TI. 
T he pri mar y efficac y e n d p oi nt of TI will be a n al yze d as a p oi nt -esti mate of t he pr o p orti o n of 
s u bjects ac hie vi n g TI, wit h a 2 -si de d 9 5 % c o nfi de nce i nter v al calc ulate d usi n g t he  e xact bi n o mial 
met h o d. T he T P will be use d f or pri mar y c o ncl usi o ns of ge ne -t hera p y effi cac y, wit h s u p p orti ve 
a nal yses perf or me d o n t h e S E P.  
7. 4. 5. 2.  A n al ysis of Sec o n d ar y Effic ac y E n d p oi nts  
T he f oll o wi n g sec o n dar y efficac y e n d p oi nts will be descri pti vel y a n al yze d i n t he T P. 
• C haracterizati o n of s u bjects ac hie vi n g TI:  
− Pr o p orti o n of s u bjects w h o meet t he defi niti o n of TI at M o nt h 2 4 
− D urati o n of TI 
− Ti me fr o m dr u g pr o d uct i nf usi o n t o ac hie ve me nt of TI  
− Wei g hte d a v era g e H b d uri n g TI  
• C haracterizati o n of tr a nsf usi o n re d ucti o n ( T R): 
− Pr o p orti o n of s u bjects wit h a re d u cti o n i n t he a n n u alize d m L/ k g p R B Cs tra nsf use d 
fr o m [ADDRESS_206119] i nf usi o n t hr o u g h M o nt h 2 4 (a p pr o xi matel y a 1 2 -
m o nt h peri o d) of at least 5 0 %, 6 0 %, 7 5 %, 9 0 % or 1 0 0 % c o m par e d t o t he a n n ualize d 
m L/ k g p R B C tra nsf usi o n re q uire me nt d uri n g t he 2 years pri or t o e nr oll me nt  
− A n n ualize d n u m ber a n d v ol u me of p R B C tra nsf usi o ns fr o m [ADDRESS_206120] i nf usi o n t hr o u g h M o nt h 2 4 c o m par e d t o t h e a n n ualize d n u m ber a n d v ol u me 
of tra nsf usi o ns d uri n g t h e 2 years pri or t o e nr oll m e nt 
− Ti me fr o m dr u g pr o d uct i nf usi o n t o last p R B C tra nsf usi o n 
− Ti me fr o m last p R B C tra nsf usi o n t o M o nt h 2 4  
• Wei g hte d  a v era g e  na dir  H b  d uri n g  t he  [ADDRESS_206121]  i nf usi o n  t hr o u g h  
M o nt h 2 4 
• U ns u p p orte d t otal H b le v els o ver ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 1 2, M o nt h 
1 8, a n d M o nt h 2 4 
• U ns u p p orte d t otal H b le vels ≥ 1 0  g/ d L, ≥ 1 1  g/ d L, ≥ 1 2  g/ d L, ≥ 1 3  g/ d L, ≥ 1 4  g/ d L o ver 
ti me, i ncl u di n g M o nt h 6, M o nt h 9, M o nt h 1 2, M o nt h 1 8, a n d M o nt h 2 4 
• C haracterizati o n of use of ir o n c h elati o n a n d/ or t hera pe utic p hle b ot o m y a m o n g all 
s u bjects:  
− Pr o p orti o n of s u bjects w h o ha ve n ot recei ve d ir o n c helati o n t hera p y f or at least [ADDRESS_206122] i nf usi o n 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 2 
 − Ti me fr o m last i r o n c helati o n use t o last f oll o w- u p 
− Pr o p orti o n  of  s u bjects  usi n g  t hera pe utic  p hle b ot o m y  f oll o wi n g  dr u g  pr o d uct  
i nf usi o n a n d a n n ualize d fre q ue nc y of p hle b ot o m y use per s u bject 
• E val uati o n of t he c h a n ge i n ir o n b ur de n o ver ti me, as meas ure d b y:  
− C ha n ge i n li ver ir o n c o nt e nt b y M RI at baseli ne t o M o nt h 1 2 a n d M o nt h 2 4 
− C ha n ge i n car di ac T 2 * o n M RI at b aseli ne t o M o nt h 1 2 a n d M o nt h 2 4 
− C ha n ge i n ser u m ferriti n at baseli ne t o M o nt h 1 2 a n d M o nt h 2 4 
• E val uati o n of h ealt h- r elat e d q ualit y of life ( H R Q o L) o ver ti me i ncl u di n g M o nt h 1 2 a n d 
M o nt h 2 4 as c o m pare d t o baseli ne, usi n g t he f oll o wi n g vali date d t o ols: 
− Pe diatrics: Pe diatric Q ualit y of Life I n ve nt or y ( P e ds Q L; pare nt ge ner al c ore a n d 
ge neral c ore)  
− A d olesce nts:  Pe ds Q L  ( p are nt  ge n eral  c ore  a n d  ge neral  c ore)  a n d  E ur o Q ol -5 D 
( Y o ut h versi o n) ( E Q - 5 D- Y)  
− A d ults: E ur o Q ol -5 D ( E Q -5 D), F u ncti o nal Ass ess me nt of Ca ncer T hera p y - B o ne 
Marr o w Tra ns pla nt ( F A C T- B M T), a n d S h ort F or m- 3 6 ( S F- 3 6) v 2 
A nal yses of  will be des cri b e d i n t he S A P.  
7. 4. 6.  S afet y A n al ysis 
T he f oll o wi n g sec o n dar y safet y e n d p oi nts will be e val uate d d escri pti vel y: 
• S uccess a n d ki netics of H S C e n graft me nt  
• I n ci de nce  of  tra ns pla nt -relate d  m ortalit y  t hr o u g h  [ADDRESS_206123]‑ dr u g  pr o d uct i nf usi o n 
• O verall s ur vi val ( O S) 
• Detecti o n of vect or- d eri v e d R C L i n a n y s u bject 
• M o nit ori n g of la b orat or y para meters 
• Fre q u e nc y a n d se verit y of cli nical A Es  
• I n ci de nce of ac ute a n d/ or c hr o nic G V H D 
• T he  n u m ber  of  s u bjects  wit h  i nserti o nal  o nc o ge nesis  ( m yel o d ys plasia,  le u ke mia,  
l y m p h o ma, etc.)  
All s u bjects starti n g m o bilizati o n will be e val uate d f or saf et y (I T T p o p ulati o n) . Res ults re p orte d 
as i nci de nce will be a nal yze d as pr o p orti o ns.  
All A Es will be c ollecte d fr o m si g ni n g of i nf or me d c o nse nt/asse nt t hr o u g h M o nt h [ADDRESS_206124]. All A Es will be liste d a n d s u m marize d f or t he f oll o wi n g ti me peri o ds : 1) fr o m i nf or me d 
c o nse nt/asse nt  u p  t o  t he  start  of  m o bilizati o n;  2)  fr o m  start  of  m o bilizati o n  u p  t o  start  of  
c o n diti o ni n g; 3) fr o m start of c o n diti o ni n g t hr o u g h ne utr o p hil e n graft me nt; 4)  fr o m ne utr o p hil 
C CI C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 3 
 e n graft me nt t hr o u g h M o nt h 2 4 Visit; 5) fr o m dr u g pr o d uct i nf usi o n  t hr o u g h M o nt h 2 4 Visit; a n d 
6) fr o m i nf or me d c o nse nt/asse nt t hr o u g h M o nt h 2 4 Visit. 
N ote t hat ne utr o p hil e n graft me nt fail ur e is a S A E a n d f or t his pr ot oc ol is defi ne d as fail ur e t o 
ac hie ve 3 c o ns ec uti ve a bs ol ute ne utr o p hil c o u nt ( A N C) la b orat or y val u es ≥ 5 0 0  cells/ µ L o btai ne d 
o n differ e nt da ys b y D a y [ADDRESS_206125] e d per pr ot oc ol ca n be use d 
(see Secti o n  5. 2 ), a n d if > [ADDRESS_206126] will be te m p or aril y s us pe n de d a n d will 
res u me after re vie w a n d rec o m me n d ati o ns fr o m t he D M C a n d (as re q uire d) a p pr o val fr o m t he 
rele va nt r e g ulat or y a g e nc y(ies) (see Secti o n  3. 5. 2 ).  
Platelet e n graft me nt is defi ne d as 3 c o ns ec uti v e  platelet  c o u nt  la b or at or y  val ues  ≥  2 0 × 1 0 9/ L 
o btai ne d o n differe nt da ys w hile n o platelet tra nsf usi o ns  a d mi nistere d f or se ve n da ys i m me diatel y 
prece di n g a n d d uri n g t he e val uati o n p eri o d. T he d a y of plat elet e n graft me nt is t he first da y of t he 
[ADDRESS_206127] ; c ha n ges i n la b or at or y 
para meters o ver ti me will be s u m marize d wit h des cri pti ve statistics a n d s hift ta bles.  
A d diti o nall y,  s ur vi val  stat us,  la b orat or y  res ults  a n d  i nserti o nal  o nc o ge nesis  (i nserti o nal  
m uta ge nesis res ulti n g i n o nc o ge nesis) e ve nts will be s u m marize d.  
Vital si g ns, La ns k y a n d Kar n ofs k y Perf or m a nce stat us res ults , a n d  
will be prese nte d as Listi n gs o nl y. 
Re plicati o n -c o m pete nt le nti vir us testi n g a n d I S A will be perf or me d a n d r es ults ta b ulate d.  
A nal yses of  will be descri be d i n t he S A P. 
7. 4. 7.  P h ar m ac o d y n a mic A n al y ses  
A nal yses of p har mac o d y na mic e n d p oi nts will be descri be d i n t he S A P. 
  
C CI C CI 
C CI 
Pr ot oc ol H G B - [ADDRESS_206128] u d y will be c o n d ucte d i n acc or d a nce wit h t he I nt er nati o nal C o nfer e nce o n Har m o nizati o n 
(I C H) G ui deli ne f or G C P a n d t he a p pr o priate re g ulat or y re q uire me nt(s). T he i n vesti gat or will be 
t h or o u g hl y fa miliar wit h t he a p pr o priat e use of Le nti Gl o bi n B B [ADDRESS_206129] as des cri be d i n 
t he pr ot oc ol  a n d I n vesti gat or’s  Br oc h ur e. Esse ntial  cli nical  d oc u me nts  will  be mai ntai ne d t o 
de m o nstrate t he v ali dit y of t he st u d y a n d t h e i nte grit y of t he dat a c ollect e d. Master files s h o ul d b e 
esta blis he d at t he be gi n ni n g of t he st u d y, mai ntai ne d f or t he d ur ati o n of t he st u d y a n d retai ne d 
acc or di n g t o t he a p pr o pri ate re g ulati o ns. 
8. 2.  Et hic al C o nsi der ati o ns  
T he st u d y will be c o n d u cte d i n acc or d a nce wit h et hical pri nci ples f o u n de d i n t he Declar ati o n of 
Helsi n ki. T he I R B / E C  a n d ot he r a p pr o priate i nstit uti o nal re g ulat or y b o dies will re vie w all 
a p pr o priate st u d y d oc u me ntati o n i n or der t o safe g uar d t he ri g hts, safet y, a n d well -bei n g of t he 
s u bjects. T he st u d y will o nl y be c o n d ucte d at sites w her e I R B / E C a n d a n y ot her a p pr o priate 
i nsti t uti o nal re g ulat or y b o d y a p pr o val has bee n o btai ne d. T he pr ot oc ol, I n vesti gat or’s Br oc h ur e, 
i nf or me d  c o nse nt,  a d v ertise me nts  (if  a p plica bl e),  writte n  i nf or m ati o n  gi ve n  t o  t he  s u bjects  
(i ncl u di n g  diar y  car ds),  safet y  u p d ates,  a n n ual  pr o gress  re p orts,  a n d  a n y  re visi o ns  t o  t hes e  
d oc u me nts will be pr o vi de d t o t he I R B / E C, I B C, a n d ot her a p pr o priate i nstit uti o nal re g ulat or y 
b o dies b y t he i n vesti gat or. 
8. 3.  S u bject I nf or m ati o n a n d I nf or me d C o nse nt  
After t he st u d y has b ee n f ull y e x plai ne d, v ol u ntar y writte n i nf or me d c o nse nt will be o btai ne d fr o m 
eit her t he s u bject a n d/ or his/ her g u ar dia n or l e gal re pr ese ntati ve pri or t o st u d y partici pati o n, as 
well as asse nt if a p plica ble. T he met h o d of o btai ni n g a n d d oc u me nti n g t he i nf or me d c o nse nt/asse nt 
a n d t he c o nte nts of t he c o nse nt/asse nt will c o m pl y wit h I C H -G C P a n d all a p plica ble r e g ulat or y 
re q uire me nt(s). C o nse nt t o t his st u d y i n dicates ac k n o wle d g me nt t hat f oll o w- u p is e x pecte d t o last 
[ADDRESS_206130]  a n d/ or  t h eir  g uar dia n  or  le gal  
re pres e ntati ve are a w are of e x pect ati o ns i n St u d y L T F -[ADDRESS_206131] n u m ber. T he i n vesti gat or will 
gra nt m o nit or(s) a n d a u dit or(s) fr o m t he S p o ns or or its d esi g nee a n d r e g ulat or y a ut h orit y(ies) 
access t o t he s u bject’s ori gi nal me dical rec or ds f or verificati o n of data g at here d o n t he C R Fs a n d 
t o a u dit t he d at a c ollecti o n pr ocess. T he s u bject’s c o nfi de ntialit y will b e mai ntai ne d a n d will n ot 
be ma de p u blicl y a v aila ble t o t he e xte nt per mitte d b y t he a p plica ble la ws a n d re g ulati o ns. 
C CI 
Pr ot oc ol H G B - [ADDRESS_206132] u d y i n c o m plia nce wit h t he pr ot oc ol pr o vi de d b y bl ue bir d bi o 
a n d  gi ve n  a p pr o val/fa v ora ble  o pi [INVESTIGATOR_9384] o n  b y  t he  I R B  /  E C  a n d  ot her  a p pr o priate  i nstit uti o nal  
re g ulat or y b o dies. M o dificati o ns t o t he pr ot o c ol s h o ul d n ot be ma d e wit h o ut a gree me nt of b ot h 
t he i n vesti gat or a n d bl u e bir d bi o. C ha n ges t o t he pr ot oc ol will re q uire writte n I R B / E C a n d ot her 
a p pr o priate  i nstit uti o nal  re g ulat or y  b o d y  a p pr o val/fa v ora bl e  o pi [INVESTIGATOR_9384] o n  pri or  t o  i m ple me ntati o n,  
e xce pt w he n t he m o dificati o n is nee de d t o eli mi nate a n i m me diate hazar d(s) t o s u bjects. T he I R B  / 
E C  ma y  pr o vi de,  if  a p plica ble  re g ulat or y  a ut h orit y(ies)  per mit,  e x pe dite d  re vie w  a n d  
a p pr o val/fa v ora ble  o pi [INVESTIGATOR_9384] o n  f or  mi n or  c ha n ge(s)  i n  o n g oi n g  st u dies  t hat  ha ve  t he  a p pr o val  
/fa v ora ble o pi [INVESTIGATOR_9384] o n of t he I R B / E C a n d ot her a p pr o priate i nstit uti o nal re g ulat or y b o dies. bl ue bir d 
bi o, I n c., will s u b mit all pr ot oc ol m o dificati o ns t o t he r e g ulat or y a ut h orit y(ies) i n acc or d a nce wit h 
t he g o ver ni n g re g ul ati o ns.  
W he n de vi ati o n fr o m t he pr ot oc ol is r e q uire d t o eli mi nate a n i m me diate h azar d(s) t o s u bjects, t h e 
i n vesti gat or will c o ntact bl ue bir d bi o, if circ u mst a nces per mit, t o disc uss t he pla n ne d c o urs e of 
acti o n. A n y de p art ures  fr o m  t he pr ot oc ol  m ust  be f ull y d oc u me nte d i n t he C R F a n d s o ur ce  
d oc u me ntati o n. 
8. 6.  Direct Access t o S o urce D at a  
M o nit ori n g a n d a u diti n g pr oce d ur es de vel o p e d b y bl ue bir d bi o will be f oll o we d, i n or der t o c o m pl y 
wit h I C H - G C P g ui deli nes. 
T he st u d y will be m o nit ore d b y bl ue bir d bi o or its desi g nee. M o nit ori n g will be d o ne b y pers o nal 
visits fr o m a re prese ntati ve of t he S p o ns or (site m o nit or) a n d will i ncl u de  o n- site re vie w of t he 
C R Fs f or c o m plete ness a n d clarit y, cr oss -c hec ki n g wit h s o urce d oc u me nts, a n d clarificati o n of 
a d mi nistrati ve matters. T he re vie w of me dical rec or ds will be perf or me d i n a ma n ner t o e ns ure 
t hat s u bject c o nfi de ntialit y is mai ntai ne d.  
The site m o nit or will e ns ure t hat t he i n vesti gati o n is c o n d ucte d acc or di n g t o pr ot oc ol desi g n a n d 
re g ulat or y r e q uire me nts b y fre q ue nt c o m m u nicati o ns (letter, e- m ail, tele p h o ne, a n d fa x). 
Re g ulat or y a ut h orities, t he I R B / E C a n d ot her a p pr o priate i nstit uti o nal re g ulat or y b o dies, a n d/ or 
bl ue bir d bi o’s cli nical q ualit y ass ura nce gr o u p ma y re q uest access t o all s o urce d oc u me nts, C R Fs, 
a n d ot her st u d y d oc u m e ntati o n f or o n -site a u dit or i ns pecti o n. Direct access t o t hese d oc u m e nts 
m ust be g uara ntee d b y t he i n vesti gat or, w h o m ust pr o vi de s u p p ort at all ti mes f or t hese acti vities. 
8. 7.  Electr o nic C ase Re p ort F or m C o m pleti o n  
Case re p ort f or ms will be c o m plete d usi n g a n electr o nic data ca pt ure ( E D C)  s yste m. T he S p o ns or 
or desi g nee will pr o vi de i nstr ucti o n re gar di n g t he pr o per use of t he E D C s yste m. 
It is t he i n vesti gat or’s res p o nsi bilit y t o e ns ure t he acc ur ac y, c o m plete n ess, a n d ti meli ness of t he 
data  re p orte d  i n  t he  s u bject’s  electr o nic  cas e  re p ort  f or m  ( e C R F).  S o urce  d oc u me ntati o n  
s u p p orti n g t he e C R F data s h o ul d i n dicate t he s u bject’s partici pati o n i n t he st u d y a n d s h o ul d 
d oc u me nt t he dates a n d d etails of st u d y pr oce d ur es, A Es, a n d s u bject stat us.  
T he i n vesti gat or or d esi g nate d re prese nt ati ve s h o ul d c o m plete t he e C R F pa ges as s o o n as p ossi ble 
after i nf or mati o n is c oll ecte d, pr ef era bl y o n t he sa me da y t hat a st u d y s u bject is see n f or a n 
C CI 
Pr ot oc ol H G B - [ADDRESS_206133] si g n a n d dat e t he I n vesti gat or’s State me nt wit hi n t he E D C s yste m t o e n d orse 
t he rec or de d dat a.  
8. 8.  Rec or d Rete nti o n  
T he i n vesti gat or will mai ntai n all st u d y r ec or ds acc or di n g t o I C H -G C P a n d a p plica ble r e g ulat or y 
re q uire me nt(s). Rec or ds will be retai ne d f or at least [ADDRESS_206134] or acc or di n g t o a p plica ble r e g ulat or y re q uire me nt(s). If t he i n vesti gat or wit h dra ws fr o m 
t he res p o nsi bilit y of kee pi n g t he st u d y rec or ds, c ust o d y m ust be tra nsferre d t o a pers o n willi n g t o 
acce pt t he r es p o nsi bilit y. bl ue bir d bi o, I nc., m ust b e n otifie d i n  writi n g if a c ust o dial c ha n ge o cc urs.  
T he S p o ns or has f ull ri g hts o ver a n y i n ve nti o n, disc o ver y, or i n n o vati o n, pate nta ble or n ot, t hat 
ma y occ ur w h e n perf or mi n g t he st u d y. 
8. 9.  Li a bilit y a n d I ns ur a nce  
bl ue bir d bi o, I n c., has s u bscri be d t o a n i ns ura n ce p olic y c o veri n g, i n its ter ms a n d pr o visi o ns, its 
le gal lia bilit y f or i nj uries ca use d t o p artici pati n g pers o ns a n d arisi n g o ut of t his researc h perf or m e d 
strictl y i n acc or da n ce wit h t he scie ntific pr ot oc ol as well as wit h a p plica bl e la w a n d pr of essi o nal 
sta n dar ds. 
8. [ADDRESS_206135] 
a n d  ma y  be  discl ose d  t o  re g ulat or y  a ut h orit y(ies),  ot her  i n vesti gat ors,  c or p orat e  part ners,  or  
c o ns ulta nts as re q uire d. 
It is a ntici pate d t hat t he res ults of t his st u d y will be prese nte d at scie ntific meeti n gs a n d/ or 
p u blis he d i n a peer re vie we d scie ntific or me dical j o ur nal. A P u blicati o ns C o m mittee c o m prise d 
of i n vesti gat ors partici pati n g i n t he st u d y a n d re prese ntati ves fr o m bl ue bir d bi o, as a p pr o priate, 
will be f or me d t o o vers ee t he p u blicati o n a n d pr ese ntati o n of t he st u d y res ults, w hic h will refl ect 
t he e x perie n ce of all parti ci pati n g cli nical sites.  
N o  p u blicati o n  or  discl os ure  of  st u d y  res ults  will  be  per mitt e d  e xce pt  u n der  t he  ter ms  a n d  
c o n diti o ns  of  a  se par ate  writte n  a gree me nt  bet wee n  S p o ns or  a n d  t he  i n vesti gat or  a n d/ or  t he  
i n vesti gat or's i nstit uti o n.  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 7 
 9.  R E F E R E N C E S  
A n gel ucci, E., a n d Bar o ncia ni, D. ( 2 0 0 8). All o g e neic ste m cell tra ns pla ntati o n  f or t halasse mia 
maj or. Hae mat ol o gica  9 3 , 1 7 8 0 - 1 7 8 4. 
Be n der, J. G., Willia ms, S. F., M yers, S., N ottle m a n, D., Lee, W.J., U n ver za gt, K. L., Wal ker, D., 
T o, L. B., a n d Va n E p ps, D. E. ( 1 9 9 2). C haracterizati o n of c he m ot hera p y m o bilize d peri p heral 
bl o o d pr o ge nit or cells f or use i n a ut ol o g o us ste m cell tra ns pla ntati o n. B o ne Marr o w Tr a ns pla nt  
1 0 , 2 8 1- 2 8 5. 
Be nz, E.J. ( 2 0 1 5). M olec ular pat h ol o g y of t he t hal asse mic s y n dr o mes, S. L. T. Sc hrier, Je n nif er S. 
Access e d  1 8  N o ve m ber  2 0 1 5,  e d.  ( Walt ha m,  M A:  U p T o D at e;  
htt p:// w w w . u pt o date.c o m/c o nte nts/ m olec ular- pat h ol o g y- of-t he- t hal asse mic -s y n dr o mes). 
Be yer, J., Sc h wella, N., Zi n gse m, J., Str o hsc heer, I., Sc h wa ner, I., O ettle, H., Ser ke, S., H u h n, D., 
a n d Stie ger, W. ( 1 9 9 5). He mat o p oietic r esc ue after hi g h -d ose c he m ot her a p y usi n g a ut ol o g o us 
peri p her al -bl o o d pr o ge nit or cells or b o ne marr o w: a ra n d o mize d c o m paris o n. J Cli n O nc ol   1 3 , 
1 3 2 8- 1 3 3 5. 
B or g na- Pi g natti, C., a n d Gala nell o, R. ( 2 0 0 9). T he t halasse mias a n d rel ate d dis or ders: q ua ntitati ve 
dis or ders of h e m o gl o bi n s y nt hesis. I n Wi ntr o be's Cli nical He mat ol o g y, E diti o n 1 2, J. P. Greer, e d. 
( P hila del p hia: Li p pi [INVESTIGATOR_176327] & Wil ki ns), p. [ADDRESS_206136] o ne, A. H., E b er har dt, K., R eiffers, J., Ferra nt, A., 
Fra n kli n, I., Her ve, P., Grat w o hl, A. , et al.  ( 1 9 9 5). A ut ol o g o us B o ne Marr o w Tra ns pla nt ati o n f or 
First Re missi o n Ac ute M yel o blastic Le u ke mia i n Patie nts Ol der T ha n 5 0 Years: A Retr os p ecti ve 
A nal ysis of t he E ur o pea n B o ne Marr o w Tra ns pla nt Gr o u p. Bl o o d  8 5 , 5 7 5 - 5 7 9. 
Ca n d otti ,  F.,  S ha w,  K. L.,  M u ul,  L.,  Car b o nar o,  D.,  S o k olic,  R.,  C h oi,  C.,  Sc h ur ma n,  S. H.,  
Gara b e dia n,  E.,  K esser wa n,  C.,  Ja ga dees h,  G.J. ,  et  al.  ( 2 0 1 2).  Ge n e  t hera p y  f or  a de n osi ne  
dea mi nase -d eficie nt  s e v ere  c o m bi ne d  i m m u ne  deficie nc y:  cli nical  c o m paris o n  of  retr o v iral 
vect ors a n d tr eat me nt pla ns. Bl o o d  1 2 0 , 3 6 3 5- 3 6 4 6. 
Ca o, A., a n d Gal a nell o, R. ( 2 0 1 0). Beta- t halasse mia. Ge net Me d  1 2 , 6 1- 7 6. 
Ca o, A., Gala n ell o, R., R osatelli, M. C., Ar gi ol u, F., a n d De Vir giliis, S. ( 1 9 9 6). Cli nical e x perie n ce 
of ma na ge me nt of t halasse mia: t he Sar di nia n e x p erie nce. Se mi n He mat ol  3 3 , 6 6- 7 5. 
Ca p pelli ni,  M. D.,  C o he n,  A.,  Pi [INVESTIGATOR_99331],  A.,  Beja o ui,  M.,  Perr otta,  S.,  A ga o gl u,  L.,  A y di n o k,  Y., 
Katta mis, A., Kili nc, Y., P orter, J. , et al.  ( 2 0 0 6). A p hase 3 st u d y of deferasir o x (I C L 6 7 0), a o nce -
dail y  oral ir o n c hel at or, i n patie nts wit h beta- t halasse mia. Bl o o d  1 0 7 , 3 4 5 5- 3 4 6 2. 
Ca p pelli ni, M. D., C o he n, A., P orter, J., Ta her, A., a n d Vi pra kasit, V. ( 2 0 1 4). G ui deli nes f or t he 
Ma na ge me nt  of  Tra nsf usi o n  De pe n d e nt  T halassae mia  ( T D T),  3r d  e diti o n  ( Nic osia  ( C Y ): 
T halassae mia I nter nati o n al Fe d erati o n).  
C ola h, R., G ora ks ha kar, A., a n d Na d kar ni, A. ( 2 0 1 0). Gl o bal b ur de n, distri b uti o n a n d pre ve nti o n 
of beta-t hal asse mias a n d he m o gl o bi n E dis or ders. E x pert Re v He mat ol  3 , 1 0 3- 1 1 7. 
Delea, T. E., E dels ber g, J., S ofr y gi n, O., T h o mas, S. K., Bala di, J. F., P hata k, P. D., a n d C oates, T. D. 
( 2 0 0 7). C o nse q u e nces a n d c osts of n o nc o m plia n ce wit h ir o n c helati o n t h era p y i n patie nts wit h 
tra nsf usi o n- de p e n de nt t halasse mia: a literat ur e r e vie w. Tra nsf usi o n  4 7 , 1 9 1 9- 1 9 2 9. 
Gala nel l o, R., a n d Ori g a, R. ( 2 0 1 0). Beta- t halasse mia. Or p ha net J Rar e Dis  5 , 1 1. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 8 
 Ge or ge,  S. S.  ( 2 0 0 8).  Creati n g  a n  i nter net -base d  data base  of  b eta  t hal asse mia  m utati o ns.  I n  
De part me nt  of  Bi ol o gical  Scie nces  ( Mast er's  T hes es.  Sa n  J ose  State  U ni versit y.  
htt p://sc h o lar w or ks.sjs u.e d u/c gi/ vie wc o nte nt.c gi?article = 4 6 1 2 &c o nte xt =et d _t heses). 
Har dis o n, R. C., C h ui, D. H., Rie mer, C., Giar di ne, B., Le h vaslai h o, H., Wajc ma n, H., a n d Miller, 
W. ( 2 0 0 1). Data b ases of h u ma n he m o gl o bi n varia nts a n d ot her res o ur ces at t he gl o bi n ge ne  ser v er. 
He m o gl o bi n  2 5 , 1 8 3- 1 9 3. 
H uis ma n, T. H.J., Car ver, M. F. H., a n d Ba ysal, E. ( 1 9 9 7). A S ylla b us of T halasse mia M utati o ns 
( A u g usta,  G A,  U S A:  T he  Sic kle  Cell  A ne mia  F o u n dati o n.  
htt p:// gl o bi n. b x. ps u.e d u/ ht ml/ h uis ma n/t hals/). 
H uis ma n, T. H.J., Car v er, M. F. H., a n d Efre m o v, G. D. ( 1 9 9 6). A S ylla b us of H u ma n H e m o gl o bi n 
Varia nts.  ( A u g usta,  G A,  U S A:  T he  Sic kle  Cell  A ne mia  F o u n dati o n   
htt p:// gl o bi n. b x. ps u.e d u/ ht ml/ h uis ma n/ varia nts/c o nte nts. ht ml). 
Jillella, A. P., a n d Ust u n, C. ( 2 0 0 4). W hat is t he o pti m u m n u m ber of C D 3 4 + peri p heral bl o o d ste m 
cells f or a n a ut ol o g o us tra ns pla nt? Ste m Cells De v  1 3 , 5 9 8- 6 0 6. 
Keati n g, S., S uci u, S., De Witte, T., Ma n delli, F., Wille mze, R., Rese g otti, L., Br occia, G., T haler, 
J., La bar, B., D a masi o, E. , et al.  ( 1 9 9 6). Pr o g n ostic fact ors o f patie nts wit h ac ute m yel oi d le u ke mia 
( A M L) all o grafte d i n first c o m plete r e missi o n: a n a nal ysis of t h e E O R T C -GI M E M A A M L 8 A 
trial. T he E ur o pea n Or g a nizati o n f or Resear c h a n d Treat me nt of Ca ncer ( E O R T C) a n d t he Gr u p p o 
Italia n o Malattie E mat ol o gic he Mali g ne  d ell' A d ult o ( GI M E M A) L e u ke mi a C o o perati ve Gr o u ps. 
B o ne Marr o w Tra ns pla nt  [ADDRESS_206137], M. A., La ns k y, L. L., Ritter -Sterr, C., a n d Miller, D. R. ( 1 9 8 7). T he m eas ur e me nt 
of perf or ma nce i n c hil d h o o d ca ncer patie nts. Ca n cer  6 0 , 1 6 5 1- 1 6 5 6. 
Masc ha n,  A. A.,  Balas h o v,  D. N.,  K ur ni k o va,  E. E.,  Tra k ht ma n,  P. E.,  B o ya k o va,  E. V.,  
S k or o b o gat o va, E. V., N o vic h k o va, G. A., a n d M asc ha n, M. A. ( 2 0 1 5). Efficac y of pl eri xaf or i n 
c hil dre n  wit h  mali g na nt  t u m ors  faili n g  t o  m o bilize  a  s uffi cie nt  n u m ber  of  h e mat o p oi etic 
pr o ge nit ors wit h G- C S F. B o ne Marr o w Tra ns pla nt  5 0 , 1 0 8 9- 1 0 9 1. 
Mi ya m ot o, T., S hi n oz u ka, T., Mae d a, H., Hiras a wa, T., M ura mats u, T., M ura ka mi, M., Ma ki n o, 
T.,  Ita g a ki,  H.,  a n d  Na k a m ura,  Y.  ( 2 0 0 4).  Effect  of  peri p heral  bl o o d  pr o ge nit or  cell  d ose  o n 
he mat o p oietic  rec o v er y:  i de ntificati o n  of  mi ni mal  pr o ge nit or  cell  re q uire me nts  f or  ra pi d  
e n graft me nt. B o ne M arr o w Tra ns pla nt  3 3 , 5 8 9- 5 9 5. 
M o dell, B., K ha n, M., a n d Darlis o n, M. ( 2 0 0 0). S ur vi val i n beta -t halass ae mia maj or i n t he U K: 
data fr o m t he U K T halassae mia  Re gister. La n cet  3 5 5 , 2 0 5 1- 2 0 5 2. 
M or, V., L ali berte, L., M orris, J. N., a n d Wi e ma n n, M. ( 1 9 8 4). T he Kar n ofs k y Perf or ma n ce Stat us 
Scale. A n e x a mi nati o n of its relia bilit y a n d vali dit y i n a researc h s etti n g. Ca ncer  5 3 , 2 0 0 2- 2 0 0 7. 
Perez -Si m o n, J. A., Ca baller o, M. D., C orral, M., Ni et o, M.J., Orfa o, A., V az q uez, L., A mi g o, M. L., 
Ber ges, C., G o nzalez, M., del, C. C. , et al.  ( 1 9 9 8). Mi ni mal n u m ber of circ ulati n g C D 3 4 + cells t o 
e ns ure s uccessf ul le u ka p heresis a n d e n graft me nt i n a ut ol o g o us peri p heral bl o o d pr o ge nit or  cell 
tra ns pla ntati o n. Tra nsf usi o n  3 8 , 3 8 5- 3 9 1. 
Rac h mile witz, E. A., a n d Giar di na, P.J. ( 2 0 1 1). H o w I treat t hal asse mia. Bl o o d  1 1 8 , 3 4 7 9- 3 4 8 8. 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 8 9 
 R u ut u T, Eri kss o n B, Re mes K, et al ( 2 0 0 2) Urs o de o x yc h olic aci d f or t he pre ve nti o n of he patic 
c o m plicati o ns i n all o ge n eic ste m cell tra ns pla nt ati o n. Bl o o d 1 0 0:: 1 9 7 7 –8 3 . d oi: 1 0. 1 1 8 2/ bl o o d -
2 0 0 1- 1 2- 0 1 5 9 
R u ut u T, J u v o ne n E, Re m ber ger M, et al ( 2 0 1 4) I m pr o v e d s ur vi val wit h urs o de o x yc h olic aci d 
pr o p h yla xis i n all o ge nei c ste m cell tr a ns pla ntati o n: l o n g -ter m f oll o w -u p of a r a n d o mize d st u d y. 
Bi ol Bl o o d Marr o w Tra ns pla nt 2 0:: 1 3 5 – 8 . d oi: 1 0. 1 0 1 6/j. b b mt. 2 0 1 3. 1 0. 0 1 4 
S weiss, K., Patel, P., a n d R o n delli, D. ( 2 0 1 2). Defer asir o x i ncreases B U bl o o d c o nce ntrati o ns. 
B o ne Marr o w Tra ns pla nt  4 7 , 3 1 5- 3 1 6. 
Te usi n k, A., Pi n kar d, S., Da vies, S., M ueller, M., a n d J o d ele, S. ( 2 0 1 6). Pleri xaf or is s afe a n d 
efficaci o us f or m o bilizati o n of peri p her al bl o o d ste m cells i n pe diatric patie nts. Tra nsf usi o n  5 6 , 
1 4 0 2- 1 4 0 5. 
T o, L. B., R o berts, M. M., Ha yl oc k, D. N., D ys o n, P. G., Bra nf or d, A. L., T h or p, D., H o, J. Q., D art, 
G. W., H or vat h, N., Da v y, M. L. , et al.  ( 1 9 9 2). C o m paris o n of h ae mat ol o gi cal r ec o ver y ti mes a n d 
s u p p orti ve car e r e q uire m e nts of a ut ol o g o us rec o ver y p hase p eri p her al bl o o d ste m cell tra ns pla nts, 
a ut ol o g o us  b o ne  marr o w  tra ns pla nts  a n d  all o g e neic  b o ne  m arr o w  tra ns pla nts.  B o ne  Marr o w  
Tra ns pla nt  9 , 2 7 7- 2 8 4. 
Vic hi ns k y, E., B ute ns k y, E., F u n g, E., H u d es, M., T heil, E., Ferrell, L., Willia ms, R., L o uie, L., 
Lee, P. D., a n d H ar matz, P. ( 2 0 0 5a). C o m paris o n of or ga n d ysf u ncti o n i n tra nsf use d patie nts wit h  
S C D or beta t halasse mia. A m J He mat ol  8 0 , 7 0- 7 4. 
Vic hi ns k y, E. P., Mac Kli n, E. A., Wa ye, J. S., L or e y, F., a n d Oli vieri, N. F. ( 2 0 0 5 b). C ha n ges i n t he 
e pi [INVESTIGATOR_32450] o g y of t halasse mia i n N ort h A merica: a ne w mi n orit y disease. Pe diatrics  [ADDRESS_206138] o p o ul os, A. , et al.  ( 2 0 1 3). He mat o p oietic ste m cell 
m o bilizati o n f or ge ne t hera p y: s u peri or m o bilizati o n b y t he c o m bi nati o n of g ra n ul oc yte- c ol o n y 
sti m ulati n g fact or pl us pleri xaf or i n patie nts wit h beta -t halasse mia maj or. H u m Ge ne T her  2 4 , 8 5 2 -
8 6 0. 
Ya n na ki, E., Pa pa ya n n o p o ul o u, T., J o nli n, E., Zer v o u, F., Kar p o ni, G., X a g orari, A., Bec k er, P., 
Psat ha, N., Batsis, I., Kal o ya n ni dis, P. , et al.  ( 2 0 1 2). He mat o p oietic ste m cell m o bilizati o n f or ge ne 
t hera p y of a d ult patie nts wit h se vere beta -t h alass e mia: res ults of cli nical trials usi n g G -C S F or 
pleri xaf or i n s ple n ect o mize d a n d n o ns ple n ect o mize d s u bjects. M ol T her  2 0 , 2 3 0- 2 3 8. 
 
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 9 0 
 1 0.  A P P E N D I C E S  
1 0. 1.  Gl o mer ul ar Filtr ati o n R ate C alc ul ati o n  
F or a d ults: 
F or use wit h cre ati ni ne ( Scr) re p orte d i n m g/ d L: 
G F R ( m L/ mi n/ 1. 7 3 m 2) = 1 7 5 × ( Scr) -1. 1 5 4 × ( A ge) -0. 2 0 3 × ( 0. 7 4 2 if f e male) × ( 1. 2 1 2 if 
Africa n A merica n) ( c o n v e nti o nal u nits) 
F or use w he n cre ati ni ne ( Scr) is re p orte d i n µ m ol/ L: 
G F R ( m L/ mi n/ 1. 7 3 m 2) = 1 7 5 × ( Scr/ 8 8. 4) -1. 1 5 4 × ( A ge) -0. 2 0 3 × ( 0. 7 4 2 if fe male) × ( 1. 2 1 2 if 
Africa n A merica n) ( SI u nits)  
F or c hil dre n:  
G F R ( m L/ mi n/ 1. 7 3 m 2) = ( 0. 4 1 × H ei g ht i n c m) / Creati ni ne i n m g/ d L  
G F R ( m L/ mi n/ 1. 7 3 m 2) = ( 3 6. 2 × H ei g ht i n c m) / Creati ni ne i n µ m ol/ L  
C CI 
Pr ot oc ol H G B - [ADDRESS_206139] at us Sc ale  
T he f oll o wi n g ta ble pres e nts t he Kar n ofs k y perf or ma nce stat us scale a n d s h o ul d be use d f or 
s u bjects ≥ 1 6 years of a ge.  
P oi nts  Descri pti o n  
1 0 0  N or mal, n o c o m plai nts, n o e vi de nce of disease  
9 0  A ble t o carr y o n n or mal acti vit y  
8 0  N or mal acti vit y wit h eff ort; s o me si g ns or s y m pt o ms of disease  
7 0  Cares f or self; u na ble t o carr y o n n or mal acti vit y or t o d o acti ve w or k  
[ADDRESS_206140] of his/ her nee ds  
5 0  Re q uire d c o nsi dera ble assista nce a n d fre q ue nt me dical care  
4 0  Disa ble d; re q uire d s pecial care a n d assista nce  
3 0  Se verel y disa ble d; h os pi[INVESTIGATOR_1314] o n i n dicate d. Deat h n ot i m mi n e nt  
2 0  Ver y sic k; h os pi[INVESTIGATOR_1314] o n necessar y; acti ve s u p p ort treat me nt necessar y  
1 0  M ori b u n d; fatal pr ocess pr o gressi n g ra pi [INVESTIGATOR_2478] y  
0 Dea d  
S o urce: (M or et al., 1 9 8 4 )   
[ADDRESS_206141] at us Sc ale  
T he f oll o wi n g ta ble pres e nts t he La ns k y perf or ma nce stat us scale a n d s h o ul d be use d f or s u bjects 
< 1 6 years of a g e.  
P oi nts  Descri pti o n  
1 0 0  F ull y acti ve, n or mal  
9 0  Mi n or restricti o ns i n p h ysicall y stre n u o us acti vit y  
8 0  Acti ve, b ut tires m ore q uic kl y  
7 0  B ot h greater restricti o n of, a n d less ti me s pe nt i n, acti ve pla y  
6 0  U p a n d ar o u n d, b ut mi ni mal acti ve pla y; kee ps b us y wit h q uieter acti vities  
5 0  Gets dresse d, b ut lies ar o u n d m uc h of t he da y; n o acti ve pla y; a ble t o partici pate i n all 
q uiet pla y a n d acti vities  
4 0  Mostl y i n be d; partici pates i n q uiet acti vities  
3 0  I n be d; nee ds assista nce e ve n f or q uiet pla y  
2 0  Ofte n slee pi n g; pla y e ntirel y li mite d t o ver y passi ve acti vities  
1 0  N o pla y; d oes n ot get o ut of be d  
0 U nres p o nsi ve  
S o urce: (La ns k y et al., 1 9 8 7 )  
  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 9 2 
 1 0. 4.  G ui deli nes f or Tr a nsf usi o n V ol u me  
Deter mi nati o n of t he a p pr o priate v ol u me of tr a nsf use d bl o o d will be base d o n t he he mat ocrit of 
d o n or R B Cs, as s h o w n i n t he ta ble bel o w. 
 
S o urce: G ui deli nes f or t he Ma na ge me nt of Tra nsf usi o n De pe n de nt T halassae mia ( T D T), 3 r d  E diti o n; 
(Ca p pelli ni  et  al., 2 0 1 4 ).  
C CI 
Pr ot oc ol H G B - 2 0 7 Versi o n 6. 0  
1 0 J u ne 2 0 2 1  
Pa ge 9 3 
 Pr ot oc ol Title:  A P hase [ADDRESS_206142] u d y E val uati n g t he Efficac y a n d Saf et y of Ge ne 
T hera p y i n S u bjects wit h Tra nsf usi o n - de p e n de nt β-T halasse mia, w h o d o 
n ot  ha ve  a  β0/ β 0 Ge n ot y pe,  b y  Tr a ns pla ntati o n  of  A ut ol o g o us  C D 3 4 +  
Ste m Cells Tra ns d uce d E x Vi v o wit h a Le nti viral βA- T [ADDRESS_206143] or 
( Le nti Gl o bi n B B [ADDRESS_206144]) i n S u bjects ≤ 5 0 Years of A ge  
Pr ot oc ol N u m ber:  H G B - [ADDRESS_206145] o o d, a n d a gree t o a bi de b y all t he c o n diti o ns a n d i nstr ucti o ns c o ntai ne d i n t his pr ot oc ol.  
I u n dersta n d t hat all d oc u me ntati o n pr o vi de d t o me b y bl ue bir d bi o or its desi g nate d re prese ntati ve(s) 
c o ncer ni n g t his st u d y t hat has n ot bee n p u blis he d pre vi o usl y will be ke pt i n t he strictest c o nfi de nce. T his 
d oc u me ntati o n i nc l u des t he st u d y pr ot oc ol, i n vesti gat or br oc h ure, case re p ort f or ms, a n d ot her scie ntific 
data.  
I a gree t o pers o nall y c o n d uct or s u per vise t he descri be d i n vesti gati o n(s). 
I a gree t o i nf or m a n y s u bjects, or a n y pers o ns use d as c o ntr ols, t hat t he Dr u g Pr o d uct  is bei n g use d f or 
i n vesti gati o nal p ur p oses a n d I will e ns ure t hat t he re q uire me nts relati n g t o o btai ni n g i nf or me d c o nse nt, as 
per l ocal re g ulati o ns a n d u n der G o o d Cli nical Practice (I C H- G C P), are met.  
I a gree t o re p ort t o t he S p o ns or a d verse e ve nts t hat occ ur i n t he c o urse of t he i n vesti gati o n(s) i n acc or da nce 
wit h t his pr ot oc ol a n d as re q uire d b y l ocal re g ulati o ns a n d u n der I C H- G C P.  
I ha ve rea d a n d u n dersta n d t he i nf or mati o n i n t he I n vesti gat or’s Br oc h ure, i ncl u di n g t he p ote ntial ris ks a n d 
si de effects o f t he Dr u g Pr o d uct. 
I a gree t o mai ntai n a de q uate a n d acc urate rec or ds a n d t o ma ke t h ose rec or ds a vaila ble f or i ns pecti o n i n 
acc or da nce wit h l ocal re g ulati o ns a n d u n der I C H -G C P.  
I will e ns ure t hat a n et hics c o m mittee t hat c o m plies wit h all l ocal re g ulati o ns  a n d I C H -G C P re q uire me nts 
will be res p o nsi ble f or t he i nitial a n d c o nti n ui n g re vie w a n d a p pr o val of t he cli nical i n vesti gati o n.  
I als o a gree t o pr o m ptl y re p ort t o t he et hics c o m mittee all c ha n ges i n t he researc h acti vit y a n d all u na ntici pate d 
pr o ble ms i n v ol vi n g ris ks t o h u ma n s u bjects or ot hers.  
I a gree t hat t his st u d y will n ot c o m me nce wit h o ut t he pri or a p pr o val of t he a p pr o priat e nati o nal healt h 
a ut h orities t o get her wit h a pr o perl y c o nstit ute d et hics c o m mittee. I a gree t hat n o c ha n ges will be ma de t o 
t he st u d y pr ot oc ol wit h o ut t he  pri or writte n a p pr o val of bl ue bir d bi o a n d t he af ore me nti o ne d re g ulat or y 
b o dies, as a p plica ble i n t h e rele va nt la ws a n d re g ulati o ns . 
I a gree t o e ns ure t hat all ass ociates, c ollea g ues, a n d e m pl o yees assisti n g i n t he c o n d uct of t he st u d y(ies) are 
i nf or me d a b o ut t heir o bli gati o ns i n meeti n g t he a b o ve c o m mit me nts.  
 
I n vesti gat or Na me   I n vesti gat or Si g nat ure   Date  
 
I n vesti gati o nal site or na me of i nstit uti o n a n d l ocati o n ( pri nte d)  
 
C CI 